var title_f11_56_12160="Upper airway anatomy";
var content_f11_56_12160=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80062&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80062&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Upper airway anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 332px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Three dimensional surface, bony and airway reconstruction of contiguous axial CT images in a normal subject. Top row demonstrates surface reconstruction. Middle row demonstrates relationships between bony skeleton and airway. Bottom row demonstrates skeleton airway relationships in midsagittal plane. Note the relationship between hyoid bone and airway. Arrow: airway; Arrow head: hyoid bone.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard J Schwab, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_56_12160=[""].join("\n");
var outline_f11_56_12160=null;
var title_f11_56_12161="HBV genotype distribution";
var content_f11_56_12161=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F68443&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F68443&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    Map HBV genotype distribution",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 329px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_56_12161=[""].join("\n");
var outline_f11_56_12161=null;
var title_f11_56_12162="CT guided biopsy Ewing sarcoma";
var content_f11_56_12162=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F56503&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F56503&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT-guided biopsy of Ewing sarcoma of the right ilium",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 390px; height: 262px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT-guided needle biopsy of a large pelvic Ewings sarcoma involving the right ilium (white arrow) of a 28-year-old man. The core biopsy needle can be seen here approaching the lesion posteriorly (white arrowhead).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas DeLaney, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_56_12162=[""].join("\n");
var outline_f11_56_12162=null;
var title_f11_56_12163="Neurofibromata and café-au-lait macules";
var content_f11_56_12163=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69606&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69606&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Neurofibromata and caf&eacute;-au-lait macules in a patient with neurofibromatosis 1 (NF1)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 310px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Skin-colored and pink-tan, soft papules and nodules on the back are neurofibromata. These lesions first appeared during late childhood. The large, soft, ill-defined, subcutaneous nodule on the right lower back&nbsp;is a&nbsp;plexiform neuroma. The caf&eacute;-au-lait macules appeared earlier in childhood. A large one is visible on the middle lower back.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fitzpatrick, TB, Johnson, RA, Wolff, K, Suurmond, D (Eds). Color Atlas and Synopsis of Clinical Dermatology, 3rd ed, McGraw-Hill, New York. p.461. Copyright &copy; 1997 The McGraw-Hill Companies.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_56_12163=[""].join("\n");
var outline_f11_56_12163=null;
var title_f11_56_12164="Cysteamine (systemic): Drug information";
var content_f11_56_12164=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cysteamine (systemic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?15/49/16148?source=see_link\">",
"    see \"Cysteamine (systemic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/61/7124?source=see_link\">",
"    see \"Cysteamine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F15510916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cystagon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F15510919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anticystine Agent;",
"     </li>",
"     <li>",
"      Urinary Tract Product",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F15510957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Management of nephropathic cystinosis:",
"     </b>",
"     Oral: Adults &gt;110 lb: Initiate therapy with",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     to",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      6",
"     </sub>",
"     of maintenance dose; titrate slowly upward over 4-6 weeks.",
"     <b>",
"      Note:",
"     </b>",
"     Dosage may be increased if cystine levels are &lt;1 nmol/half-cystine/mg protein, although intolerance and incidence of adverse events may be increased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maintenance: 2 g daily in 4 divided doses; maximum dose: 1.95 g/m",
"     <sup>",
"      2",
"     </sup>",
"     /day or 90 mg/kg/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F15510956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/61/7124?source=see_link\">",
"      see \"Cysteamine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of nephropathic cystinosis: Oral: Initiate therapy with",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     to",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      6",
"     </sub>",
"     of maintenance dose; titrate slowly upward over 4-6 weeks.",
"     <b>",
"      Note:",
"     </b>",
"     Dosage may be increased if cystine levels are &lt;1 nmol/half-cystine/mg protein, although intolerance and incidence of adverse events may be increased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <i>",
"      Children &lt;12 years:",
"     </i>",
"     Maintenance: 1.3 g/m",
"     <sup>",
"      2",
"     </sup>",
"     /day or 60 mg/kg/day divided into 4 doses; maximum dose: 1.95 g/m",
"     <sup>",
"      2",
"     </sup>",
"     /day or 90 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Children &gt;12 years and &gt;110 lb:",
"     </i>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F15510958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15516523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15516524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F15510970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cystagon&reg;: 50 mg, 150 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F15510918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F15510960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sprinkle capsule contents over food or mix in formula if unable to swallow capsule.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F15510923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of nephropathic cystinosis",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F15510932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;5%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (22%), lethargy (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Vomiting (35%), anorexia (31%), diarrhea (16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;5%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Abnormal thinking, ataxia, confusion, depression, dizziness, emotional lability, encephalopathy, hallucinations, headache, impaired cognition, jitteriness, nervousness, nightmares, seizure, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dehydration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, constipation, duodenal ulceration, duodenitis, dyspepsia, gastroenteritis, gastrointestinal bleeding, gastrointestinal ulcers, halitosis, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia, leukopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Abnormal LFTs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Hyperkinesia, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Hearing decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Compression fracture, genu valgum, hyperthermia, interstitial nephritis, intracranial hypertension (benign), joint hyperextension, leg pain, molluscoid pseudotumor, osteopenia, papilledema, pseudotumor cerebri, renal failure, scoliosis, skin fragility, skin lesion, skin striae",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F15510928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cysteamine, penicillamine, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F15510929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone lesions: Osteopenia, compression fractures, scoliosis, and genu valgum, accompanied by leg pain and joint hyperextension may occur with higher doses; dosage reduction may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS symptoms: Adjust dose if CNS symptoms (eg, depression, lethargy, seizure) related to drug use (rather than the disease) develop. May impair mental alertness; patients should use caution when driving or operating heavy machinery until the effects are known.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermatologic: Withhold if a mild-to-moderate rash develops; restart at a lower dose and titrate to therapeutic dose. Do not rechallenge following a severe skin rash (erythema multiforme bullosa or toxic epidermal necrolysis). Skin lesions, appearing as hemorrhagic lesions (on the upper extremities), molluscoid pseudotumors or skin striae have been reported with higher doses; dosage reduction may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal symptoms: Gastrointestinal ulcers and bleeding have been reported; promptly evaluate if signs and symptoms occur; adjust dose downward if severe GI symptoms develop (most common during initiation of therapy).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic: May cause reversible leukopenia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic: May cause abnormal liver functions studies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Intracranial hypertension/papilledema: Intracranial hypertension (pseudotumor cerebri) and/or papilledema have been reported with treatment; may be managed with diuretics.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F15510936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F15510937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F15510924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F15510925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use only when the potential benefits outweigh the potential hazards to the fetus; in animal studies, cysteamine is teratogenic and fetotoxic. There are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F15510926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F15510927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is unknown whether cysteamine is excreted in breast milk. Discontinue nursing or discontinue drug during lactation.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16570458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Cystagon Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $43.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (100): $127.95",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F15510962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood counts and LFTs during therapy; signs and symptoms of gastrointestinal ulceration and bleeding. Monitor leukocyte cystine measurements every 3 months to determine adequate dosage and compliance (measure 5-6 hours after administration); monitor more frequently when switching salt forms. Ophthalmic examination (periodic).",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F15510946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Leukocyte cystine:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Normal individual: &lt;0.2 nmol/half-cystine/mg protein",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cystinosis target: &lt;1 nmol/half-cystine/mg protein (if poor tolerability to cysteamine, may still benefit from leukocyte cystine levels &lt;2 nmol/half-cystine/mg protein)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F15510944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reacts with cystine within the lysosome to convert it to cysteine and to a cysteine-cysteamine mixed disulfide, both of which can then exit the lysosome in patients with cystinosis, an inherited defect of lysosomal transport",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F15510947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As reported in children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 1-1.8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 156 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~52%, predominantly to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 1.4 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Gahl WA, Thoene JG, and Schneider JA, &ldquo;Cystinosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2002, 347(2):111-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/56/12164/abstract-text/12110740/pubmed\" id=\"12110740\" target=\"_blank\">",
"        12110740",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87033 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.61.31.66-186E1AD1F7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_56_12164=[""].join("\n");
var outline_f11_56_12164=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15510916\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15510919\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15510957\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15510956\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15510958\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15516523\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15516524\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15510970\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15510918\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15510960\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15510923\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15510932\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15510928\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15510929\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15510936\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15510937\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15510924\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15510925\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15510926\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15510927\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570458\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15510962\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15510946\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15510944\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15510947\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/87033\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/87033|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43122?source=related_link\">",
"      Cysteamine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/40/8836?source=related_link\">",
"      Cysteamine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/49/16148?source=related_link\">",
"      Cysteamine (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/61/7124?source=related_link\">",
"      Cysteamine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_56_12165="Electrocardiographic and electrophysiologic features of type II atrial flutter";
var content_f11_56_12165=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Electrocardiographic and electrophysiologic features of type II atrial flutter",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/56/12165/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/56/12165/contributors\">",
"     Jordan M Prutkin, MD, MHS, FHRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/56/12165/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/56/12165/contributors\">",
"     Peter J Zimetbaum, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/56/12165/contributors\">",
"     Ary L Goldberger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/56/12165/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/56/12165/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/56/12165/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H271917264\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial flutter (AFL) is characterized by rapid, regular atrial depolarizations at a characteristic rate of approximately 300 beats per minute. There is typically 2:1 conduction across the atrioventricular (AV) node, meaning that every other atrial depolarization reaches the ventricles. As a result, the ventricular rate is usually one-half the AFL rate in the absence of AV node dysfunction.",
"   </p>",
"   <p>",
"    AFL has been classified into type I and type II; the latter will be discussed in this topic, while the former is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/53/15192?source=see_link\">",
"     \"Electrocardiographic and electrophysiologic features of type I atrial flutter\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other topic reviews discuss the clinical aspects of AFL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/60/13256?source=see_link\">",
"     \"Overview of the evaluation and management of atrial flutter\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36228?source=see_link\">",
"     \"Atrial flutter: Epidemiology, classification, and risk factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/49/18201?source=see_link\">",
"     \"Restoration of sinus rhythm in atrial flutter\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18328?source=see_link\">",
"     \"Control of ventricular rate in atrial flutter\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24888?source=see_link\">",
"     \"Maintenance of sinus rhythm after cardioversion in atrial flutter\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/40/37511?source=see_link\">",
"     \"Embolic risk and the role of anticoagulation in atrial flutter\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28602?source=see_link\">",
"     \"Atrial fibrillation and flutter after cardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;When first classified, type I was separated from type II on the basis of rate, the existence of an excitable gap, the ability to transiently entrain (in the electrophysiology laboratory) type I but not type II, and the observation that type II could change in a \"stepwise\" manner to type I [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12165/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2001, the European Society of Cardiology and the North American Society of Pacing and Electrophysiology proposed a classification that takes into consideration both anatomic features and electrophysiologic mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12165/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type I AFL was classified as a macroreentrant atrial tachycardia, with the most common circuit including the isthmus of tissue between the inferior vena cava (IVC) and tricuspid annulus (cavotricuspid isthmus) as a necessary component. AFL involving the cavotricuspid isthmus has been referred to as &ldquo;typical&rdquo; or \"isthmus-dependent\" flutter.",
"      <br/>",
"      <br/>",
"      In the most common form of isthmus-dependent type I flutter, the reentrant circuit rotates around the tricuspid annulus in a counterclockwise direction, and this is the arrhythmia associated with the classic electrocardiogram finding. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/53/15192?source=see_link&amp;anchor=H2#H2\">",
"       \"Electrocardiographic and electrophysiologic features of type I atrial flutter\", section on 'Electrocardiographic features'",
"      </a>",
"      .) Less often, the re-entrant circuit rotates in the opposite direction. This arrhythmia is still type I, typical, isthmus-dependent flutter, but is referred to as \"reverse\", or more commonly, \"clockwise\" flutter.",
"     </li>",
"     <li>",
"      Atypical type I flutter is an intra-atrial re-entrant tachycardia that does not involve the cavo-tricuspid isthmus. It may revolve around a prior scar, often from an atriotomy incision from prior open heart surgery or other fixed anatomic barriers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Type II AFL was considered unclassified because the mechanisms were not fully understood. Type II AFL was defined as any tachycardia fulfilling the classic ECG definition of a continuously undulating pattern but not fitting the typical flutter patterns (counterclockwise or clockwise) described in the original classification [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12165/abstract/1\">",
"     1",
"    </a>",
"    ]. The main distinguishing characteristics were an atrial rate greater than 340 or 350",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    and the inability to be entrained from the high right atrium.",
"   </p>",
"   <p>",
"    This classification was used in the literature and by clinicians. However, this terminology has grown out of favor due to the relative infrequency of type II AFL. As ablation of AFL has become more common, AFL is now more frequently described as typical or atypical based on whether the flutter circuit involves the cavotricuspid isthmus.(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/53/15192?source=see_link\">",
"     \"Electrocardiographic and electrophysiologic features of type I atrial flutter\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of type II AFL is difficult to discern as many studies of AFL grouped atypical type I and type II together, but it is likely that type II AFL occurs very infrequently compared to typical or atypical type I.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ELECTROCARDIOGRAM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electrocardiographic features of type II AFL with normal AV nodal conduction are (",
"    <a class=\"graphic graphic_waveform graphicRef68846 \" href=\"UTD.htm?23/35/24119\">",
"     waveform 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12165/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      P waves are absent.",
"     </li>",
"     <li>",
"      Biphasic flutter waves (F waves) are present at a rate that is faster than that observed in type I AFL, ranging from 340 to 440",
"      <span class=\"nowrap\">",
"       beats/min.",
"      </span>",
"      They do not necessarily appear sawtooth.",
"     </li>",
"     <li>",
"      The F waves usually do not have an isoelectric interval between them.",
"     </li>",
"     <li>",
"      Although types I and II may be morphologically indistinguishable at times, the F waves have a positive axis recorded in the inferior leads more often in type II.",
"     </li>",
"     <li>",
"      The F waves are regular and have a rather constant amplitude, duration, morphology, and reproducibility throughout the cardiac cycles. This uniformity distinguishes type II AFL from coarse atrial fibrillation.",
"     </li>",
"     <li>",
"      There is usually 2:1 AV nodal conduction in both type II and type I AFL. AV block greater than 2:1 in the absence of drugs that slow the ventricular response suggests AV nodal disease which, in turn, may be part of the sick sinus or tachy-brady syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22008?source=see_link\">",
"       \"Manifestations and causes of the sick sinus syndrome\"",
"      </a>",
"      .) On the other hand, a 1:1 AV response suggest accessory bypass tracts, sympathetic excess, or parasympathetic withdrawal.",
"     </li>",
"     <li>",
"      Even ratios of input to output (eg, 2:1, 4:1) are much more common than odd numbers (eg, 3:1, 5:1). Odd ratios of conduction may be more common than in type I AFL, at least at rapid atrial rates, since there is more opportunity in type II flutter for partial penetration of and concealed conduction in the AV node. Odd numbered responses may indicate bilevel block in the AV node.",
"     </li>",
"     <li>",
"      The QRS complex is narrow unless there is functional aberration, pre-existing bundle branch or fascicular block, pre-excitation, or ventricular pacing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The determinants of the ventricular response and the pitfalls in the diagnosis are the same as those for type I AFL.(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/53/15192?source=see_link&amp;anchor=H3#H3\">",
"     \"Electrocardiographic and electrophysiologic features of type I atrial flutter\", section on 'Pitfalls'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Type II AFL also can drive the atria at very short cycle lengths producing fibrillatory conduction and an ECG pattern that has the appearance of atrial fibrillation rather than flutter, but the uniformity of the F waves usually allows the correct diagnosis of type II AFL to be made. [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12165/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Type II AFL may start and stop spontaneously or convert to and from type I AFL [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12165/abstract/4\">",
"     4",
"    </a>",
"    ]. It is likely that type II AFL only exists as a transient phenomena and is not sustainable before converting to atrial fibrillation, type I AFL, or normal sinus rhythm [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12165/abstract/2,5\">",
"     2,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ELECTROPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type II AFL is not characterized by either an excitable gap or an ability to be entrained, two properties found in type I AFL. The excitable gap is the portion of a reentrant circuit that has recovered its excitability and can again be depolarized. The excitable gap allows entrainment with overdrive pacing during type I AFL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/53/15192?source=see_link&amp;anchor=H6#H6\">",
"     \"Electrocardiographic and electrophysiologic features of type I atrial flutter\", section on 'Atria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This could mean that type II is an automatic rhythm or that the reentrant circuit is so short that the head of the circulating wave front is \"biting on its own tail of relative refractoriness\" [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12165/abstract/6\">",
"     6",
"    </a>",
"    ]. If there is no excitable gap, paced beats cannot enter the circuit and there can be no entrainment. This smallest possible circuit where the wave length equals the pathway length is called the \"leading circle\" [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12165/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. This type of reentrant movement creates its own refractory center. Areas of localized continuous electrical activity consistent with this model have been described in a small number of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12165/abstract/8\">",
"     8",
"    </a>",
"    ]. In addition, a study of 14 patients with type II AFL demonstrated a shortening of the AFL cycle length after conducted beats, due to shortening of the atrial refractory period from atrial stretch after ventricular systole [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12165/abstract/4\">",
"     4",
"    </a>",
"    ]. In contrast, in type I AFL with a slower conduction velocity and large excitable gap, there is a lengthening of the AFL cycle length after ventricular systole since the path length of the tachycardia increases.",
"   </p>",
"   <p>",
"    A study of 12 patients with type II AFL demonstrated that transesophageal atrial pacing was ineffective in terminating AFL. When",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    , an antiarrhythmic that slows conduction velocity, was given to six subjects, four showed an increase in AFL cycle length and rapid pacing was able to terminate AFL [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12165/abstract/9\">",
"     9",
"    </a>",
"    ]. This further implies a lack of excitable gap as a key determinant of the type II AFL mechanism.",
"   </p>",
"   <p>",
"    These observations suggest that the mechanism of type II flutter is not intraatrial reentry around a gross anatomical obstacle, but rather intraatrial reentry based on a leading circle. As a result, it is possible that types I and II AFL may coexist [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12165/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study that included 20 patients with type II AFL and atypical type 1 AFL demonstrated that AFL that is not typical, type 1 is a very a heterogeneous entity [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12165/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It involved the same circuit as type I flutter in some patients and was therefore amenable to radiofrequency ablation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24888?source=see_link\">",
"       \"Maintenance of sinus rhythm after cardioversion in atrial flutter\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      It existed as an independent entity as a result of reentry utilizing a circuit that was similar or different from that of type I AFL",
"     </li>",
"     <li>",
"      It coexisted with type I AFL and atrial fibrillation, but resulted from multiple independent circuits",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      localized atrial fibrillation and was less amenable to ablation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The electrophysiologic events that occur in the AV node and the infranodal conduction system (including those seen with abnormal AV nodal conduction) and the differential diagnosis are the same as described for type I AFL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/53/15192?source=see_link&amp;anchor=H8#H8\">",
"     \"Electrocardiographic and electrophysiologic features of type I atrial flutter\", section on 'Atrioventricular node and the ventricular response'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12152581\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type II AFL should be managed similar to type I AFL, as the presentation and outcomes are similar, though type II AFL may have faster ventricular rates. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/60/13256?source=see_link\">",
"     \"Overview of the evaluation and management of atrial flutter\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/49/18201?source=see_link\">",
"     \"Restoration of sinus rhythm in atrial flutter\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18328?source=see_link\">",
"     \"Control of ventricular rate in atrial flutter\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24888?source=see_link\">",
"     \"Maintenance of sinus rhythm after cardioversion in atrial flutter\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/40/37511?source=see_link\">",
"     \"Embolic risk and the role of anticoagulation in atrial flutter\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28602?source=see_link\">",
"     \"Atrial fibrillation and flutter after cardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This may involve rate control or rhythm control, including direct current cardioversion as appropriate. Stroke and thromboembolic risk are similar for type I AFL and atrial fibrillation and should be treated similarly. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93461061\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type II is similar to type I atrial flutter in that there are absent P waves with continuous F waves lacking an isoelectric segment. There are significant differences in type II flutter which include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A faster flutter rate at 340-440",
"      <span class=\"nowrap\">",
"       beats/min.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Electrocardiogram'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inability to entrain the rhythm with rapid pacing. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Electrophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lack of an excitable gap. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Electrophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Instability in maintaining the rhythm before converting to atrial fibrillation, type I AFL, or normal sinus . (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Electrocardiogram'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12165/abstract/1\">",
"      Wells JL Jr, MacLean WA, James TN, Waldo AL. Characterization of atrial flutter. Studies in man after open heart surgery using fixed atrial electrodes. Circulation 1979; 60:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12165/abstract/2\">",
"      Saoudi N, Cos&iacute;o F, Waldo A, et al. A classification of atrial flutter and regular atrial tachycardia according to electrophysiological mechanisms and anatomical bases; a Statement from a Joint Expert Group from The Working Group of Arrhythmias of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J 2001; 22:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12165/abstract/3\">",
"      Waldo AI, Cooper TB. Spontaneous onset of type I atrial flutter in patients. J Am Coll Cardiol 1996; 28:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12165/abstract/4\">",
"      Ravelli F, Disertori M, Cozzi F, et al. Ventricular beats induce variations in cycle length of rapid (type II) atrial flutter in humans. Evidence of leading circle reentry. Circulation 1994; 89:2107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12165/abstract/5\">",
"      Cosio FG, Arribas F, L&oacute;pez-Gil M, Palacios J. Atrial flutter mapping and ablation. I. Studying atrial flutter mechanisms by mapping and entrainment. Pacing Clin Electrophysiol 1996; 19:841.",
"     </a>",
"    </li>",
"    <li>",
"     Allessie MA, Bonke FIM, Kirchhof CJHJ. Atrial reentry. In: Cardiac Electrophysiology: A Textbook, Rosen MR, Janse MJ, Wit AL (Eds), Futura, New York 1990. p.555.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12165/abstract/7\">",
"      Allessie MA, Lammers WJ, Bonke IM, Hollen J. Intra-atrial reentry as a mechanism for atrial flutter induced by acetylcholine and rapid pacing in the dog. Circulation 1984; 70:123.",
"     </a>",
"    </li>",
"    <li>",
"     Cosio FG, Arribas F. Role of conduction disturbances in atrial arrhythmias. In: The Atrium in Health and Disease, Attuel P, Coumel P, Janse MJ (Eds), Futura, New York  p.133.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12165/abstract/9\">",
"      Doni F, Staffiere E, Manfredi M, et al. Type II atrial flutter interruption with transesophageal pacing: use of propafenone and possible change of the substrate. Pacing Clin Electrophysiol 1996; 19:1958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12165/abstract/10\">",
"      Boineau JP, Schuessler RB, Mooney CR, et al. Natural and evoked atrial flutter due to circus movement in dogs. Role of abnormal atrial pathways, slow conduction, nonuniform refractory period distribution and premature beats. Am J Cardiol 1980; 45:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12165/abstract/11\">",
"      Gomes JA, Santoni-Rugiu F, Mehta D, et al. Uncommon atrial flutter: characteristics, mechanisms, and results of ablative therapy. Pacing Clin Electrophysiol 1998; 21:2029.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1064 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-190.92.87.115-B12D491B22-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_56_12165=[""].join("\n");
var outline_f11_56_12165=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H93461061\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H271917264\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ELECTROCARDIOGRAM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ELECTROPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12152581\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93461061\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1064\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1064|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?23/35/24119\" title=\"waveform 1\">",
"      Atrial flutter Type II",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28602?source=related_link\">",
"      Atrial fibrillation and flutter after cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36228?source=related_link\">",
"      Atrial flutter: Epidemiology, classification, and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18328?source=related_link\">",
"      Control of ventricular rate in atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/53/15192?source=related_link\">",
"      Electrocardiographic and electrophysiologic features of type I atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/40/37511?source=related_link\">",
"      Embolic risk and the role of anticoagulation in atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24888?source=related_link\">",
"      Maintenance of sinus rhythm after cardioversion in atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22008?source=related_link\">",
"      Manifestations and causes of the sick sinus syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/60/13256?source=related_link\">",
"      Overview of the evaluation and management of atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/49/18201?source=related_link\">",
"      Restoration of sinus rhythm in atrial flutter",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_56_12166="Doppler echo of AV canal defect with AV valve regurgitation";
var content_f11_56_12166=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F86334&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F86334&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 575px\">",
"   <div class=\"ttl\">",
"    Doppler echocardiogram of atrioventricular (AV) canal defect with AV valve regurgitation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 555px; height: 354px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFiAisDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5bRS5AHJPQetdE3gXxaOf+EX13aeQTp8vT/vmudBIBx9a/Qu73GFkMTgerHA/OgD4Mfwr4gRiH0LVVI7Gzkz/ACpY/CfiKU4j0DV2PoLKQ/0r7Ju7GyEpLMskh/hQ5p9lok08yFDFboTj5Rlvz7UAfHqeBPFzkBPC2vMT0A06Y/8AstTf8K58bf8AQm+JP/BZN/8AE1+gegaAlgiO8xkfHX/69dCKAPzb/wCFdeNv+hN8S/8Agrm/+Jpknw+8ZR/6zwl4hT/e02Yf+y1+kxIAyeKoale2UMJN1KgA7ZGaAPzek8HeJojiTw7rKY/vWMg/pUEnhvW4/wDWaPqS/wC9auP6V9oeJNShubxxZ2ylem48f0rANtETuuIocHt1oA+TF8O6033dI1E/S2c/0px8Na4Bk6NqYHvav/hX13AtnGn7u3Un2FZup2hvCQkTn6sRQB8otoeqqfm029X6wOP6UqaFqrDK6beke1u/+FfSg8Kyl9znj0AJqzHpMFsmC7D2zQB8x/2BrHfStQ/8Bn/wo/sDV8ZOlagB/wBez/4V9LS2MLDCMwPqABToNEEhG6QsPQigD5ifR9RQ/NYXa/WFh/SmNp14vW1uR9YjX07qXh5Y48rDG1cVq2m4kK/Y5Cf9np/KgDxT7Fc/8+83/fs0v2C76/ZZ/wDv2a9HurIwtzaygfQVAJFjGDBN+VAHnv2O57283/fBpPss+ceTLn/cNeiCeBjhoSPqoqzBaWlwfljXd7gUAecR6XfS8x2Vyw9omP8ASpv7C1U/d0y9b6W7/wCFemx6TcoN1tA+PVVOKmjur+1b5sj/AHs0AebW/hDxJcrut/D2sSjuUspG/ktPfwX4oQZk8Na2g75sJR/7LXrtl4x1K1YbWbA/utVu7+JF8FCskjAeoFAHh7eGdcU4Ojan+NpJ/hSf8I3rn/QH1H/wFk/+Jr2VPGs9823zXTP95Qa3dNS+ucNHOHXqeKAPn+Pwt4gkOE0LVW/3bOQ/0qc+DPFA5PhvWgPU2Ev/AMTX1HY6dIVBa42P3A4rYg02eaEqdR2egcUAfHs3hfX4BmfRNVj/AN+0kH8xVN9Lv04eyulPfMLV9PeL4tQ06CQmaOaPH8NeTaheySSNhCDmgDzc2F5n/j1uP+/Zo+wXQGWt51HvGw/pXfRz/NiVMe9W2ltSm2UDBHagDzyw0i/1C8jtLKyubm7lBMUMMTO74GThQMngGtU+A/F68N4V14H306b/AOJrv/hZF5Xxh8NNZyEFvtJyvBA8h6+q3LiIqElJPVj/AImgD4Ml8J+IoWxLoGrofRrKQf0pq+FvEDEAaFqpJ7Czk/wr7Mv7Gy8xnmaMuf4FOSTTbbSZJipgEcC/99N+VAHx+ngTxa4+Xwvrxz0xp0xz/wCO1OPhz42/6E7xJ/4LJ/8A4mvvnw34bS3hSWaYysfWuqVQAB1oA/Nz/hXPjb/oTvEn/grn/wDiabJ8PfGaDL+EvEI+umzD/wBlr9JTgCql7dW0UZNxMir6ZBoA/NyTwZ4niOJfDmtIf9qxlH81qvJ4Z12P/WaLqi/W0kH9K+3PFOo211dmLT7USE98da586HeSxGebTD5GevlMQPqegoA+QB4e1k/d0nUD9LZ/8Kd/wjWuAZOjamB/16v/AIV9pWnhpY51hm/s62YgkSPdRAdfQEn9Kz9U0vTZolP9omQlgrxwQyfKCcZ+bbn8D1PpQB8cvoOrr97S78fW3cf0oXQtVb7mm3rf7tu5/pX1Hd+ENPaRXgvLx0/iL2Yyee2HPbua1l0jwrajm31jPo11GP5LmgD5H/sDV++lah/4DP8A4Uh0DWMZ/sq//wDAd/8ACvre0m8NW/mLNod1eFsEeff42gdcFEX+pp1x/Ylx5f2Hw3bwAZ3ie8nl3emNrrj8c0AfIb6NqS/esLsfWBx/Sojpt8v3rS4H1ib/AAr7CuPs8UAK+GtBkwMfPFKSePd65XU9btoGKnwToD/SCX/4ugD5l+xXX/PvN/37NKLC7PS1nP8A2zNe26hqdj5zyyeB9GBY5+V7pR+QnAH4Co9O8SaBb3IOpeBLKe3wcpBdXcTZ7fMZXH6UAeKGyuh1tph/wA0n2WcdYZf++DX0F/wmHgAj5vhuR9dYn/8AiaqzXngLVb1HHhXUNMi2YK2uprICeecSRkk9B1A6d80AeGR6beSf6u1uG+kTH+QqZdC1ZvuaZesPaBz/AEr2o6JoMl7K9jJrVrZYyiLaJcyA4GckSIDzk9B2GDyansNOsxbvJJ4jjsplbasN7Yz5bgc7o1cAZz75B4AxQB4zb+EfEdx/x76Bq0v+5ZyN/JakfwT4pjGZPDWtqPU2Eo/9lr6Aht9WsrO2udK17w9fGY4EUGppBKB/tLOI8H2Az7VZ1LVPF9jcx2h0u7u7iVS6i0C3WRzwTEWweOnpzQB83N4X15Pv6Jqi/W0kH9KZ/wAI3rnbRtS/8BZP8K9vvPFeqxyiK+t7yyZyVAngIyR1xkDpVzTHvr0ho7lX3egxQB4QnhbxA5wmhasx9rOQ/wBKmPgvxQBuPhvWwvqbGX/4mvp7T9NlZAJpgj/TFbdrp87qYzqLKp4GRkUAfH8vhfX4s+boeqJjrutJBj9K9s8C+GvBFr4T8LnxZ4NnvtQ1G0u5ZbkXtxE5mWeRIYvLVgBv2qgPHzMvrmuz8U22o6fbuy3cc0YGflNdb4E8TeE9B8H+GdS8SXtjbarciS0RZ7lEZYjduQ5R2A2KyAl8cYoA4/RvAPw/vp/B5m8CWkVt4ht0kQrrd4ZY2MZdsA4QqMY++GOchTiqXjjwz8MPCur+INOfwDJc3FhAktpt1S6Auj5YklBO87NiHd3yAemK9Qn0610XXPCb6HpFnqOkSvb2+mMNfuHGwRH9+tv5bRNsi3EPv5GOQSKv6UbDxL4m8XeH9Y0awMs1vGb6ex1F7lSGVohG5KIYZNi52r2Oc0AeP6r4K+G17pfjldJ8MRWc2k6dfy2U0l/emWWW3DK0iq37tkVwOjsem4DOK+Wa+3fHkcWlL40tpPD4tnv9C1ea2uE1N7jYgQGRzbkbIBKxDZUksR82DXxFQAqnH4V90O13q8pbULvy4c8qnFfCw7V9/eF4bFFMl0kk8h6Bl4/KgCnFbWFsNlqsjn+8Rmuk0G2R3VhaSye74AFb9lbmZwWsVhi7b8Z/IVroqoMKAB7CgBkIYIAyKnsKh1K9hsLZppzwO2eTTdTvI7SB3klEeBkcV4X8QfHMSzvBalZ5P7xbOKAOs1vx+3muI4lWMdNz5Ncrf+Jxf8SMFHqvWvOoU1PUpPM27EbqxGMV1Xh7SltJ0kuLhpG9OooAuJbm5ObeKZge+M5rRsNCu96sLcj/AH1rtdIvLny1W1gz77K27B7wSh5YJpDn7qx4FAGDpunX5hCLZBlxjcEx+taaeGbkruNrFv8A9uYt+mK6+1lllTLwGEejHmrABoA4W4ga2UxzQQAjrtFYd9pFveHJgh9ckkV6fdCEIWmVTj1Fclq0Ms7EWkLAZ4KMBQB59qenWWnrvkMA9gc1iHXrABo4W2npnFdHrfh7UJXYyrIy+nU/zrg9asIbAndvRu4KigA1TUmX5opzID2rJGrzhv8AUt9Rg1UlngZsFS49zitXQbCC9uVQIkZJ6k0AZF/ql6wKrbsw9TF/hXPTQPcyZKyIxP8AdIr6FsPAwMAcXacDO0LmqV/4W2kqI0YjvsHNAHhUOj3DPxlx6Ef/AFq6PTfDyyY/0YB+2SP8K9O0zwdLPcD92FGf7gNejaL4MS0CGV4HA52mAUAfP66DrsYIs7WIp/tf/WrStvDGvz27NNYwkD+62a+mItPtY0Ci2gH0jFZ2o+HLK85UNA3rHxQB8ja9pMttI4khaNvZa5qW2cn5mYKPVa+n/F/gR2t5HDySJ6jBIrzdvCghl+W5YkH7kgoA860awgEys/zZ7V7D4Qt7BY0BtZg/Yqayv7ChLqJokB/vYxXW6LoU1miSQTtJH1IWTkUAbk1paXEO05jYdN61zl9bTWM24bmj/vRtn9DXSzm58rKXDAj+CQZrnNTv5CGjne2DejLj9aAOf1u4tb+EwyTHcezrg/mK841TRoo5TszjPVTW/wCI5rmKZigUr9ciuckmM+d64b64oAz30qaVSITGx9DwaxL61uLUHzofl74rbuI5EJIeZfoc1SneV0ZVuVfj7r8GgCx8Jb5LH4seHbqJd4jF0Np6ZNu/+NfR895qGtSkz3CQQf3Ur5j8EqR8SNDC4jf9/kkZAJhb8/8A64r6u8L6N5O2XWIpQTn5Zh5YGCAcKeTjI6Z60AVIrTTbTHk+ZLKf4tpbmt3RbdJnDC1mfHXPAFdTBb27BPItwYzj+DauMe/WtNI1jXCKF+goAjtQyRqDEsYA6A5p1xcR28TSTOERRks3AqO8nWCFneQIAM5xmuHvI38RCUpcuLVWMfndSx/2ew+vNY169PD03WrPlit29gSu7Lct33jKyubxLHTbe6vbtzxEhVFI9Se34iqQh1i7kk+1WmnWwMeAzJ5xDeu05X078VpaVp1rpUHl2MKxZHzvj53PqW6mrdfn+ecZqTVPLbpdZNLX0WtvzOyhQa1qIyLnTL64ihSTXNRQRDCi3KwjGAMYQDjjjOcVzHiDwkNPaC4S5nvLq6m6SgE8gksSPcD86708njrVQNenVT+7umt4l+6sZ2uT/PFY8L5xjMVjFCvKU162S83p+GnqaVY+67WVvJGDo+nagsQVLMP7iPH862U8NXEgDyWce7/alxj8BXV2U00qjdatAB/fI/lVwD1xX6YeecNPavYoEnt4FHTgE/rWNe2FveE7oIefrXp04i2fvgpX/arlNXVpXZbOEnP90gUAefaho9nZI0j+SuOcAmsGXXNPgJjjIDdM4rqNb0DUZyxkWTZ6Ehq4PXNLiscmUSIfdaAG6lqI2b4p92eduKw/7XmGR5J+oxVeaeAnA3OPfirmkWtvdXKII1TJ6k0AVL3U70p8tuzD3iBrnLlJLpyXjkjb2QgV75pPggSwK63aDI6Bc02/8K+WxTaJCO5SgDwOLSLhmG0lh6YroNM8PrJjfbEv3PT+len2vhCWW4UCIKM9dgr0DQ/A4t40aSWBlI+6YRmgDwhNB1iEf6Bbpt9XrRsfDXiG4B8yygPHOHFfS9tptpDGFFtBx3EYqrqWgWV6uNnkt/eiAU0AfJviLRZ7aRhPbtG464XNcjc2szHBZ1X/AGlNfVXinwK8tsximmlQduCa8ruvCXkTsDcyK+fuutAHI+EPEmv6HNajT9c1GG3t8rHb+YXiAbOf3bZTqSenGcivUPDep2l5HGL3RrQsqkBraIQEkkZJEYUH8QfpzWGdBjIVZY0P+1tFdLoPh6WBBNa3OR/dDjj8KAOxW30We3MbQ3dqf4SQHUc5zyBWFfaMkEym01CFkOAC++Ik59cFQBnua02+0iHCzvGwH3ZMHNYWo38yAx3L24HbcuP1oAh8QaFfHTGnkhlltDuxNHtmTaM5YlCcDg8nFdF4W0/VrXwho1gnh22v7W2cXtvK2peSdxcyKdoQ9N3Qk15Hr95f2U/nWEpibpugfGPoR0/+sK+lPB08t14S0S4uHZ5prGCR3Y5LMY1JJP1NAHH3t74hTxQmqSeGIJbyC08iKNtYXy4ldyWZR5OdzbFBOeiLjHOeWh0/xTDc3NzJpup3V3LDHapcv4ijWWCFJfMCKVtlzk8EvuYgkZr1HVMDV5cA58iLJzxjdJ/9eoa/O8+4pxuX42eHoqPKrbryT7nXSoRlG7PEPiJc+JNA8L+M9autOvDbarbywXccuq20yRLMpiTafsolKIZBtTzAOvqc/I2DX3H+0N/yRnxL/uQf+lEVfD2OeK+l4ZzKtmmEdava92tPkY1oKErIRe5HUc1+lukaGNPPm3lysrgcDG1RX5pKBgnuK+11u9d8QT/6Q9wYzzti4/WvfMj2e61bT7RC1zfW0ajrmQZ/LNcJrnxStYXeHSLSa6cdJeAh/GqEXhh7eHI04F8Z3SsSf1rB1LSoIi5vbgK4+7FCuf6UAZ+ueINS1zc2o3xihPSCE4x7ZrkWjtIJSY4hn+8V3E/ia0dUQLlYi6oTjpyar2OmNLKMwSFPVzg0AaWnN5ihYlDMeg5Y/lXW6Ha3O5Hkshj1lO0Ve8K6FM0YEBhiXHXBLV0Enhi9bBhYSP8A35DwPwoA63RG3WqfuoYxjpHWjketcZbeHtUBHn3eAP4YsAfyrf07ShBzMxdvqaANWikACgAVk65rthpkJ+03kcUmOBnJoAn1UWyxbrlguOcnmuA8V+I7KzhIgDu/YoNtc3r/AItutSlkTTfJkHQM8hFcbL/aUs5bUGj2HtG1AFLXNd1u+uW+yTSRx9suazray1e6kDT3DN7EZ/nXV2djBMuYoJ5D/s80l0t9ZjEFnOo/2ozQBTTT5ljAkt4m467QDWz4bg8i9WQxrGM9THuFZ9nqFyJP9Jtt3/ASK3rfU0KhWV419FGaAPWNL1ayW2Ak1KDOOnlhahuNUtTLlFS5z7Ba8snuI2bESTt7kYq1psDzSA5aMe74oA9ZsLmKVQTYiMeoYGr8uo20OA7ED6VzOi29vFAN0sTN7yE1sR/ZpDt8xVz6c0AF54n0y1Ql7gZx0xXC698TzaSMtvbGSMfxqa3vFmjRzW5eO4XI7DFeY3P2SCdkkkkJHoBQBg+KPiHqV+5NrcSRZ/hLkVzP/CUXbuPtkUjn++prr9S0+zvmG6HePXbg1Ui8KxM4EcboPQtQBY8P+ffqr28zlT1SQE16FpehSzxDIeN/VJKTwV4aW3ZCUkiYdHBBFejxWY2jbLG2O4GKAOBu7C703DzpJKg7nmuM8V/Y76NiI3SQD1xXu1xbMYGVwHXHNeLfEOOK3aRoSyN/dKjFAHj19dvDK0UqzbOxzmqJBkO63kD/AOyRzVy8vVkc/a7N3XPLw9RUmk3NmbgG1uDuH/LOZOaAMmS42/LKTE/vWddqJARJsYnoy8Yr0TVRpt9b4vLcLKB95RkGvO9Ws4rV2ezkBUdsn+tAGr8H7e6Hxl8Lrb7WmY3Plkn0gevsXT9CmS6+06reCZzjKgYHHTJPXFfFfwy1qex+Kfh69tIg11ALnC4zndC4/lX0HLq/iDXJ9rtMqH+CFeaAPabjUbG2UtPdW8agfxSAVxWu/EywtZxa6Vbz6hcOdimJflz9axrbws6QeY+nNJKRktMxJrMutNFlex3VxcpavFnYkK5P5YxWGIdX2b9glzdL7GtD2bn+92OvFhqeszR3GrXUhtgg/wBBhGE3cfebr+GcVrRRpFGsUaLHGowqKMAD6Vw2n+OV08Tf2nLeywkja0UCjj/aG4fyrrtK1fS9VhWSxv4n3DO1/kI/Wvg86yziLHYeLnCUoLe3Ly/JLW/m1c0jUw9KdlJfj+pdIwMCs3VryS0iBQgmtQqVBPUeoORVSewF8mFiaT3XGPzPFfD0cBifbeydN83azud9KdNNOWxN4OuXvLaSafy2Jc4IJJAHGPaulwpAzj2zXCQ+EdRjumkgumt4T1RG5J/UD8q6aw0cwtunkaQ+7Gv2fKKHsMLGDp8lumn6fqcOM5HVbpyumbVFNUBRgdKoatq9jp0LNd3cUJAzgkZ/KvUOUm1EQmAmdgoHIJ5rh/EevafZQN5bM7dPkUL+tc14m8ZPezvDpbJNz1eUgfkK4S9fV57gtdtCsfoj5/nQBB4k8RatezsLKSSNM935rFhtdavGBuLtiD2JzXU2dtbzDiGaR/8AZ5p9zDdWilraznAP95CaAKEGnTxwhZYY3PqVGa0tFtDHeRuYVQAjny8iqtvfXiyD7Rb5GeQVIretdUXaF8toweyjNAHqegaraR2qLNqECNgfL5SrUt7qlo0pMTpcH2UD9a8qnuY3+4k7k+1S2MUkrj5WQe7YoA9Y0+7jkxmw2j+9uH9K1Gv7eFBuJAHtXIeH7aBIgZJoiw9ZTmt9GtXIXzolPT74P86AJbjxHpsClpZwuO2Oa4zX/iUtmT9jhEyDuDit/wARaRFcWZZLhB+VeVahHb21y0ckjkg/wrmgDJ8V/Em+vwfskskD+hciuMbxTqDt/pqSTH+8GzXaalZ2V4oDQmQerLg1nR+FYW5iikQZ/vcUAO8PTS6iyvBNKpz9x816Lo+iy3EYEi7Gx95XIJqr4M8MrFLEzRyrjGHUg4r1KCxAiVfNRsdyuDQBw1zpN5YrvbzJYx2bk1y3iSSzvrZ0eF1cDua9sa3fy8cOPavJviHbW8SyMgZJBnqoIoA8S1WdrO4aPZOY8nGGzX1v4EO7wR4eI76dbn/yEtfI2p37PI6XFqZYwesfDV9c+BCD4I8PFQQP7Ot8A9f9UtAFLxBdrbazIH720ZH/AH1JVAatGew/Os/4oXq2uqWq9Ge3PP8AwI1xP9q/7VflXEmC9tmFSXp+SPqcuy5VsPGZL8fNQS4+EXiKJerLAOv/AE8R18Xg8da+m/i7qJm+HOsR5zuEX/o1DXzIADzX13CNF0MC4/3n+SPKzfDrD1VBdhgr9P7SO2srRWxHEuMknAr8wFHfPevszUPEOsa9J5WnQ3CQk/62c4H4Cvpzyz1LxP4jtFgaG0ljkc8M+eFrze6a3ndil5JdTN/BEOB+NaujfDu8vIEm1G+aUnnYMgVpXPg1rAKsMRIP8MX+NAHn01hqdxcFLeKKBP7zHcfyra0nwNqVxKrPeZ7lmIAH4V6D4e8KQxnzb2AH/eNdKqadaYCiFT6dTQBzej+E7q32GbUCyr2QYBrq7WzS3xh3Y+5pn23JAjhYj1PyinS3cMYzLcxR+24UAW6a7BELHoBmq0d1bS8xzqR67uKxtc8UaHpUL/bb+F3A/wBWJASaAMrxdrlzJbPDp2n3tw4z/q1O386+e/F1jrlzdM89k1vk9GAJr1jUPiksoaLSUht4+7EgnFcH4h1yO+bfNqIaQ9QCKAOL0211mzbfHah/qcfyras7rUPM/wBMsrdB7vitXSba5nAeByyn+Imt6z8LPdzZl2St6AZ/pQBo+FdYxEIUiiU+schJ/lXYroWp30RePdtYfxyAD+VL4b8FGCNH8qKEe4O6u5s7KO2QBS5I9WP8qAPLtU8Dakyl3giYDriQH+lZFt4dmtpMtbJkepzXuTqrKQygg+teb+Lb17a6dIJYU9t60AUbe3kUAGOFAPUVs2NpYBWa7mgX8q89u7y5kDGS6nA9V5H6Vz2q+IEso2BumkY9m4oA9dGv6Np9yRCy7h3xkUzVfG1t9jfb9lYEdSQDXyzrnii+89jE7KPUGs+08S3kr7Z5cr70AfQB8VwPNuGWGeivkVtWmr+H9RQC6gW3l6bmFfNkviMW7AqQcehxWhYeOVYBZDn/AIGKAPYvEaw2yO+mSx3I7IDXN6Rqss2pRxX2mXcSFvvc7a5NfEAlIKlueeGrrvA8f9qaiqzTMUJ6FQaAPoTwhpllb2KT2hl+cchn3Ct2eOIqTIilQOflzWd4c02HTrJVhYsG5yc/yrVkQOpUjrxQBy95bzM7NpN4u7PMYf8ApXFeLLa7mjdNRtY8/wB8HFdnr2jpF/pEY2tn7yMVI/KuH1a7v8GOS4kki9JlyfzoA8e1OzaK8IW0Zo88tGwyPwqzZwWLRgmRfMH8Mi7TW/qVo4dpRFuHX5TzWXJc2gUrcQsD/tDmgCvc/YypUrgj0rgvELRRSOrwnyz0Ydq7O+SBsvbPlfQHmua1XZLGY2we2DQBV+FEML/F3w0A25HNxn/vw/Ffb+k21vbWSuESMY5JAGK+I/hrJb6N8WPDt3csEgQXROex8h/8RXuWqeK9S1VzDpEV1LGf+Wshwg/CgD1nXvEVnb2skdvNHNMRjAPA/GvMb+a3u5md74yTMf8AVQDOPxqfQ/AOp6pCs+o3zFW52LkD+lbk3gf+zoA0CZPTEfJNAHnd/bam9wiWdpEEbq87jI/Cr+leAr+9lR3ljdz94gBFH4V6NoXhNCwe9gJX0cmurS20yyUAJChHQZya1hWnD4Hb0v8A5kuKe5ymk+EL6GOJLjU2aGMYWNfur9AeAfcV11np6WwH7x2x2P8AnNON4vCwwuw7HGBT3uURQZpY4vUFqw5Um2upTfQsoMUufWqcV5by/cuFb/gQqhq3iDR9LjY32oQr/seYMn8BTSsBn+JtdkjgkgtLO5nk9YlJ/pXz542tdevZnkl06W3GePM6mvUdU+Klusjw6NFFGo/5aMQc1wviLxINRVmudRTzG6quKYHntjp+s20vmx2+4/XFbkF3qvmj7VYWyr3LSYrS0qGW7YNbSGT3PT+VdBB4clvJB57xsx/hAJ/pQBZ8LayINsawwKW4+SUk13cGlajqcYki8wKemXGB+lQeGfBBQJIIIogO7AgmvQLDTY7VFw8hIHTccflQB5vqPgfUpAzNDC//AG0H+FYEfhme2l+e2XIP97Ne6kDGD0rhPGd19lkYQSQR+28A/rQBg21tKgCiKJMDrtrZ0+ztSc3ctuo+tcHdX95Mx8y5mwO8fI/SsHUtaSyDF7yQn0bNAHrEmsaLptz+6ZC4PUAEU+78b2n2Zyn2ZwB/GcGvlnxD4pvDMxhY7c8EGsSDxRfvJtlmyvuaAPoa58Wwy3DFSDz0R81p2Ou6HeqI762WNj/y0Zc/0r5wn18QkNuUnvjirdh44UfI+MdPvCgD3HxBHZRxl9KuI5D/AHAcZriY9XuRerFd6ZcIueXQ8VzKeI1mAZc/N/dbmuj8LStf6gimeQRk/dYZoA+gfAWm2Jso7y381ZMDIMmR09K69442B3qpHuBWD4P0iHT7NZInY7wOOQK6EjII7UAc3qEO+UnTLxI5P7m/+lch4nt9ReB01K1jkXH3q7DXNFjkQzBQWHcMVIrhNWuL+MMgupjF02yqGGPrQB5D4gsjDeHy7QyJnnYwyK+ovBI2+DdBXBGLCAc9f9WteB6vaPJIZAgY55xXvnhOVV8LaOrAqRZwgg9vkFAHlv7QF4LXVtI5wWhf/wBCryk6tyfn/Wu2/ahuNmsaFtbrby/+hLXiRum3H5q+YzDCKpXlI/Q8jcVgoXfU1/H+o+f4R1CPdncE/wDQ1NeLgkcCu/8AElyz6LdKTnIX/wBCFefk4NeplVL2VHlXc+d4ka+tK3YRfSv0L8OHSdOCz3YHmY+/Ien0Ffnn2J9q+/NB0Wd18xtNEzEcGQ8CvTPnjrZ/GGmqCLfzp5OgVEODWPea/qUgLPGYkP3UA+ap18OalOpzJb2a+iLk1iXOhXRnZILxiAcGQrz+FACz3+ovlrmcWsHU5PNY114x0/TP9TMJH7s3NaM3g2KRS93eSsuPmeYkj8BXF69YaHp0jJ5qSsO+KALc3xQkdysQkk+i1m33xDuVTNvpxeT+84rj9W1+ytA3kJkD+6MVyt94omugUgt5MHjjAFAHQa78RtZuHK3EywJ/ciWuWuPEfn5yHdj3as+6SMKZLkyBj2zWBPOm/wCTcRnuaAOqsLz7VcbZCqAnng8/lXe6Pb+HYoQ15Knme4NeUWWoSxIMSBQP4R1pLnW5zIdoyPcZoA+htMGk3YVLa6k2dMbiAK9c8D2WlWsCG2Z5J+7ZJAr5D8Ga+xmSO5uWgUkdBivpP4bTWTmNoLuSZsDgtgUAeu0U1HDgEEfgc06gBr52naMnHAzXmHjGxiN2812sMZ7hTuNeharqKadAZJY5GUd1Ga871TVNO1K7LbI1c95EIoA4y71iG2heO2ilcY6+XgV5f4y1ZWZi1u+fXpXumqxTR6dJ9lm0sjHA2ndXhXjG2klnf7XOqHJ+4hK0AebanqDTSdDt9MVThuCG+Xr71qalpqAkrLFIPyNYZi8onYRn060AT3Epf70OfUiqy28JY4V1J9DUL3E6H54vl9RWhpcc1/IEtEEknZO9AGpooMEqbTI3PevdPhnp2paoFawtTlcZZHA/nXmvhnwrrFzcxpJAYQSMgqTX0p8K/CF7ozJO7lQR/cwKAPQvD8WowWyR35LbRxyCf0rWLgYzxQSQMkZ+lNL/ACklW/nQBX1BTNaukTfe4yOa801jQNaW5d7a4injzkxuMY+leiXNzYQndNKIW9WyKmgu7GcARTwS/wDAgaAPI7iFYIdt9E8Enoy5X865TV4bJiSVBB7qa+iZoLSdSk0cLqeCGArzP4geB5Hhkn0mJB1O0CgDxm+t4YyfLwy+jcH864vWbq23kLvRh6mui1eS8spJLa/tRnOMNwfqK4HWbN45S8RlKnnDc4oA0/B7G8+Inh5CVkObj7w/6ZE8/lX1b4Yi020CTX6gkdC5wq/hXyf8Nbe4ufiPoEdsu+bbdMFzt6QMT+gNfUegaNcSkPNYNOR2c5FAHbS+L9JiXETvKw4Cxp1rKvPEd/PuKRG3g7BsbjTx4f1Kc4RbWyT/AGRk/kKydQ0C6hnMcV40ko+8xGcfSgBs2panKMmX7PD/AHmbBrGu/Fen6Zki5Esw5LHOM1oyeEDcDddXs0nqZDhRXIeJNL0DSVcy3Ecm3kkjihu2rHGLk7LcL34tqkrRxyNI6/wolZl18SpJQWi015nPQyYA/nXHNLYz6hNPaqixtgAeuO9XYijDGK+bxOc1YTcYLQ+2w3D2GVOMqt22u9iPWPHviS7BTy47eH+7EvOK5W71a7nJM8csjHqWrtvsxdfljzn2qtNpUrtxCefauenn1S+qRtPh/BSd0mvR/wCdzgUvXa42yJ5YJ6nNdroVvoWwPfTKX6n5WrU0D4dXXiTVYoJJjZwZJeYJkjA7DIqh4h+HGr6ddzQvdNJHGSBII8bhk4PNfUZI3m7lGnKKcd7s+Rz2jQyyooxk2mdTpR0WciOzuHCjjCEgV6l4E07SbdA4d5bjOQASR+NfMMC3+gXaLdSyJA3BbGOPX3r3L4b3VjOYmjvZJnPbJAr0cdl9bAyUa3XZrZnl0q0aqvE9xUgjjpS1FA6sgwRnHQHNS1xGoGvPPHNkk0pkuo4EAHYbia7q+uhawmRo5HUf3BmvO9c1rT9RuNrRhW9ZI8UAcVc6nb2W5bZJW7HEfFec+MdYEinfbufwxXtc0LJaubOfTOR0I5rxbxxDPLcP9sljjH96NCRQB5VquomUlQCB9KzI7jDDGc+9bep6ZEAxSaKUehG01z7wCF8rgH060AWLiVn+9CpB7iqfkRO2WRlPtTJJ542+aLKeoFWNPL3kqpAA0pPCHqaANHSo/KkBQyke/Ne0fDezvdTlWOztQ7jur4P6157oPhjWZZkD2zRKfVTzX0R8LvBV/YPHdbiuechcAUAen+FbTVbO1jivySgHQlSRXRlgBk8UiAhRuxnvTWcgn925HqMUAMuDvhYIwyeK838Q+H9XedprK6iZe8brxXoF1PZxnM7eUeuSpH9KS3vdPl+WO5gk9twJoA8oa2ktYGGpwtCw/iUbkNdtpd2q6ZaKp4ESgEDjgCuokjtZBtdYmB7EDBrgb+5WC+uoo8KiSsoA6DBIoA8h/abn36joTZ6xSj9VrxPzh616d+0fdlr/AEM5+XypcfmtePeeRke+K4qtNOVz6rL8RyUIxJtalLaZOM9h/MVyBGTxXQajNuspR6j+tYS9K2w8VGNjys3qe0rKXkMX09a/UiCMxxheMAdAMCvy2HWv0T8afELTdCtWEU6y3BGAoFbnlHaTzxRqd7Ae2ea4Lx1400/RbN1g8sT46nGRXkV98RtW1SdmW+S3i6BY05ri9avYLq4LXE8kkrHlpDlj+FAG5rfxD1LUZ2VbmcpnovArBnWa/wAyTXEit/dALGnxafCsYeMEd9z8VJFf/Z2xFImfUjIoAxp9KkiUvOZSvYuMZqqtsWJCOEX2FdHdXfnIWuJfMI5wBxWBdu0pIQ7F9qAMnVLJGJyS5HfNc/Pb7CQCq+1dBcxpnmRm9cmq0i20KlgNz+9AGKiBT8zt+FSsYtp2sxNPklluG4+76AYqCRSmc8GgB8E00UimN2HOa9Q+H/ia+t5kWa4uBFxwJNoryTzSrjaD1rrNC15LZFDBQw7lc0AfZfgrxHbXFqqfffHVSWP511kmoRpHuKyH2xXyT4T8aA3iok0w5/u4Wvb7HWLO608JNfsjsOzE/wBKAOp1y+F5bmNgkSdy5B/pXA6hDpcbsJSrt/s4/wAKzPE0EaxNLa3E1x9XwK4YTTGY+YrRj2OaAOo1i2glt3FgpSTszZxXnOuWeqxK4luYXX0CdK7JNTSGPak5L46MtZOtX88lq2VRh64oA8m1KCUMxmBPqe1YkzxKeU3e4rptXe4eVlQKVPtisN7dBnz43X3BoAzn2zcAMM+9b3hjTZFu0ljO0joRVW2htDIAH69mrvfCejRzuFtpokc/wsetAHdeDblPOiS7JOSBlmxX0roUcaaZAYCSjKDy2a8N8G+B3mnRLwxAkg5XODXt2gaRFpFt5UO7GMY3kj8M9KANWkNLQaAOA8VaiTK0Xkv1P3GDfoa4XUorpVM1hLP7hQVYflXp3jCyMsXnTbNi9GHDVyenTAzABg6e3WgDh7LxPq8VwI7m6n2A871PH44rQ1LxfqlpbGWDUxIg6xu3/wBavQb7SdLvISVmVZcdJF615d420RI1ZIlUN39DQByPiDxbDrsZj1CxXzRx5qGuRltJEb93IZIjyAwzTNT0y9srgyQJgA9uR+tQDUiB/pMRib++vSgDpvhJbiH43eDzHFhn+2bsHAb/AEZ6+yLWLyUC5GB0AGK+PPhFcB/jZ4KdpFKD7c27p/y6sOa+ovE/i/T9G0q5u/N8wwlVZVGdpbO3PpnaaAOklmjiXMjAVx3jDxXp2i2TsPKE3YtivGtW+J2randN5F0ltATwQuTiuM8QapFfSbry6lmkJ5aQ/wAgKAN7xF8SL++nZILuYR54VK5m7ebVhuubh9p/hPzE0lpp9vJEJYgxz3bgVL9r+zNiORCw79gaLX0Y4tp3T1Mc2Vxp8qyASNAzYBK4xXbaJEhiV5Bj61ykmpyy6gPt8okVfubRhRmuktbgyqBERt9q+MziKc3GCsfpWXOpLDRdR3fdf1udL9ut4xhVFN/tBT0UDHeqFtYlwGJ/Wr8enKB1GPrXzko007HV7pYt/FEmlkvATu+tRah8V9RZSh8lgBj50Vv51Sv9LjZSQ3OK46/0SVnOwZFd2BhRi3JNp+TaMZ4LDVnepBNkfizxG/iCeN75Efy8hNqhQufYUzw9rV3pl7EsNxMLdj90PjFS6Z4O1PVLlbexhRpmOFDvtBP1qSbwrrGiarJbasLf7RFxiP5gvtk19vw/gKuYVeTDy0jq7v8AQ8PiDFYLB4b2Uo+89rLY+hvAHie3mtkRzvcgdGLNXetfxqgOHHttr5NtHvtPmE0F3JEy8jDdPwr1nwd4it7/AERPt995cwJVtrHnFfU5lktXBQVVy5o36dD4HD4uNZ2SseharqX2iBolRUXuZCK4DUYNMjZvOdHLf3QP8KpeIbeGWJpbW6nm+rYFeeSXFwJyro0a56hs1451nXalBZSRMtmrB/7xPFeda5ZapFv/ANKhK9hsP9RXUW9/HDHj7S+73UVT1LUZpIGBCSD1xQB5JqkM4ZjKN3uBWBO8SH5lDH2rrNbluWlYRhMZ5GK5yW3yxNxEQfUGgDNkZZAVVWX8a1dA012vI5EJBBByKihjsw4HmEE9mrtfC2lQzyoIZYkc9Nx60Adv4TuTE8aXRLKOMs2K+l/Biw/2JC9uSVb1fcK8O8K+DJpph9raIxvwGXNe4+GPD8GiQhYCcEdFc7fyNAG9SHpS0GgDi/Fl/wCU5jET+nyMMn8DivP9SjnkRpLN5Vk/u7cH9K9W8UWbXNoWby2jTnDDkVwdtJtuAsbqVBxjvQBw8PiLWbO5MUtzchM4xIDx+laZ1a4kZpDEzljksGAyfXmvQ5tO0u+gXzZRHL/tr/WvKdTuBb6jdQqw/dysgI6cE0mr9SZRcutvu/yPOfj/ADzz2+gSvEqKXuEXJ3MSBGT04A5FeOtO5YnY3Xuea9P+Mh8+50xz8w8uRf1U1520HzH6mvawmURxFJVGP67UpLli9jOuJXMTArwapHg9a1r2LbayEen9azB0rjxmFWEqckSvbSre9IYoyQPUgV9GmxgvpvtF9Pvc87TyB+FfOSnDD6173HqiLGiF1iTocdTXEIZrOxMxiUQRj+FPlaue+3Wtt/qAC/8Ae6n861dVm0w5aSSRx6L1/OuTu9RtQx+y2vA7saAN+3uJLn55pCkY561LLexJkQojY6u5rkW1GaQ7ccHoq9KjuJJyg8xwg9M80AblzfT3L7I7kBT/AHRiqt0phTJkkc985rJt7+SIhYmC++K3bSE3kOZ5ySewoAwZbnb0DuarG45y8Z+ma2NTtYbbOSzt6A1gzZJ6EegoAnN5kYEYUD0qN7tAPunNMRAR83FNmfBwvNADBLG57itDTrZZ5QN2B71nICfvMMfStXSmVJR82frxQB3Oj6VaiAbJ5BL6hsCuq0u7nsWVZpZ5IR1COMmuKjuZI4co0aD2OT/Kqn9tSxtxM4P0/wDrUAem6jqFpdqQj3UB/wBuT/61cXqN4baYpG88nuGrnp7m5u5N5vwg9CaryTXEDFluzIfTANAHVQXl3cKFVFXPdjzWvZwXvl/LJvOPuA5FcCuskJtlicN/eBrV0XXRBKCbp8f3TQBqavZTu5a5jEY78Cs+20CxuejiST+7nGa7myms9UgBIRyeuVq/baDppIeHCyDspwaAODh8Kwh8NaugPevRPBPhiGN1QTquezj+tbemPZqBDcxxMB3k4/WuntJ9Iso1Yxw49Vk/xoA7PwnpkunIoNuXQ9JPMyB+FdYOlcXpPifSlVUjvQq/3SwOK6q2uob2HdbTKw9VIOKAItQ1OKzHzqxx6DNYM/jC2XcI2Xd2zV/UrWcbnMZnTsEJB/lXIaj9mMu27sio9Xjxj8aAE1bxOdSha3uLdXTsynFYFhJ9hug8W7b/AHWNa66XZSqGtZijDnGSRV6y00SYS4gSdcfeHBoAsjXbO4tdl1BHuxjBGCK4Xxkbd4HayO5u0ZYGvQZfDkSws3ls8ZHQ8EfjXmXjW0SxkPlxsy85V15/OgDzKfXp4JZIZYAxHZu351g3F8kkx3W7Lk9NvFbOpWkF5OXiASUf3uv51BC5t8Jd2hZM8OBnFAFHw7qC6T8Q/Dt7Zx7pEW6XZjGN0JX/ANmr0rRIV13Vriw1O5CjUo/IVS2VEuQ0WeG43qoJA6M3qa8513yf+Ek8MyRKACLr5gcZ/drWsuprECgCr6kjrQBJrUaWyvAjfZlTKsNu18g+/I/z9K5h7y1t2JhHmSf3m5Ndn8Qv7Jllt9ShuXlt9ShF0wVeUkJIkj7AbXBwAANpU85yfPbqS1fAtIWjA7s5JNYVqrprQ9bLMDDFNud7eX6mjb3st2xDSbEB6E1Ye/tovlj2SMP4nPFYK0kmAp6VzrFytsenPIKd2+ay6eX+Zav9RlmYIHTZn+EYFPt7i5TaIZnLHsMistGYyAqDx7Vq2bsrh25PvXLiZxkndXZ6+X4V0bU4O0V+J2eiapdQWwExJPua0pNbmYcGuZhuQyjBq7AN1fNVaEObmkj2rF6TUZ2BOTWZd6pcqpCtirT28pXg4NZtxY3BOSc1VKNO41Yqre6pcyCO1klEjnaNjlTyfXPFaDeCPF+la041vz4A6hgXuRNuHrkMaNHguYtQgdABhwc/jXuvj23ubm206+WMyK0AVmHZh/8Arr7Pg/Hqhmapxsrxf9M+I42T9jBpdTyI+G7y4TatwxPTmtrw54G8T2kN1dwRtLaJhtqTqrv04APTjPJq0LiaD7iMWHtWvpXizUtPYmKKYqRhlC5yPTpX6NnEcVjMLKjScbva/c/PMLUjRqqbV11OU1XVrcBoruDUbOZflIds/wAhXBXl40d07Qy3cqDoWlI/TFe3eN5tA1jQPt97Y3FnqDMFDi1kMbfR9u39a8cubG1dWKyLnqOD/WvyKePxNKpKjiI2lB2dtvkz9RyvLsFjKPtqadpdGQ2uo3VwCqRj6uc1rWMF71Eoyf4VOa5bJti4U7genOMU+x1OS2mDNPKgB6HpXr0cTCokr6nhY7Ka+GlJqPu9zc1i0upRmeJEUdTxWRBotjcN88wL/wB0cZrtNM1C01O3Aco7EY+ZCa07bQtMf5gEEnscV0nlHCJ4WgBH+iOAf4utdt4N8MQxTxgS7QT0dciuk0v7LbYgnWNk9ZDXUWT6TaxiXyoCOp2S0AdX4Q0iXTwjiDzYz/EsgwPwruB0FcJo/ibS41VY7sReqlhXX6fqFrfpm2mWTHXBoAde30dohLhvwFc/c+L7WNmUMARxzxWnqNrOAXUGZf7oJDCuQ1UxB8XVkwGeskR/nQAmo+LXuUeB4Y5Yj3zg1zEQFvdLNCHUbs7WPFbCafYTjML+U3oCcVdtNO5CSxJcJ+RoAs2mv2zQCO7hjJx/EteIa/eodc1Hy+E+0SYGe2417z/wjkRj3Rwts/uP2+lfNHimUQeKNXiQFUS8mUDPQBzQBzvxAf7U1ivJChz+eP8ACuSMJJJx1NdZq4FzHGSfmXP9KzzaYYjAxmv1LIMLCeAg31v+Z5OIr8tRo5fVYithKSOw/mK53p2ruPEVt5ekXLAdAv8A6EK4Vs54r5fimgqeMjGP8p2YOpzwugFeg3esQomYULP7ivPl610FzL82I1z7npXyp1FmW+luX3Sn6KOBUctwQuBnpVXzGVcgZPrUJJc5kegC0tyQD61A8ju+SQBUeQ5xH09aliiAXPU+9ACpgHJPIrSsL3yT0Lex6VkycHPWi3di5yhwOlAHc6Z52qgoLcFf97aKh1bw9cIu4/Z0UdlYn9ao6ZqbwKqsny/3Rxmp9W1maa2KCKOJMcetAHPXUBhYgkMfaoAhJ6CmuWlfLFqfyi8GgAwM4P6VPDuGMZA+lVlY5zmpBJIwAGcUAaS3zxDHmsR7ClW6MjZ+bI9aZoehza7qcWn2cyR3MiyMDKSFARGc9AT0U1c8B+HbvxTra6bZXNvA5Rnaa6cpFGo7sQDjJIA46kUARPMCOVQn6VXNxh/nVcewouoZbe8mtrhTHLC5jdTwQwOCD+VM8sZ4Y596ALCyl/8AVIOa0dPtrt2BCR/lWQjyQEHblfetnRtSzLhyEA6c0AeheGJr6FAiCOP1J5H8q09Ui1KMedCAT1JERI/QVR8P31o+zdLHGfU17X4GlspI1S5S3uEbumP5UAeGfbNVvYzGXhUjI5Qim2elXsk6rcyqiE9QOK+ndU8F6RqieZCnkvjgoorlrzwFfQti2AmT3UCgDgU8OQWsSSRuJ1I5KknFdV4Vu7zRkeTSZoQCMPFcA8/Q1J/wjGraevmra3CEHOFG4flWZdtNLIUuYmRxxnYVagD0nRfGsV0fKv0SCbOMo2VP51v30MGoWZEjq6kfKwFeN6bp0kcgkV5Zl6lGTNdZZXl1bxf6DG6H/dIoAvDRZobnMaq6E9V4rsLC28hV3ImcdQOa57w/qmpXs7JPbwsF6sBg/jXWjt2oAr6g4S0kLo7Jjnb1rxDxpfwSTyLbzMGBIKSDmvbdS88Wrm2KB8Hhh1rwfxnE9xfMt2WgmBOGA4NAHJSQQSvuuIsN/eSrttpUjxedZtHKg7d/xFLa25B2SNn0deQa1bDzbOdJMJJFnkjg4oA8r+JqJYa14ZmaFYCftW4r3+Vf8a5e71i3CkgFn7DFd5+0HLa3Go+FWgCqCt1uI9dsdeQ3kyh8RKWPrjigDtNLln8S+C9XtQYxNosg1SOPOwGB9sU/zcDdkWxGewfHOBWXbuskCOB94A9MVn+D9TtdK8R2V1qsElxpu4x3cUTFXeBxtkVSCPmKsQOR9RWteWC6TrOoaUt1Fdx2kzLFcxkbbiPqki4JGGUqw5P3q48XDRSPoMgr2quk+pE7EdqgYkmrMijvUBwOg5riiz6WaZLCQo6U8zEHjFRA4HIpGJzxUuKk9S4zlBaF+yuW8xQx4zXY2Ei+UCO4rgItyngkCtm01J4UUHnFcOLw/NZxOujU517x15mOetN3hu9c2usO7YC1ftbmSQgAcmvOlh5Q3N0jfsV3SoAQDmvf/CAju/C6WlxIrkjjJ6GvAdOtZJMMTjNdRo93cadMrwXEikHOM8Vxe3qYWtHEUX70Ht3PKzbAfX6Psb2PYrPwhaIwZwjjOfatddOtLOIlIolwPQVkRSPq2gwzfa2s2UD5lOFNVbfSY7gHz9YMue3mZ/rX6Xl2OeZYWGJlPfdWe/U/K8TQWHqOko6o434rardano9xp1obdGyMSbMlcHPHNfP99oXiKytjf3dr/oDSGPz8gAsAOgzn9K+rLrwXp0ykm6JJPXIql448K2Op+Ef7PW6SAW6Fw27Az6n8qM4hhKeE5sLRvUuruzvbr6nqZDmNbD4iNOtUtTvqfJ5R25NQSxnnP6VdvSsF5LFFKkojYruU5B57YpkQeVgFQnNfMtypWbR+oWhVWj3R0nhOa9hKBERc9HyDj9DXT6lDqLxecm2R+5EZP8hXK6FHPZOZREGzgc9q9u+Hl9ZzFRMtvcDA3R8Bl+or1sLi6dZcqep8DmmW1cJUcre73R5A1/qs4aF2hBHA3IRUNvp2ou4FxNGEY8kZr6nv/Cei6vDuihELeqKK5W+8AXUJYWbCZewZRXbfSx49jziz8NwxWcc0cqzuR8yqTxXTeFZLjS5ml0uZIZ+6zglSPyq7/wAIlqtqGl+ySow7xgHP4Cs++e6D+VdwsrDjJTaaQzvtJ8bl5BBqcMUcvTfG/wAv5GupYwajaH94JEYdgMivFbHTH8wSxyTPznYybga6ywuJ7df9DieOTHIwR+lAGlcaHJFckwBZEz24IrqtMtDFChaOMnHUjkVz2i6zqtzeeRJbxye5GDXZR52DcADjoKAGzHbE2ELYHQV8ReO5RB458QxKciPUbhR9BKwr7cm3hcoVyOoPevgnx7cuPHfiQSkeZ/aVwWx0z5j0Aamlx/bLJzjO2Tr+FWjpxyTg1N8M4Te6ffHGdsqj8xXYf2Z6L+lfo+S4v2eDpx9fzPAxcb1meYeMLIxeG75yOgT/ANDWvK699+Jtj5HgfVJNuMCL/wBGoK8BzXz/ABHV9tiotfy/qejlytTGit1pETLP857AdqwRwc1aVpJuOiCvmDuJJ7ndJlj8v90VFJK8vyouAewpNwD4K5x2FWkJxuYKiigBbWJkT52A9quKVA9apNcxJ93LGpIHlmOcbV9TQBO68ZJAFQ7mB+Tk0svA+Qlj3J6UxTjO7n6UASo82QS3PtSyPM/LuxHvUZkI54FRpOkr7WYn6UATKTnBIp8gA75qRBDtHGPcmrUAt0XJXdQBlhcnvVyLATLcYqd9hOVG0UzCEdc0AbngXU7TRvFFpqOoCX7LGsqSGBQ8gDxOmQCVBwW9RWxpOueH/DOmapbaRBNrU2oiGJ21K2a0VIlYuyjybgsSXWE53AfKciuLVcHJU7aFjLHKqTj1NAHSeONWste8S3Wr2sLwS3ipNcReX8onKjzSpySVL7iM8881geZg/dYfQU0XTqdqxr6c05llYZZf1oAu20SzJ87Nj0NLm3ikwsTZHcGqtvIFGGZgfYZqS3km84Yi3KTyStAHZeHZLKSI+c6xkf8APWTH6V1ulX72M6SWl7lQekZBrhra1tcq7oufQnNdLpq2UjJ5AVZBjG0f/WoA+hvhv4kmv9sM53ZH3mODXpOB7V8/+AZNQtr5XZlaMY+Upg4r2221q1lRfvo3cFaANTAqnc6ZZ3OfPtomPrt5qxDPHMuY23VJQBlDRbeE/wCifufbGRUc1i0MZbYXf1i6/ka2aKAOasEukvC0S8nqJYyufxAroYWdl/eIEb2ORUlFAFDV7yO0tmeWMuuO3avJtejGpTMVRgCTjPOPxr1vU7ZLi3bd1A7c1yB0UEvLaNHlecA4/Q0AeZvoLh8qWRvXsa0TbWsloY5VlhmA/wBYvQn6V20DlSUdI9391hwawdcmhXMUluYZG+6y8g0AfO/xwt5bK+0APIsozclWH+7H1rzYuv3pDuP90V6b+0ZG8R8PMTjJuT+GIq8eSSSX5V4Xv60AT3FyWYjJVf7q9TXd3N3DqXh3w9rUbhZoU/sa9j3ZYGMZglOWJw0Z2DgD/Rmx6Dzx2CtsIz7Cu4+HDWN+NT0HVPtSjUIM6aICTt1FM/Z9wGflbe8fQ/63t95YnHni4m+GrOhVjUXQvLaNL0BIokszGORgVoeHbpbjTUd/vjKsDwQR60l/J5hKoK+bdScZuD6H6dCNOpBTj1VzIcKo5qu0q5+WtCSxldASDiqJtGRzmuuE4PqcdWnUT0Q0OSOKeknI3GhkwvSoWRqpJMyblA2La4iUD5QTWpZXRyCMD0rmLclWwa39KaMjLtg1w4iko6noYer7SOu50cGoyIo4NVNT8QXEMTCLIbsfSmvcRKuFINUmtW1CTy0HzNwK4KVKF+aS0N5Rst7BonjPxBqiDTbvVLl7dGJWMnAFd3oxv4wv76Q/8CNaXhD4QadBok+r6rcXVpfcGIs6iPHfjGTn61veHfDwuL0Rx3sZjB4JOciv2bJs3wmIyyHsY8qjdP3bL5H4hm2HlRxk4t387lvSri+EaktIffmrshub1vszrvEvylW6NmvRdM0G0tbVUYB27k1xPxJ8N3zQm50OV4XRCco5Vl+hHNcdPG0q9bk0j5swnh5QjzSOL+LXh/RNN0vT7e3srSC7TJkaKNVYnqST35rzKKO3iA24rn/Eh17TfEEiazJfTSzEsHuSzsw9dx60kd1KV5r85zHLcRh8RUhWnzNtu6emrufrnD9aFTBQjTb0XU6c3ixrwRVWPWJYtStZIZWibeBuQ8kehrE89u+asaYkNzeok7ug6rtHU1hhMPy1U1ud+Y8kcNPn2s/xPo74ceKri4eOG4bzOcZY164MECvm7wcdQhvImjkzGDwHjr3mw1u3kto/MDJJgAjHFfVH5ebOBVa5sLS5/wCPi3ikPqV5p0F1DPxG+TU9AGUNCtIzutlMTdsc0yXT2QFiokPqgw1bFFAHMQxXIvFaEMjZ/wCWkWP1roYGlKjzkVW/2WyKmooArX1ytrbtI6syjqBX5+fEGcP498SMmQG1O64/7atX6C3cCzxFWHOOK/O/4jusfxC8UpnBTVrof+RnoA9Z/Z8sze6VrD4ztmQfpXq40fIHy/pXF/shQpd6B4iDDO25i5/4Ca9/GlR/3a9mhmHsqah2PJxFFym2kfPvxq037P8AC/XJduNoh7f9N46+Uieelfcv7R9glv8ABbxJIBgr9m/9KYq+GcntnFcmNxDryUkdeFi4QsxvepUaVflUGohwQfSrC3JBGEWuE6x8cMvVvlFPDQo3OZDRl5/vcL6U8RArtAVR3NADwFkwSAPpU8YA4HT1NXvDvhy/1z7X/Zot2WzjEs8lxdxW8caFggJeVlXlmUdepq9a+Dten8Vjw5Hp7trB5EHmoARs37t+dm3Z827OCO9AGLMqhfmJqIFT93pU92oiuJLaeIxyxOUdT1DA4I/OkdUVQEWgCHG7jbn6UrDAACBcd6enHPApFtxLIGdnxQAsULNzGjOR1qykVyxC/d+gq5Zu0HyxnaDxyM12nhLQJL66jmneMwA5K8DNAHEw6TfTqWjgkdR3xVZoZIpNsg2sPUV9STvpI0Q2iPbWce3BKIu8/jXjmvaXEl3I0WZYiThynJoA4Uysy7cbqhdiB1C/Stq90pGzIm5cdsVjSQtHnIYD3GKAK4BLZyamDMRgAAVPbIHBDMRUdwqxsQDmgB1tKYXB6mtKW7M6qDwfbisqG4WM5IGfXFPa6DuOAfwxQB0WmvEv+t2k+55rpdKkuoJ0ktoFcZHJXgfjXHaWWldFWAHJ6k17/wDD/wAIvcWImuGCKADjcDnigDqvAek3evW8bXMnkxKMnYQfwr0zTdAtLEDaZJCP75rgrCS90KUDTNjRngqUxn9K7mK41C+03eFjicjkqxyKANctHCuWKIB+FRPfW6qCJFf2Q5NeYalqFxZ3jJPeZOfuu5qWC8WXaz2rbu0sMhFAHpsV3DL91+fQjFTg5ryz7VqMFyDC0zRnpk5/Q16LpFwZ7NDK6tJgZwMfpQBeooooArXSlkPyvkdCh5rNn0sXOHMjRuP4sYzW3SMMgigDlp9FdQW81XHrnmsO90tp3Kkg54w3INdTcweXMQ25M9MHg1zWpw3aXSvaM0g3dB1H4UAfPX7WWitpEHhHLOfNN2djfw48n/Gvn2MyJwoNfTP7ZP2iK08DG5bfJi9PTpxBXzULoj+EUAOjhmbk8e9W7O8fTry3uYJ2W4t5FljYYJRgQQR+IFVlklmGPur7CpFjCrgKAfU80Aenaq1vH4jM2mxxQabrES6nbQxrhYA+fMhXCqCI5BJHwB/q+gORV2ztlLDdgk1zmk3NndeBXUxmPWNEuRMkiIuZrSZgroSEz8koUqS3/Ld+OMjp9EhaSJJWbIYZHNfP5rT9nLn2ufe8P4v22G9m94/kXZYFWPBrAv8Ay42PFb+oP5cZ5rk7t/MkOTmvOwictWe7KVolC4mGcKKYrFgOKsGNT6UBVFesmktDzeSTfMxIo8mrkaFRxVVXweK1tF0+bVLkQxOqgY3MxxgVnKEpuxsq1LD03UnokQxl3bZGC7AdF5P6VqeHfEUGiaxBJeQbkVxuUjB/I16zpEekafoxtYhaWzlcSTbFLn8eteV+LdOgF9LLaSNNGT/rCpya76GSxxMlQk/iaX3nzeJ4ol7zjT9311PoiVdO8c2cF9b3V3DbhABE0BAHHY9Ks6F4d0uyuP3OoO8o6qVAx+tYXw310paWVpO5NtHGkSK5zsUDAAz0A9K7i70iK7mE8D7vQxsDXNnmJ4gyHloUpKdJdobLzPlKEcDjJSk7xv53LF02qRJi0VZVHcNmsRdX1OO/iF1HiLf8wA5x3rqkt5LW0PlEG4xwGYVxepaLrt3cFzLEmTncX4H869rJ8esThufHqNN21Teq/wAjz8VQ9nO1K7R5N+0Lp+pRa5DezyGTT5ARCSmAOASM15RHIMDJGa9C+OlpqA1KytZNUkvLWEbjE+4qknfGeOnevLpY2QE7sYrwFh8PCChh6qnHo0rdfx9T9MyrFYpUIyrU+VJd+ncvvKFHBFaWjfao3E8EQct6rnArmrOV5ZAoTdzjk17f8NPCkt9B5kmyNMA8MDmvRw2EVJ8zPEzbOni4ujTVo9TrPh3ZXuvQpFIVhjHVkwcV6xpvhq0scHfLKw/vNx+VcHbQXWhSBtKcZHUGMc/jXd6Xf6hqGn5aKOOUjk7jn+Vdp8+bYVIlyAqAfhUTX1uFJEyNjspya83167u7K6xcXjA56M5qK2vknRWktjKM/wCshcigD02K9hk4D4PowxVgHIyCDXls9zfRSB7R7gx+hbJ/UV3fhy7e4sENxIDJjnK7T+NAGxRRRQBBcglD8jN/unmvm/xJ+zHJ4g8Ravq//CWC3/tC8muxEdO3lN7s2M+aM9fSvpes/WIdVliiGi3ljaSB8yNd2j3AZPQBZY8H3JP0oA89+C/wwn+F+m6narqS6t9tlSXd5PkbNoIxjc2etehNPeggCwDDufOFcE3hfRU8V+INdk8I2wsbO3e0ENvpiebqLygNcSFdoMq4KoM5yfM65FVvhezaHpmo2cmh6mllqGq3Bga10ySzgSIW4csLZjvt0JRkAOSznI+/wCsiH9o+HXNR+D2t2thoyzB9slywu0U28EREzS4IG/8A1YXaDn5sjOK+DsivtWxs7CH4bfE2703SL7QorvRpgmmT6dParCkdvKodmkRVeZ85cqW6Lkn7x+KaLj2HRjLYxkntViGMKxLc47elRW43MQQSPQVbVMjlQMdFoAFmB4RSfftRG4kOMHHc04iRvvgKPQURoN2W4UdhQB3HgDW9K0XTPE6atawXq3lnDFFZymULOy3MTkFoyCuFVmB3AZUdc4rq7nxH4bXUtf1r7VeXr6naQWVrZWxNrPYw4AdPMMTJ8ixJGCoO5Xzwc48njdOympGk/Ae1AHQfEq+03VvFM+r6TuWPUFS6nhIJaGdh+9UttUMd+47gADu/Ac0C7rgcCrEa7huK5A9TSyyMQFyka/7NAFURkH7wz71N8w6HNMJA+7z74o+Yg4xQA5i/V2/Kr2mzShw26QID0D4rNCFjy5+lP2vjAdl9s0AeqaJqVvIi+VFM0iDv81LrviFxCYktwzdOmK5Pwrq02mt87r5ffd1rR1bxFFd/KCAPUCgDl7q4Zp2YqUYn++TiodxZ8yMzVfYWjyEtuZjUUs0UB/d4U/maAKzTbT1wP92mzSBxw3Hpin3NwSoZAXJ6kmqqs0rYy2fSgADIOChP41o6fFHJwcp9aqquDyjfWrkQLjjPHY8UAdVoUMVvIDKwC/pXrfhNpbho10+XDccpJ/SvJPC1/BHOiXkqxJnkvzivY9DvtCsws8N1G7442LQB2ktxd6OsUmpFSp6kHkit+y8beGLxVjXU/s8wGCvIP8q8x1NY/EylGtriQD7rB8j8q8j8T+Hbix1F1hhIUdNxI/WgD6zmtvDeuhjLfW1yAMDLqrD8eDXP63p40OBJNHuxdWxODGXDFfoa+SpfNjcfabNh7rLj+WK1NPuk09FntnuVf+4szcUAfR1vr/mkRTkxN6lelb2g6vPDdANcwPEeAe9fPul+Jrq5iBjMuR13Gt231G6vmVWLxuOhHQ/jQB9NC62iN3mi8tvQVfBzXlfgfUrm3tore80+eXJ+WQAsD9a9NtJfMjGY2jP91higCeiiigDP1FZ2RgYFni9FOGFVtKhgnywVtyHowwwNbNJjFAHy1+3APm8EjBI/03gf9sK+Xo4gWy2PoK+o/wBtwZk8FDnH+nfd+kFfMiJzjbtHpnk0AOWQDhFyR6UJNufaoJx1pcO3BARfT1pFjG70X2oA6nwBrUOieIYZr7LaddI9jfKASzW0w8uXbjkMFYkEdwOoyK6O2nudEubzSrwk3dhO9tKM5AZGKkA9xx/ngnz9DF0IyO/0ru/EOoWup2nh/V4IfJuJLb7BfAPnzLiAIBLyxPzRvHngZZWPPJrkxlBVqdn0PXyXF/VsTbpLQbeahLcfeOB2qiz5PXmopXbpgZqHZJk15tOiktD7OriG9kXUQHqaUpVKOSRT8x4q2lyCuOKUoSi7ouFSE42ehGyHdSKxX609pQTxzTetWm+pm0uhu6BcWYmQNFO1wF6g5UfhWvrOumO2aIQbmIwAVxXKafdS2NyJoSNw6g9xWlqfiMzRfvIymeCQK9XA4hQlFrdNHyOb5fVVSVSzcWvU2fCviyWPbHcnaBxwK93+F+uW17cFRNlivAJ6mvlG1mAO7OcnPNeifDi9lGpxiJiTkYwa/Ws2yyni8K5p2bR8Fd0al7aH1LPvMp8zO73qIg54zSaNd3U9rGLi2Zhj7xFaMtvAB5j74xjJAr+Yc04GxsaspUZqd31dmfT0cwpyXvaHnPxL0XQ7jRri81mVbXyUZ9/UscdMdSa+UZbyC7mdLdZEizwXAya+w/HF1pt7ot3p5gWYTIyMXHOMdvSvknxNov8AZd/5aArEx+VTX3HDnCmKweAnVxDTcdbX2XlobviCpb6tTk7P0/AsaNbJBKrsw2E9cV6t4UlEuxbKT5/9lsfpXlHh68jguUW5cJHkAlq9j8PXOgRLFOt3G7gZ+Va9I4zvAdQsLJJb0qU9Sef5Vuab438NSQpbT6h9muAMMDxz9a871G5j8QKbdYJ5Y+gKPx+VeVeM/C8thdkQROB1+bigD6nc+HddXY+o290o6rIy5/Pg1i6volvo9sZ9Duw655g3Bh+Br5EnW5hOJrIsM8MJOf5Vf06WO2XzojcpIOSqzHmm4uKuxH0jD4gff5NyGjJ7lc4rZ0nVZ4bxWjuYGiPrww/Svn7SfE9zOmxDPkdd2a37fVLm62xyLIvo45pDPp2K6eSONxPDhiAfrV5GDKGUgqeQR0NeS/Du7u7K1uje28zxxoNsqZY72IULgc55PPT5TXqOnzeZEuYXi4GARQBbrL8Ta3b+HtIe/uop5wJI4Y4bdQ0kskjrGiKCQMlmUckDnkitSqOuaTZa5pk2n6pD51pLtLKHZCCpDKwZSGUggEEEEEAigDjr74lpY3j2tx4V8Ri4iMCTIotW8p53KQoSJ8Esw/hJAyMkVMvjI6tJo7aal3aL5l5PqEEkSvNHFalopIyF3DcZigG0nIDbT3Gxa+DdFtlcLBczO8lvK8lzezzyM0EhkiJd3LHaxzyfY5HFP0vwrpml32pXVks8b34YSKJWwhaWSVyh+8pZ5nYkH0xgAAAHJ+IfFVr4u+DHjS/sbeWCFdKvYwJZ7eVifs7H/ljJIFPOCrEMCOQK/Puvtn9oS7X4cfCy/Hh+3Er6/c/2dey6hcT3UrJJbyqWEjyFtwCKFySB6V8TUAOjZlzt71ctsqMuetM02ISzlT2Ga0/Kj6AfiaAI0w3O3P1pSFzzg+wpS4U7UH501lJ6NyaAEZ3HCqFoHTLEn6VKlsAu5nLP6UqoR1UfhQBAHmPQMq06NM8yE4p03HSmBXP3ulAEkm3A2E/iaZGedu4UvlM3VTilVCvUY+lAEmVj5GSfpSorSHIBH1pAufug/jUqgKuXB/CgA2OmPmOKmd18sZXn1quFeZgFyB2qRoJEwGIP1oAaNx5RWpVErfeiJ/Cr9us6Q71UY+lOiaeU8gD60AQQ27y4Bj2iri2SoPlkVT/tCmNLt4Kg47g1E8yvwAQfUmgCMGRptiqzHPB7U6aO7RsFCR7CrEVvNkHIHpzW5Yl40CuDL6ALmgDL0y0N6pUhg/TmtSazvNECmeVmQ8gAkVrwWmEEyWkkT/3s1U1vVnePbdKz7RjG3NAHSeDPGrWjCNp41X1Y112p3dnrMSyJLEzn+7g5/CvEY7vTJusbxMO44rc0q4g+VFmdk9jg0AdBr3h2WRCUjUD2XFcu9hNZKwaJjnuDXoEYljtle2vDIgGdknOK6Hw/BpuswG31F4QcdV4INAHj2najJbS7G4B69q3tMN1cXiCHzsMeNnSrHj7w9Bpt+w06SaRRyMgEfnVDw5rWqWoVIEikVDlgVwy0Ae++CNJv4bRJjLMW67G4P4cV6hpN350W2Vm80dQ4wa8z8D+Lru/0hFlni8xBjYVANbsesM8qrJ82D06H8KAO/oqlpl7HdW6lN2QOjDmrtABQTRTZRmNx6g0AfKn7bEjC78I7ZAcfa+B2/wBRXzVa7slmJHua96/aoEsuv6BDMcgNc7fpiL/CvGPJjHGKAIoyrc4J+tDdf8KexRBhOTTCCwyTz2AoACxUZRcY5zXWeDL03eh674dmR5Wu0W/sipOY7m3Vm4G4A74jMmMMSxjwMiuWS243SuWb0FaGhahdaJrdhqmmtsvLKZZ4jjPIIPIHUHoR3BotfQcZOLUl0NG0dZIlYHOR19asnAq14ktrO08Q3H9i21xb6Ndqt5YJOpDeRIMgAn7207kOCeUYZOCaprxya8erHlm0ff4Kuq9GNRdSGQM3QcVCybepq5LIFjJ9KzHugTu2sV9cVth6NWtfki3YyxNejQdqkrNlhWK/dFTxlj1qCCeNxlTUwcdjWU077G9KaaumWAQBWbdzGWXy0GeasNJweap2sTi7PvzXt8N4CGMx0IVFoeHxDjXTw/JB7k/2d1j69BW34F1qbRfEdrPkuFYZXPvUQiGw5rPVltb1JPRq/aauHi1y/Z2Z+dKfOmj7A0/4lrNAm2xIJHY1s2vjFLpfntmAPYGvJPho9trNvGEdTL0217Tp2j2ljGDNt3enWvzHN4YHLpNVfd9XY2oyr1fdjqcV4u1eCRC0Fm4b6V85/EjUZLm6NulpIs0Z5JXBFfZlzIiqRaybExghRivH/iZ4Ct7qC61e0D/b2AZ2OSX/AMTXyP8AxEDDYepLAwp76c17rX0PZwWTKrNc07Pordex806bA9y5jk3KxOBmtp9LvtJjFw0rGI9FyVrUsrUTRiU2bqy9JAep9abquqSrbeTPuZF6DGa7otNaGlWLhNxe6NHwh4wewlVTKig8nec16Be6tZ63ag+fE0hHVSDXhqXmnSZWWFo29RxWrpVzbp8scrlfTOCKZmddrvh6SaPciAjruC4rkpNMnsWbdGWHscV3Ngr/AGQPa3rYxzG5zW94fNnf5ttRaH0PXNAHkVrfS2txkggdwa27eae5mRoBIN392ug+IvheysJM6bLM+eQOGFYHgq8v11a2so/LCSTIj7lwygsMn8Ac0Ae+eCtM1CHRLGOMzROxe5k8zKlskKi9B0C5HJ++a9J0a7bYIbgssg4AcY//AF15x4T8cyarcXht2jt7YSFbeJ4lQrGOFBA4HGOlb76zI8gV9rDPK45P0NAHf0VlaJqMV1bqi7wy8YYVq0AFFFITQB88/totn4e6SPMBH9qx/L6fuZq+OK+qP2vjMug2scjZj/tFGUen7uWvlegDQ0QZunHX5P6itGSJ+m0qPeqPh+5W2upWZAxMZAz25FaEk5uG2ocE9aAIBGQeBuNSiHjLHA9a0LOyRcNKQQOvNaC2seov5UW2JB1NAGB5iIMDNMLs3C1ualZWtugit42eTux7/hWMbeVWIdTEB/e4oAicc89adGhwCVP5U1iFfCgketWMs0eB19aAEbzCucECoiO7Nj2qeOBTkySnFQPHHu4ckUAPEiqMDcR7UpZ+qDOKYHVTgKSasJkn5h8vpQAgMsi7mcLjsKagd35OQKlkaJFwi5PoKt6Pby6jci3t1KM3BJ4FAEL3UpUJk7R26VPFHHtDM2WPbmvoDwL8C49Q0WK9vZ186TODvJGPptrS1T4AzMmbK+i3+/A/lQB88wQK+Nq4+tbdhojajhI4w0h7Kv8AWvatM+BF1Dn7TPDKT6tx/Kti1+EN5o5N3p1xH56niIfNn9BQB43F4YbTUC36IgbopIJNdJong68mtJLjTrd3A5wY8131/FdNdR2+vaQTyBvVQPxzXoGl6LYwaYE0u4aB3GSHbIFAHzFrr6pZyGF08pxwVbiuYuZbpIyZlg59a9h+Kfg+8W5aee7gLDkFM8/nXlN5pcpG24aGUgcAnDUAY0DtI/EMLn0KU2eaKMlHiCN2KVo21rMD5SNtTp9P0qK90hYiX88OfTFAFO3ubyLm3vN6D+Bic11Wja7CkCpdwkSH/loGwRXHw2aGTmcL7MKW8yqfuZJC69sAgigD015xKoeO4EkZ/vY4pkFpucyNbuY/+esXP8q5TwnflsCa3RlB5DNjNdtdxp5Qmsbg2u4cqjlh+VAFaKIQ3ge3vGSX+6SVzXo/hfxK9q8a3kcM+3j5uv515/bWc9xGZfOt7kpyynhq04jaSwDC+XIvG5HzigD3HSdegjuFEbBYpDkoecfQiuxR1dFZDlT0NeNeF5YzZxtNClwgwFkBwwr1fRrqO5tF8tQoUYxmgDQrE8UXhg06VIZEEzKcITgn6Vt1j+J9Ogv9Nk81fnQZVgORQB8afHK9vrzW9FS/QqYjc7D3I2px+lecSRuMgLx6mvV/j/ENO17w8XIkXFz7Z+VK8pnuxOSB1J6UAVjHz6n0FSLFnk4FXbSyGVaVgV6kVpeTFdEW9uqR+rUAYe5Ixgc1G0hbIUcn8a6C+0+1tIQiqZJT1Y8fpWHJbyhsbDGPU8UAdbHd3Oq+BLUzRKz+H5/KM4QF/ss5JCsVXIVJEbBZutwAMDFZ32hdoxzUngG/hsfEZs7vyW0/VYW0y8aRAQscuNsnKsQY3Ecg2jOYgMjJNZcqTWU8treRSxXUDmOSORdrIwOCGHYgjBGeDmuWvS5ndHu5RjvYp05OyJL6Usm0d/ep7nUFXS0t4olUYwTis9wJWBZ9qrWjY6bNewsUI2Y44r7PhWjJ0K1GDtJre36nh51iY1ayqyd0jEjcIflZifapfPkx8ufxNSXds1nLsdfxxU8MAKA5BzXzWOoSwlZ0qy1R2YCFbEr9zKy9SCIyzNhj+ArZtYDEoYgj61nuBblZFXkfjW3AyXFuhDjJ4xmvv+EJ4ZYVu651v5I8TNY1qdVxncgluGVTzis7KSs7Svg9hg17h8N/gy3iDTpL7UpkALfIBIcY+gFdJq3wAM0BW3vIw38OOAP0rkzbiKjiZfV4NqN9ZJ/8AVDDOnHmtqfPmjaheafeRyaZdXFq6nPmRuQR7ivqTwjYf2rpMVyviq7vZGAZjMNjZx0I6frXIaZ+z/dQTq9zdiTHZZNo/PGa9V8E+EG8O2EkV7ClyQwKsjbjj6HFfO8RYXKc5oQTlJzhom939/Y6cPiMVhJP2SST8kTWumatDZXg0vU1+1GLbE8jqAjblOSSrjoDxt56ZHUcv/ZvxBHwgubFtZQ+KTBIFlF6gbaYmAQNsyHyQA3mcN8+8D5K9OsnswQsKiJyPuMu1vyNTSw24OXjXNfJUcvrZfSVHBWau3711v6f5HTKv7V89XfyPnD4yXGsQ3+mreXkN3eCyCzTwupjZvNlOBhUx8pX5cEgEAlvvHyeeW8Clp0gwe5PWvoD4yaRda9FHcJcLDZwqVjQseSGOTjp6V4Xd6ROi+XPLFIg6BuCa9fklFJSacra2M1JSV0rGIkjyS7RFCx9ChpJ5Y4jtkgVCe6CrsNrNC+yH5V9Ov60t7pAUeY86s3908mgZmw3FxGc2t4Qv/PNyRXS6JrogjIvoQ7H+INyPpXKi0BlwZtg9GHFS3KbYSiSuWXpjkGgD0lLoTwhoLgPGeqsckVs+G1jtbbVdSa3Mkyw/ZYGjJyjShlZiAwPCBwDzgkZHSvLfC99IJNs0CMqnnccZFes6vPGugaXYWJNgY0+1ShGOTJIAR1J48sIOg5J60Ac9NCi3IeO5aKTtkbc/jXd+G/EM1mY0u/KmUY+WTv+NcXZWlxdhs3dvOy/wOME/pWjAbZ4fKkQrKv9184oA9s07xDbrLHLD+6EmA0ecg/Su2t5kuIlkiYMh7ivEPCDp9nKyRrcxL3Jwy1634bu4pbVYo02bR60AbNUNZuVt7OQ+ZGjsp2hzjd7Vfqlq1nDe2UkU6BhtOD3H0oA+Pv2j7/UbjR4YL5CIlvkdGJz/wAs5OM/jXz/AF9G/tM2AtPDVkRIXBvkHPUfu3r5yoAs2ClpSAMnFakCEN06elZ2lnE7c4+WtRZsOQOaALf2kgYC5Pqa09PLwJvAVSw5Zqy4VES+ZP8AKO2ajlv2cEKNqetAHRRXiRszLiST1xWbcQXN1MZGhd3b2wKy7S5kD7lOMdK04ry5kmyJmZvboKAJLDRb6+fZFbNgdeK0L7w1LZwL9qmRGPRQa7jwKZBZPIR5jAc7mwKm1vw5capDLdEqnp2UUAeS3FtBEvLM3qe1ZzhC52AhfU1tX2lzJeNCZGfb3A4qjPF5Mgj2MT7igCtA4U/IA34VKVkf5ugq065VFkUIB7YzXR+F9DbVrlU8sLF65oAh8BeEb7xTrlvZW0e4O2CxOAK+q/Dfw08L+ENPjk1OVTcqAXy+Rn2HWuc8N6n4a8E6EYYLNk1HblmHc/XHSvOvGXxG1HUJJIYYbWBDn94oJcj/AHjQB7Br/wAUrLSJlg023uZ4U6CNQi/41z+qftF2drayCPSpWu8fKuRtB9zmvnXUNVvJtwe92Z/2jk1mxl3QhFVz3YnJoA9hj+Ofja6uHntkhEG7IQxqwA/GttfjH4tuoB5qWsY7qkWCf1rxPT4WjjZ5rnyVH8OeK19Jms5J9kt5LnrlUJoA9z0z4lahqUC2xsxJcHGWcgV6J4TuNRu7bf59lG458t+a+ZxJaQMJHu5kXOMq2D+lS6jqJS3V9K1GYN33SGgD6S8T6h4ZiBfxRJFFOoxlJC2fpivnzxz4j8O3izppEDlwSEduQa8+vb2+nuib5Gk9TuLZpkIiZ/8ARIlZv7pIBFAEmm300krIV8r0I5FacGm3lzJiNY5Tn7wyDWer3O4/uUBFa2mXLR8M+x2/iTjFADNT0K6jhImgVZMfKSax7a0MbsLuNww9D1rsUvdQhO2RvMQ9pBnNVr7zZ8EwovptHWgDlZpp4Zt1rGAB61p2NxeXUYaOZcj7yE1aFu0bA3FvIB3IHFTy+HxMgmtWMeeQxHH40AT2mpNayL5qk8d//rVtxbJibvTGZJsZKYyGrD0yEws1tq8e5D91wc/rTYpG0vUt1hdNtz916AO98JalJNdhEJhmz8wXgE/Q17l4PiuPkaaM4xw68fnXztFBdahcxzwqqSnHzIetfQvw4uJv7KS2u3bzUHG45yKAOzpkyh42VuhGDT6bIMowxnI6etAHyL+1vZGDVfDG3Y6Obort68CGvCI0YPg8fSvcP2qraa117w+HRo1ZrooCe37rNeJrKA2ByaALa3PlgDGW6c1f00uhMuAG9WNZ0KEfvJRtUetD3u4lYRhfWgDfF3EJN7fvJO3HSqV4lzfS7zGz56ADisaG4czfKcD+daUd7cuyjzXyOAAelAD7bSL66lMUVs2R+ld58QtCu7/7H4kv44rOTUoR9p2bVElygCyybVAALkLIeMZbuc4XwAZpHdnzI+M43Y/Wu4k0yfxFoOraaYh0S8tsNhUeMEPj5urIzE8clF9BgA8DltIYQRvZz7dK+h/gn8MzJYyaj4ltJGtriLy7eCViMsxGGA4weAM15Bo2kNbeMbOGWUtiTcMEcYPH8q+zdF01p7Gynmmd2G1xnBzg5r0auGq0KFKvCs4qTu0rq9n3MHiYrmoezTbtr2PB/GPwwiSLULhLRRa2cixzstzG7QuwUhWAYkHDocEdGB6GuBtvhlrd60z6R5E8EaGRvMkCtgc4Hqa+ibT4WWOkx+IGtLy4L6m6FfOiiCxKBDkDauRzEThAi4ZV2/IpHnvxI0/U/DV3p2n6FrM0aXyOs2wbGA6dcnjGavHZ1hcXh3hsU4+3fwrW+2nXuPA0q+HxClh/hW/6niej6Pd6zq8enWkW+VmCnHNfT/gv4SaF4a0+OfXZV+1Y3MPNAUfn1rnvAY8M+CNM8y6tWbUXXiTOTx71ynjT4nX1zI8Vrb2caN0lYFm/M9K8mkvZRsna618zvxeJliqnM/kj1jxB8RdK0CIW+kx3E8anGIECj8zXO3n7Q1lZQMJtKnM2MKu4cn35r521HWb6ctvvSu7q241kxM7M2NszHqznNUcx7FP8d/GN/qDzabDFDbfwx7QwH1yK14PjN4vurcrOlnGcclYuTXienwSBiZJvJA9DWpp09m9yqTXkuCcZRSaAPbdP+JuqXcUMEtqZLoSIysMDGGye9eqWPiiy8QKLGDzVvyu54nXbt98ntXzA/wBjVMm7lVBxvDYNQXU1v9nWbTNSnmkXg73wfwOBivYy6GHrR5K8uRrZ20+b2/rc4sVCV7xW59Oanquj2lr5XjO4treSPIQxz/eXsdoOc14n498S+E5pZ4dIjkmOSFlJyPx715jqd7dOCJY3cnqclj+feqURhLKIYh5vdZODVZtgKGF5XTqc7d72tb82a4ec5rWNrE9rqEv21lZNiE8Mn/160lsru6lAj2TE9OoOKosboNj7OoI9TWjp9w8ThpiEJ4BXIIrxToJbrQLuODM9uAMfKxPesOOykS4Iuo29iprsEvdQhwwlMkLDjfyDUd48twuTCg9Sic0AZfhu0hvPE1hBcqUsBJ5t0wViwgQF5SNoJyEVjwP5VZ1jxBe+JPEGpamStvJdXDyiEuG2KTwucDOBgZwM4rc0y0/s3wnqepXNsftN2w0+1zGG2A/PLKuVPRQqcYOJTWMdDjvYhPAzI397GcfXFAC2t5LbMvmqSQec/wBK34GgviJ7MtFdjn5eQawdPtprG48rUkE1s3AcHNJcBNO1BZtOuWUZyFPSgDs/D+pStqHly5huQcFk+XP1Fe4eD47l2jeRCy/3xwRXz+PtGrLFLhPOH8SHFe6/CmW5trIWt47HurMcg0AejilIyCKBQelAHzL+2FZiHwdYTRlDG2qKMdwfLl/Svkuvqv8Aa/tZYPDlrIYikL6jGRzkZ8qWvlSgCzYnDsfarsdwkBycuevFZsKs24KCSR2qykBUYkPTkgUAWnupb1gWO1B0WmXAkKEK21aYJxCM7cL2pjzvcHYnAPUmgAgmEI5Ys3tV+0vJN39xP9nk1ktAwPy9M4+taFvE+weYR9AKAO20XXpbZQlrGTxyS1djp3ima6iFtNbF2PA5wB+FeTIHhAxkE+9d94FNxNOsFlbRyTsBud8mgDqbxtHsrD93aBrluSz+v5V59rVwk1wZZmiBHRI1FeleJfCd/DGk2tXNrbQkdF615xr39mwSLDpSbh3kfuaAK+j20d9dgzvHFGO8vNepWmsaRo2lrHZLbIyj55ljGSfavOLCzMtszgDOM8U53ijsHW6lCAH5QFJP50AbF34vnmnkMaBlPAdwBmsF757q5d7mNXH+zWF9pUOfmK88FhmrdtcTOiiOVWGcEYxQBekFvOpzbqPr1pEscwM0ZAGPugda6/w/4b/tuzAhMZmAyQen8q57XLT7DI9rJHJHMDjsAaAMqC3ZmKyN5Y9xThHKsh8mXn1Xiq8tsYgpnZmDcDBFW47a5tUSYENEegU5NADUllt3BmV5DnkA1fWZpl+ULEp7P1pk6r5IuJAUYc5YU+KaC4tSzYfb3A6UAWUCw4baZT+QpjRwyq0qKyuDyoxmq1teBgYlZSvowIrStdPjMTTI6bRyQGyaAM9Xx/qbgbuhWQcirenXMlvLvuFicDsBnNObTbO5yVR3l68HFNuLCOxQSPBKvuOaAOoGv6JLCHuLaSJgOQMkVr6Yug6hB50VwVX2bkV57HcWdyvlwSssnoy1A4aAkrJsJ646UAelzxJExjiuUljPQSJ/WqTG7ty0W1BE3HTiuHtr2aABRc7Gzx3Fdh4X8WLA5g10Ruh4R1WgC/YWCz+Yk+xl9Dxj6Vnv4WElyZIblTGDyr9VrsNTv9IbTFniSPfjh0PB/CuMTUlsb0XKpJ5RPzEcigCaRLnSbqKaC4wgPODxXtnwz13fJGkjeYkqgYHO0+teVa1bWt5ZLdRRmS2cZbYeVrqPg4baw1aNGlaa1k4jJPKHPegD6EzxVPVJ5Le0kkjGdozkc4/Crlcx401c6XbZwMMpHPcUAfLf7T2s3Oqah4aS6aORoPtYDoMZBEfb8K8RWWOJst8x9BXffG66+2a3aGEEJmbaPqFzXnEdu6j96cA9RQBbe9lvCEU7Ih1FEwcJtjO0epFQrIITlANo702W6aUbEGSaAGwSCEne5J9qvW13IXG0bF/M1lPAy5GQT3q7ao/lgSHA9hzQB2Wia01rhLaNmkPUluK77wv49vtMvLeaGAmaJxIqocKcdjggkEZBHcZryCMNCisMgHpzzXX+DZZftMaw24lnLZBbJx+VAHpuvWWmaJc3JktD5j/vbd92N0LfNGQQT1Ug8H2rnf8AhZnibTT5Nvq0i2gOFiDZKj612ni7w9q+peEtPvNXnjiaz3W8kjtx5BG6IDrkg+aPptFeSeIItKsl8vTi082cNMwJU/Su/B5hUwzSdpR7PVfd0+RjUoRnr1PevCvxPmtNH+26s813AFyygjce3esLxJ420/U72a+UQ/KuyMth/LT/ABNeT6ReXNxpTWPDJ/eFUUZgs0LkKp45HU/U9KOIqWXrEQxNCzlZ2t0v+vl0OnJcJXrSlS2XX0Ol1PxbcT3RNuPNUdGYYrCvJru+nEs8alR/CF4rT8PWEU0jM5U46jNdO1nCE4VQK+KxGbShLlSPvaGR4SkrWv53POp/IclHtkX0zzUcFkGVvJYJgdMV2VjoC6pqFzbI483OAp6D8a5zxNpcmj3LWlyjLMGOGXhGGP1r7DJ8LLM3GCdmz4bM4Qw1aUIbIx0hPnFJG8sep6GpGhaN/wBxMpPqtUXh+USclScA5zVm3tLlYRcw48sHkbhn8q97FcPRo0uf2qv06a/eefGu5O3KTmSeEhp90gPYNV2C4MyErH5IP/PSoyq3Nv5sylNv8TCpLO4hmiZSRIF9Fr5p+77rWp0lmGMRqHO6U9cDgUrpDc7m2GOQc7eOfxqnBehHMUbfKeMMpFaFnYRTM0itCCBkgPz+tZ2AoqwDHy7jY46rKM1atJp4Zw8/lug7Adamk0+zuCQ6s0g6YOKjk0tLWEytbygL3zmmB01v4g0eS32XVq6Ogzlc4NaekSaBqkZeKQLgH5N+D09K4GG7spAY1d1l/wBoVu+B9Ht9Q8UxR6lIU0+2je9vdn3jDEpdlwCDk7duVOQTntQB6F4lhttPg07TbG4jkS1jLy5AIMshyeQxGQuxT05X6VzTi6tCTEkflt12jiuLuNVvLnULi9nuv3txI0xcE4LMdx6k92NdH4X8UyWlwI9XMU1mwwGVeaANSxszPcFZfL8thkg8Cql54WSe53W86BQeUc5x9K7J9R0a70wzRqjbejIcEexFcRc36R3Yu4Ukwpy2w5GPpQBLd2VxpixyW1wF28Eq3FerfDfxA4MEkknmoeHUYOa4S5Frq+li7tY/MGP3iDg1b+Gi2un63DIju1mzYkif7yGgD6cRtygjoRkUy5d44mZF3EDOO9PjZWjVkPykAj6Vj+KNSOmWIlA68ZNAHzX+1Zrlzf8AhS1s55I5I49TWRCowR+7lGCK+X69t/aE1FdQjjkjBVWuFJHbOx68SoAsWbMrtt6kUskgViQdzH1pLIgM5Y4AFKtvvO/opPSgBpbevygsx6se1C+YFIjUgetSSukXygZpBNuTCqQaAJIZPKUs/wB8+tWbWeUuCEznpmqVvEztuYEj3q9DkHfIQq9gKAJ5/OY443/yrovDPijUtDRls3AcjG4dq55b7eNkKA+5GakBkWPBYAnnAoA6O/1++1SVpdSvJJpDwA7EgVQRg0wJmDt7VTs1Z/l2739BWhEU01SZlDSv0UL0oAvaSHe4YxwTzsOnzYWn6rdSSSFJvLhIH3QBkVUi1OeNSYmMWfasia5kaZyHLMerHmgC3CiSzeWY2YE/eZhxVkWey5CQlG+hziscCRR83mlutbehKjupy5cdu1AH0F8J7zT9P0YfbXTPOWaLpWV8WYLPVIDc6NH9pZRyVi2/rV/4f6da6ppwFxbwoqjB3ykE/hV/VLEW9pcpplvM0aqcBh8tAHzz5wil8q9gdGHqQastLHGo2SJGp9RV7X9JnuLmWacxjYSdq8Guba5DHyWi24PBbmgDTlu4VCl3WcD+Ad6JmspYVlMZtieNoPBqlG4UhUWNG/vMuRTLuV3IiY5Pqi8f/WoA1LZ1uE2SonlheGxk57D2qvcWLSgtZnaFP31OAeh/rXbWen66/gjwrd6Ppmp3DWlxdyNJaW7zCIh4ypYqDjpnn0rpPEsmnab4evtXtHSMeKmSS3iBxth+WSZR3GJSqf8AADQB5pYvJbQLIk+6TH3hypp7SvMjS3LvKvdUPSkmEMi7oCI8HnPIq48VpFYBoA0kpPzbelAGNFYJOTJbqxA6EjFPurMzxbTbM0i+j4zV2zgmMiRJvhVzkbuhrrrO0tbZEN3cRjcMbgQTQBy2leDtR1S3XybC5T/aPIIrSg8D6hYHllJB+45/xr3j4W32my2klg2oQBx9zIANdP4k0fSm0mX7fNDI2DiVQAwPrxQB8tzvLbSvBd2/kn0PRvpV3Rnkm3QRRkt+YIqx41W0e5MMVyszxE7WHUj3qLwi0UF7FLvIkU8oxwDQBOh1DScq0bPbnkgDlfwrsPCk1ixW7huVSRTlk6VQ1y/gmuFZJzay54DplD7VNZaCNUk2IUtLrGfNQ4R6APUo/HJVFMF1C20YKsay/EfjTTdWt1ttUxbMflVzyhP17V5TrGlz2zSBZjb3sP3hn5ZBXJTa1uzBO2QeDzkUAZnxps0sdX057bDK/nEENkHhOn515pPIA/Jy3vXY+OpBJNpY8wtGPNxk5xwtcc0PmuzLwvT60ANDhh0LOfyFCiQZEakE9TUkm2Fcfxe1JHccFdvNACwsYyWlOSPWrEE8jyAiPIz1NU443lkORlRV+ANkE4RF7UAWpjM6jIwxHArY8Ma/faHJvtmG76dDWOt8udsKhn7nrT0MoUk7RntQB6d4Q8Vav4h1uXRr+8il/tuE6fGtySY4pGZTG+ORkSLGOjcE4HeuJvIpYL2SC7DQ3ETmNreRSHjYHBVgeQQeDnvWZalmba2WbIYD6Z5+vNerad4L1b4g+KY77QjDNJfQR3Go3MiBYrO4ORKJMKAZGZWcIo6OvOPmoAq/CLwhpfjbVvsWqeJv7K1LcfK08W25p1AzmOUsFJwM42k98Yr3TV/hd4C8GeHbrWddt7zVls49wF3cH965OFQIm1CWYgDK9TXnuqeLvDXwptrjSPh8sWseKHXyb3XJwGSI55Vexwf4F+UYG4swIqh48+Ik/wARYvDtlYyFbS0t4bi7IGBJeNGNw+keSB/tFvQVjiK0aNNzl0OzA4SeKrRpw69fIxNN0+RJZ7lbW1tHuJWneG1jEcSFj91VAGABgD6c85NXrq9S0j/fNg1ftbVorcCSVScVzPieJRl/NzjoK+IjP61W993uz9LpQjRgoQ0S/I7v4Q3ltbyTXN6yN5jl/wB4mQorV+KS6XrulE6aq3U8eThYTxx69qxPhdZwX9osFxbxKAOXklK5rrb/AEyG0eWPTo5GwvIAJT86+8w8nSUXB2sfl2Km6tSUm73Z8zyo1jOY9QtpFGfusQQP0q+JoI0D25jjU+qitzxTpVxeahKZ/Kj2noMA1yMsqxE2zQkKDgM3NexiMS8bBON+b7Wulu6v1OSMeQ0ZLqIpuaZZB12gcGnFrO4g8x4GtiOMg9f0rNjYR7UVEDHo5AxT7uZ1Xy3KtnvGox+VeXKNtTUv28q7VjYReSf4iMmorqCKUlLeQBh/EpAqnZSNCyrLKBnoGHFarmObBuFt2OOsRwagCTS1kt4tzTEyr0I5FTmea43NcSu6jqiGmKIJYf3B8tl6kj+dWreG0WzkkBMlxjjy+lAGQLOG7djCH467uorqE0k2fgK8vLlT9p1SX7DbxB2BeGNllmYgjaCHECg5z98Yx1xbeKbzF8lJYzKcA46mvSvE2lWmjX9tp813BMNOgS2kdGDfvT88gBwMgOzKM8gKAelAHm2h+Fr/AFSIRw6fcL23g5BNa8PgHUbNmMjbSP4WOP0r2X4W3umRXLWbahAiSfdDqM/hXo2qaRpj2M326eC4THB4BA9jQB8p3a3OnS+Td2/l5GA4+6wqXSZiZ/KjU5b7p61vePUsI55LSG6WZVOU5+Ye1c54dEKXcbu7JLGwIB6GgDWMWo6ZI0scbMjnLRgYxXReGJrG8fzfPEVwp5Q8H8aXXNRgnijZ5Gt3AGG25FNstIXU3jSXy45n+5dQ8A/WgD1O08aiG2SKG8iLooG1zVXWvHlld2fkasoijzjzU+ZPxHavK9b0KezeSGa4Md3GMxTKflf61xlxrMsLtBcSZboxU5B/CgBvx3s7aPS7a6snWSGS5UB0OVPyP/hXi1eg/ECYPoVukcjGI3AIXPAO1q8+oAs2EayTfN0AzWgUB69BVHTP9cRnHFax2BMHk0AZdwkIYs2RmorcAZODk8KKuC1E9xkcitez0mSc/u12xjq5HAoAxFyOGc5PYCpX8sja5Nal+tvbDyrZvMfozCs1lHYD+tAEluAq/IOKuxZC8YGfzqkIZGG4A7alUkEDOKANS1nFup8tWZzV1pYpod9xKVlHQKuax4WKSjD45rcuZYFEMflKSRySKAMyadREQzsxPTpVETOp4RT6CumXRzfLmGDdjk4GKyZrY2Vzh15B7igBqRSSJ8z4lb7q10GlJPa26Bgmc9QoJ/lWdp8ol1GAFFOWH3vlFeraxctp2k23k2NsEZeXQqf1oAd4cvbSSJFadobkdctXdaXG15dQ2n2iZLd2G50xgivDbVvM1MzJGME5Zt2BXsGhRXVhape2kmQV5WQ8Y+lAHFfGSxhttY+z6bbu8YGDcFu9eYxymKfZc/OB6mvaPFAOo2txIqJ5oBzjpmvFtUj2oVu4DHLuOCO9AGvHBayxmRV2kd81VuoQo3q4cVnaf5pXaHKIOxOQanubiWVVSCILt6sueaALsUSTRfPM/ljkrjFRk2nkOqu0mPullwQfrVVUu7gAcoO5LcU+WfFsLUxgvn7woAuW4LQMSpRPXBrU06QfZmjil3J7LWJAJgBFNKNvXYR1/GnqZl3/AGYLDjuD1oA34288CIY3L/e4rS0nRodQLLcCQhRkbDyDXKs7zxxC7YDnhlGM12OiaTOsSXMSefb4G4hsEUAZF/HrNhqm1Im2oMJInXHvXpvhrV5v7Ka31UvcRuoDKByPpWv4Y0bSdW0qSSab99EeqkFgPcGpPFvhy3tNGW70eRnkC5LxjaQfcUAeX+L9BiNz9rss9dwBb5itcc+s28MwCyMsinDKw6V2Gsau91YtBqMW2ZMhZF4P41w32e2kvg3Akz36GgDs4tZt57dA8yS9ARivWfAkUOq6aYmZUkVfkZDXiUGjact3GbjMLHHQ4Brv/C9u2i3ySQSSC3PKyBuPxoAh8XXn2XULi0vIW+0p0bswryTXUigldrfOG5IPY17h44mtb+QXgKSTKMOEPUfSvHteaF5pBGFZW5U/0oA4jVJmuXs45Twm8CozGCMY4FSaim28tgOMlv5U5doXnlqAM+5SInL5BA9arw7DITyVHQVdlgE8wx0rTtNKechYEzj7x7CgDITdnluvQDtUhKBdrk5NbF7DbWC+WjLNP/FgcCsp1zn5cE9xQAW4VB8g4q/AxA3KAPc81RSF3HyqcCplJXg/KKAPZPhx8LornRo/F3ju/Gh+FQomQs+2a7UjjbjlFbtjLt/CBkGt/V/GU/jTQda8P+AoD4f8N6PZNdtbxDypbu3XiQs3RR8ykrncw3ZJJ214dNqd/cWVhZXV9cTWVln7Lbu5KQ7iS21egzk/5xXR+H9Wg0a/028kjd1jlBnVCVMsR4dDgjhlyCO4JHQkUAc688caMN77eigLjgcVreF7qS2wYsAZz0rU1/ww1prl7psYS4EEhCTxqAssZAMcgwTw6EMPmPB61z80E2lzkHIweR/+qubGUXWp8qPWyfG08HX5qmzO+Or5i/fPg47VzepXbTy5RiRkVkrcvMQT39TivUoD/Z/hmCWCxtSW+86FWJ+teXhMt5Jc2x9JmWdU6MOWmr8xH4Wv7YxJHPK0dxwFOcfpXfWTSSeXDFcTbJDgyJg14lNKbrU1nSFd2cn59oH6V6v4Vtp0tIr61kIdR91j8te6fCmb8atMt7HyIdPhkuZSoLylwMV4wxktplS5y/OdpI4r3fxBK2p+aZVTzgOSOleH61E0Us/2uAqNxCuoq4NbPZ72V3+IrF6BLS5UsIwCB61FcxoVLBw4XjHesawEu7ajsi+uavTXD+X5UUa7+7jrUvR6AiaG3jnwztgr2KdKkaa0BZQVYKO6YIP1xVJUu5Ywm0qf72akaX7LC8Eq7mfowJpDLVnlw5VTt9RWlpcioGWKTdn7wx0rEtVmj2qZMRt2IqcB1kYQKkbAZ3igD0DwJbQ3erSPdyAWumwSX0pMiofk+4oB67nZFxlSQ5wQeay9N0mK8mEVx5si4+Y7vm/PJ/P6VETPY/D9ftlyRNrFzwkbFSLeHIy2G5V5WOMj70JOT2n8PaRPNCk9pmZF6ru5oAra1aappt1HHbRGS2Q/I4Hzr9fWu98FaxfQ2pXUHaWN1wY8c4ra8HaXpmqxTQXchSRFyqsfmB/GtbV/DFguhPPp0vm3CHB2DYy+/vQB5l4z0G2vpTcWW5O6iQ4PuK4K41OK2bypHdJ4zgqRnNdvf6rL5EtnqsO4L0kH3hXn13BbzXYLud2flYjP50AdbY63BPZANMrYH3SK9P8AhwbbUIRbSFQh+6ymvHU0mxPkyXIMW4feXgGu30DTl024iubKWVoT/GrdDQBr+OpW0rUXtLpHc9YpB0Irx/xIIRcNNEGDtksDXuXjG5ttWtI5WkSW4iXjB5avG/EjwGf5EGxuP90+9AHnut3LvYLESfLEu4D8DWFW94iQLApAxl/6Vg0AW9N/1zfStRIgT8xqjo1rPO1xNDBJJFboJJnVSVjUsFBY9huZR9SB3rUtrhVfLL+dAE8LRIwCxHaOvvU17qsslv8AZ41EcPfbwTVW5ug78ABfaoY5MOGZcqOxoAdKQsQxHtz39ap5Jbpir1zctPztAHQADpVdEYthRlqALCMwgI3hF6kHrVdCDJgcn1rUs9JaSJpppVVQOTWdPGIJDtViuePegCzA0ET7pWyfQVIbprglgMY6VnCRS2XXAFOLuVwgAB70AdhoF+bTCTP5cb/fcNziuu8Qav8AD8eGgtnHLcamG6huSf8ACvHS0vR5Pk7j1qSKJcgRxgH1FAG1HfCfUY2+zgLuwFAzXX6hbzyQxRyLJEoGRk44+lcVplwltf27n5gjgk12fiTVJtWhQouSFCgLxQBUNzDa3ESsGbOOd2AK9y8KwS6xobxW9yhjEeXmLZ2jHbivm9IpYmKzgmQ9FznFer/C3xPd6fKkX2JHGQg3NjP15oAfLLa2l1PBdXDn5ioJ4B5615t4mtVjvptkjSr1GDkCvbfiWIbZkmvDFbXk6b1SMBl/GvF9euI5o/mlRJCcEquAaAMHz44oF+YGTsM1E91ISuDtA6kVRugq3G0/mKtMIliIWTOR3oAt296TOdzZQeverlwYZikpQRHPAPesK1gMxJU8KfWtOSd7grFuRnX7pC0AatxqEcUcWGjdTwR3FW7KKKSEojIyucjnmuZuGkaZVMYJxgjFX7OaBXwVKyJ0HSgDoNL0uK61W3gZ9oLgEE5Fevr4SmtdLPky+VEw+9H1H4V4xoWrxxXnnyWxDryGIr1Hw940jKmO9SaS1YcNH1WgDR0trDRQIdSlZJm6XCfdYe4rYtddtNNn8iWZLi1uF/hfK/XFeZ+J7vT7u+YwTz+UfUHj6iuAiupYtS22s7E7uEbPP0zQB3XjiW0gvZ2+zlo3yY5IzwfYiuDKwXpLwPsYfwseRXUiSO8geDVUdJFG5SvFcjPFbxyyNG7MVPbrQBqbrkQosrgsv3SxyDXbeEby+NuyShmiA5BORXK6GkVwoUq0kfcHqK6eFZ9FRPIVzbz/AMLc5+hoAZrrQiVntpHjc9YyeDXneuRywzv8w2NyB6V3mrXMF1YSBl+cHr3FcJqEzOPKugSB0PfFAHMX0m66ts9t38qesYJ+bik1iIW95asrB42JwR+AqWKZRIOOnrQBPH5SYCR5J6k1bm1V0tjb2yCNT95h1qpc3QbAUY+lVlk3HlePegCTgQk7OvVjVJiWPStC4uWlUDYqqo4AqoAd3TLGgCxAzCLAIT3PeoCw34HzVpafpj3O55JFVRycmqd5CsUp8sMYx39aAJY/JUhpWGBzgHmpHvPP+VFIVenes7zAxG8YAp6ynBEYwDQB6glxdXnhLSteNws0lpjSroMw3xKAXgc85wyFkB2gDyD1JNaj6n4AXwzc/a0luNUKZBLclvauF+Ha/wBoX154duruaOPV4fJt0RyI2vV+a33DBGDINm7HAkPTO4c1KwfbtXJ6DH+fXNd2GwtOrSqVJSs49CZSaehqXGoxzXCCG28uAHCqeTiuwkimk0yJRFJFG4yCDgVwUDLE0ZPzEHJB4xXfanrUmo6TbxIOI1wMcZrh2Lbb0ZnTyRWax+YS+DjrgV7N8OTJqWnLbWc0cjMnO5uIh+PWvn7yZ4n3TqRu+6pOa9B+G2v3Wk3aD7GkiA8EtjNAjotXMGmaxcxXdy7AHG7GAa868YWsf2xmilaRGG4BSa9v8eyxzaXb6jqaRWrTriNYvm/OvEdbuUeF98sauOjquMigDl0ljhhYsx39AOlMe7lK4Tge3NVNQ2o4GdwPORU0PlJArJITnqDQBajvT5yDflfU1euWguIlLRqmOjHvXP20JllYKR6mtOSdmiW2JU4+7heQa1jT517mr6ivbc1nvUhs02tE23qp61c0iEX80cVovmzXTCJIVBZmY8AADvmuZuWm+RGRdw45HWuv+H6XFvcXeswwMkWjwm4M+zckczfJB1VlJ81lIUjnaemCaUqfLFSugubnjqyQ+KF0wz7l01ItPBU5UeWAHwCMgGTzGx23V6BpHhCS30xZLSQKhXlk6/WvFdO1WI34d7d3Rfus3OR25r07w542Mbr5kcklr91kj6r9KzGa2mQ2uiSM2qzNJuPyXCcFfqK2oNctNMljniuUuLeY7SFf+YrgvGGoaZfXKtbTXOxuoYYIrzW9uPs+pH7Nct14z0agD0v4gz2Rv5LiKDfbyDhozgqfQ15i7QXkjLETGwP3WNdPa3BuEEGrRttdcgrx+Ncxe21qlzL5cjNsPy+tAFuEXUcHlSSbk6oScgV1ng67vgxQbjGPxBrmtB8ub5VDOP4kaustoZdJgW7sVkETnaQ3K/SgCzr7QHMkbNDOvbPBrzrxDHNHKZQ3yv1Fd3dXsFzazLMnOOh4IrgtRmcboZQXizxnrj2NAHI625a2UHtJ/SsWug8RwoltHJGwKs/TuOK5+gCSCQxuGX8RWlBKZuV7dc9ayakhlaJsqcUAbqMvQYOKaWYngVStZt7ZJx7VbWNpXAVtoJ/KgBSSSeM49KXcVTHTPer09vDax4EokkI5A7VTJVRk0AaGlNmVfNYhB0B6Gotclke4yWAA4AFQRSBhuU4I6VBctuO53yfWgCmRM0gLYVR701/tCISH3D+VMlm+Yr8x96sKxKjJO3HTFAGv4V8Py65a6jeS6nY6daaeqSTTXgmI+d9igCKN2JyR2ro7zwlqGlJqEtxJbONOnhgnEMhYkTRl45F45RgOvByQCBVLwT4qj8LaXraLbQXNzeLAIkubWO4hISUM29XyMEAgYGQeeODXS6R478P3XjfUbvUINVk0fW4P9PtnCNJFKGVwI2LYZVdVAJ2naSMccgFLU/C8elS7L5Va5MEc5WNyfL3qHCtkfeAIyO1Zxht/soKNJ5vYZzWn4t1sXuqXWoXsiNLdTNKyRNwuT0+g6D2Fcybz5Xa2Zhnn6UATQXTWzFjKm/PzBueK6DRb3TzNE0rzR7iCXR+D+FcPb8z75V8zce561sWkCtqEWyRUUHhSaAPZ/EVjFeaLHfWt4Lny0xtfOVGK8s1BZr4vEipsH8QGOa7j4e+dNdXdm94TvX5E25BPp9KpeKbSbR9UA1O2RkB7IApoA8nuIZLZ2EgIcHGGHWqxAOd4KnPavSfGOl6dPZJc6fJ94ZPGQn41wJt3YnbudRxuA4oAdCEEeUbHv3qSNJo1WXtngjiq5jKfKQRmplmaODy1OT6GgC+08ioAURyf4x1FV5biRJQGVnFVQZJI8Z+YeneiWJkCkyZY9u4oA3orp3tmjhVlZhgA9M113w91qTStQje6t2IGAQTuU/hXndnfSQZ3Mx45HrXT+HNSt7qUebIoK8mNzjcPagD23WNItvEm2Q2kECkZV4OK8o8SWEOlzyRgEyxHo6YP1BqS38WXOm6sp06WWOzQ/KkhyAe4zXQ+JtU0zxjZxzSTLYXhG3zBgqT7igDiH8UH7MINQt1kQcJKPvL7E1zFxeOJmlt1BGa0PEFm1vGI5ZFZlOMr0PvXPgqVYBiHFAHR6LrU0fz7FV05+vtXpekeJLe90tLO6VY+dy7+qn2NeN2MRKlhMFcD7p71rxaiqokc4KnoGBoA6jxNMwvzBPsVto2yoOHH+NctrF3BFZFnlVpF42nrUuu6vFHConG9AuUbPINcBe3b3UpZycdhQAXNy80+89jkD0q5bzeccAYI65r2fwyuuXfgvTbZU8R+HdPTTZA17bbJtHmQhmMtwvCq7Z2nJZvukDOFrwaKRo33KcGgDfRlU44JpruS3A/Ks+3n8yQbjt9feruxnwQQPrQA8sScfpQMqDuwM+taH2WG3gUySh5WGcDtVEYyS1AFnTyfNUOxWPv71Z12Rm27WAjA4xVCN1YnB6elR3Dl2+dxx2oApP5rsOy+ppCs4yVkBHpTJpgrFeTnpipYmYoADgehoAnsg8bxyJI6zIwdGRiCrA5BBHSu88fWSRarb61b+StnrlsNUiEIOIndm82H7oHySB1GM8BeecVwaPtbIxx611mhxQa94F1WCA7L/RJRfpFsJMttKUimIwnVXFueWAwzkdM1rRjGU1GezE12DTdLhuo/OuYnIIyjZ4b3p8UVr5Mg3OrA4UZJpoMVjpkfnum44yiPk1nG8RpGa2LA9cdxWXoO5KszW8rMZArjoHHatjSr6xdle4eRWJwXjfAH4VxxZ5LrzJd0gzznvWokIeWHYyxKedrHigD3B7K31Pw3HJaXzTLEMrE/UV5dqLTXJa3jRO4Y7cYrpfArOmuLBJeMkLrjaBkH8Ks+NtMvNLuVkvoY5ID82RHgEe5oA8ivraS0nbzNy4Pykjg1SYgsSylSfSvUdesdL1HRUuLM7ZgMGMcgV5y9q4dkQmTHUhcimnYQ2227CVbGPzqdIpthlHIB6g1XeIxHlT9RU0EzRRlFY5bselbYfESw8+eISXMrMvJNN5OfLjlZuACeRXQ3+oXOm/D6ysFjcNq94b522gmSCIGOLkNnaZPP4IzmMEYB55fSrK81i/ttNs4991dSpBCisF3OzAKMngckdTj1rZ+IF/JqfiGUtMWtLJV0+ziywCW8I8tMAs2MhdxwSMsSOtZ1J88nJJLyQJW6leyuj5O1EdHI5yK6DwdqVxpmoJJNC/DZypyCPpXFWl08EnLnjoK6LQtTiubhY5ZBE4PG/oagZ7vqEdp4qtYiLK2jR/44vlbPvXmfizRbfSJ5ITy6/MvmJnP0NVZvEk2nX0P9lSzQRKQXTdlc+oNdNq/iXT/F2kxx6iVt7qLjz0wT06kUAcJB4ma3g+z3UCzWw6FvvJ9K5y/vRJcNLbDjORmtXXtPNjE8T3EcwBysijhhXLoyAlCxB7c0Abmk6tKJfmQKw5Br0rw34qiksXgvEVFkOHDDjPqK8fs4d7fNNsYdM962YL8Qw+XcJkZ+8DQB2PiiYRyRRtt8p/8AVzL/ACNcpfXMEdrL50q5TkZ6mn6nqkUdlGJf3kB9+Qa4LU75ruU8kIDxQAy/uzcucfcB4FVKKKACiiigB0UjRvuXrVy3mctksSepqjT4pGjcMvWgDYEoAHXB9ahuJQxCLksaSORWjMhIz3HpTIWbBZzjJ4zQBZ3+XGFHHrVG5mzlRye9JK0hlBTJA6e9ErlApZOfegC1pkKzSBSRHnjc/NX9TtRasEjYsuPvHvWKs5WcScjHYVfubx5497gqMYHPWgDPNw4dxzip7G5Ecm7OJOxxVUyfvN+OvY1PFPHkZVc/SgDajmhZ98uWYjJz0q1a6lbQxyeXbjnjnmsfCnGeM1JKo2gBfyNAG3p91ZtfIZotxboM4AqndXBF9Lsj2uG4I7VWt0MmNi4Yd6v2VlbbWe6vDC/XpnNAHa+Ar3+yyb0r9pL/AClS+Gre8c2o1DSRq32WZQzbQM5XP0rz21v5LaxMNvJvhdurDn8K6O71W+l0dLV/Pt0U7gobGffmgCTQtWhfTpLDUYklVx8uVxsrmtUzY3m6KMCBjjA5FULjVr6BwWk/dqcfMOtW7e9S+jVHO1/QgnNAHY6FdaHc2wtSx+0P99HjBU/T0qr4q8DQw/6bp7MbcpnZnkGuZs9P1GK+MlvaE7Rxt5NdJFe63ay28U8xCgbtkykfrQBwktpNbqHdCFzj61DJKM89B616nqVvZa1EkkkkVvevwNuCn4iuE8TeE9T0yRJJYCI5BlGU5VvcUAZLTgKvyqfqKryYGWTgg5BFVrhpVUJyi55yKbE8gcjblQPzoA6LR9cMED214PMgbkNjkGpowl5FJHE8eV+Zc8E1zyksu7ZgelWbRS/3OGHocUASXMssg8qVyGXgA1XIx1/1g9O9Tzh1X94p+tQMhZd+c0APlkHy84IpJrtVjPmdR096imkRIQzEf1rFlkMjkk8dqAJLu5kuHy5OB0FQUUUASrbTtayXSwyG2jdY3lCkorsGKqT0BIRyB32n0NRV1Onf8kt8Q/8AYZ03/wBEX9ctQAqMUYMOo6Vbhnd2yzHcewqnSo5Rgy9RQBtLN/Fkk9M1HcSqFwM7m6VDDMsi7nIBHUUsbMzMzYCdjQBPGfKiAxgmqt3NglepIplyXJwm4j+dNkd1Qb4zn1xQBPpyLJKo+6T/ABN2rW1GyW2jQxt5m7knpWB55Lq/QDsK0nvpJ4V3AqifrQBQeZ1mxnj0rd8A6pYaf4qsbjWY2l01i0F0FUFhDIpjkKjB5CMxGOc4wRXOyyh5dwHSpY51HLAfgOlDA67xJpVxoHiK90nWGV760maGQxNlGx3X1B69B7gHIqtaX9rBK7R2+cDGc5rS8S/2fqfhXw/q1kdl2qNp+oQ5yRJEF8qX7xIVosKBtUZhfGa5llURgKPxzVSt9kDXgu7SS5ieWLv90cCjWbhPt52RY/u47VlwqWKIqc9ia0bKzheUte3JgxwD1qQOm8EXBhuft7/vnj/gY7fyru/Eif29ok+ofZZ0SJeVD5H8+a8v0+9axhn+xzGWNjglxn8q6Sz1a/XQ3tlE0EcgzvXgPQAnhrVUtI5ba9iSS3kBXYV6fjWPr0YtbkzWcSrCewyQazbzUryCRsS/KpzlhnNTWmp/a4ykxCOTnJBOfpQB1Phu/wBEMKxXbMl1IMYKgqfarPiHwPaXFrFfaaWRMHegPX6Vxg029/tCN7a13gfMCDnNdIl1rtpFCryyRB2yEkU4ptW1ApeDG1bwxe6j4k06Ipc6VAViuHj3KJZv3QHTbu2NKw3ZGVBIOCDxzybcKVCj8v0r3XxBcR3Hg3S9J1IRWb3B/tFtoHJOUiyCuQAgZhg4IkH4eWeJ/B2o2saXaxiSBzhZYjlW/wAKQGB54MfCg49agcqxZlwPpVa4M1uGQqyHODkdKhjeQSADDL69qAOg0TW3sy8c2ZIJBhgQM1cR4ruWWOF1CMMqWyCK5xHZwSExip7Ub2wBg0AWblpELQzMQAeO4/CqrLxhvvYyDViVJMHzFLAdz2quw3JuHOKAHM48lQ3UUr3aKmJD8tQu6CDexAA61jTyl2JGdnagCW8vJJ/l3HyweBVWiigAooooAKKKKACiiigDr/hZJ4dh8e6HJ4zjEmgmVhcqSdvKMEZsEHAfaT2wDweQfQv2j7fwFFrukt4Dm09meFzerp0geBcFfLI25UMfnyB6DPv4dTo22uCMZ9+1AGmoJmyMbKgvZVf5I+3U16D8XLXwFpg0UfDzVbrUFmgZrzzyWKH5dhJKj5j82R2wOma8zcFWxnI60ASOqcNu4x0705bhQAChb6mo95Z8gAdqjJ5z3oAc5BYkd6RGAcEjIpflLAseD1xU7PAi4iBL+poAnW5Gzc6kelRx3Ls5LluPuqKrySF8ZqSCRkcDK89/SgDbsZzc7ICQm8496vT2Re5a3bdIyf3B1rBs5GExYt34wK6PSic7ZlbzZvlDbgAB70AVL6Y741jRowgxtPWr0WryNte4fzP4cMc4FVdW0w207otxE20ZGGz+FZEasrfMeO/FAHQeIvLZVVVUZAYDaAKyI2nR8ofLIHDA9K07NRcmFfMLbSAQwzVjW7dYh5dvbhGUZLE5z+lAFTT/ABDfWs/mRXJDDhg/Rq3rnxVdayEja4jgYcH5R81cQAGkyfv/AE4prqCNz7SAeD3oA9PtHtXt4k8iP7UG2mQHr7moNYvHtrhLa7uS8K8ou/cB9K4LSL25t71ZLZmJBGFYZBpNYuJWv5JLmNYpmOcL0FAHYXOkWd/ayXCFEK84B65rlr/TLixwZU2xsflbsaq297JEwZ3Yoeu2tX+0IL2xMLzSZB+VW6UAUAmY+TxUUhaNd0JOexFS+YYzhguOlRF9q47GgAtdTdiYp1zx3onljgQvkbf7uar3Yj8oM3Ucg981mTzNMcsaANzQ/DWr+Job2601LQW1q8ccsl1fQWqK0m7YoMrqCTsbgZ6Vkapp93pWo3NhqMElveW0jRSxSDDIwOCDXbfD3xNoeheF9ctte02DVvtOoafMtjMZU8yOMXHmMrIQAw3qAGyDu+6ecYHj+7g1DxfqV/bar/asV5KbgXJhMLfPztZCAFZc4IXK8cEigDn6K6S08R6XBawxS+DNAuZI0VGmlmvg8hAwWYLchcnqcAD0A6VL/wAJPpH/AEIvhv8A7/6h/wDJVABp3/JLfEP/AGGdN/8ARF/XLV6dYeI9LPw312UeDNAWNdW09TCJr7Y5MN6QxP2ndkbSBggfMcg8Ec1/wk+kf9CL4b/7/wCof/JVAHLUV1P/AAk+kf8AQi+G/wDv/qH/AMlVzd3Kk91NLFBHbxyOzrDEWKRgnIVSxLYHQZJPqT1oAveGJNOi8R6Y+uxPNpK3UTXkaEhnhDjeowQclc4wR9RXt/7RUvw2n0zQz4COmi+LHzhpy7U8nHHmAcb846/N1z2r59p8ThSTzn2oA0iC0iCPkDk0y9lQjy4+W7n0rvfiFa+AtO8LeGX8HarPeanPBnUY3XOxtq8n5RtO7IwCeB+J80k4bdn71AC7FKg7xx1FSJMqqPlJx0BNQ+YTtAAGKa2dxzjNADpiGfcMDPYUitj3HpSt82Oee9Tg26JkAl8UAdr4Ae31ax1jw5eExyahAJ7Bs8C9gDPEvLKMSI00QB3fNIuBXGi5aSQbiwTsB3qXTNWudMv7W+spGju7aRZYnUldjq24H8wPSt74hWWnab4meTw7KJdEvo1vbDL7jFFIAfJY7m+aMlo2+Y8pzzwADPsrpmTYcIWOOetalzY7ZI7dm80lcjbXO27t54JYYHoM10OmSlJfOmWQ54Qg4oAhvMRwxwIjRbOuepqxbarKIkErkrGMBGOeKdrGmfZ5U/0mM7xv+9kj2rBCusp3NnnrQB02tSxyWMTKoXzB2XA/OsBVkVl2gJjoQa0LQedAsYkJCnOGrS1O0igt0SO32yMMlwePyoAy7TW723mUpcssidC3Q12Gja/f+KNQ07RlvI7SW4mSLzzHkKCcFj7AZYn0HWvO5QpkG4fMOK6vwfex6Jpmv60UDXsdt/Z9gw48qW4Dq8nDKeIlnAxuAZ1JFAHY61rFrrGq3941rGGaXFuqgAxQKAscfodqKq5HXGec5rN1u7ls44opbk/Z25CB8gH6dq83tLqWC5D27su3pnGP5Vd8QXdxPcie7hWN2UY2DAPvQB1badZ6tFIw2KVXdn1rmL/SJrRWl8vNuThXXpWbb3kiNvWQ4HXFbFrqlvPC8Ek0gBGduOKAM6Jcx5BFMZdo3RnkelSbzEexHamM+ASBwetADYdTlSXy5xkGnyyRqrSDAHpUFwI2iPmHjsay5Z2kAB+6OlAC3U/mykjhfSoKKKACiiigAooooAKKKKACiiigAooooAM04c02jNAC54xSHmijB9KACl6eh9s0lOY5XjHFACDpT1R88An8KjHHNXrSQt96THoKAHQq24E/Lnpiri7w/lSs23rmkEGAGBGPepJpVAIyWJ4oArq+ybA3H3qwzZ+bcpA9qks9u/YQCQCaR2TkYA9aANPSdQgs3+0ndJOBhVI4+tStdG4kc4cmQcgnp+FYUbA7l3cgcYrU0q9WC9haYblIwRQBXu7cBpFkKxMvIA71lXCMQfLxgjnNej614b3aEdSSe3ID/KitlmHNcIbYTziLcM5xnNAFGzLhWV3I29B6VsrLFeWix3J/fR9HIzke9V7zR7iyKPIpKSfdYc1W8l4m37yQewoAZNAiOPLJIzk0zbvdhgr71cKqyjruqJlGe4P0oAqTZyY2ch+1TPJ5cQ8zj096humRZfmLcDg1TllaQjceBQATStI3zHio6KKACiiigAooooA6nTv+SW+If+wzpv8A6Iv65auksLmBfhvrtq00YuZNW0+RIi4Dsiw3oZgOpALoCe24eorm6ACiiigAooooAKeo3cE0ygcUAL0zSUUYOM80AA607HHrTadnK8dqAEGN3PFdyTFr3wzaPyoY9T8P3AkDKCZLi0nbB3ccLHLtxyB/pBwAfvcL396674c6pYWXiWFPEWG0W8RrG9O0Fo4pBt81cq3zRsVkHBOUGKAMCFCNrHCr2x3q4BKjKGZ9re1WdR0ufT9QvLO6wLq2meGVeQQyttI59wew9+ajeVVABYntQBXkIimwhZh2NWN3mDIdSR2K0W20TIjDOfWnyuqsRtAPtQBd0q7t7edZpizPGMouOCfSrkuoG6m85lcs4OVJxj6VgIwMuzd7irtpc+TLE7jcFPT1oAlu7UhyjhUUrkMAea2PHTW1h4Y8MaFpyL50dt/aeoSDcDJNcYaMMCSpCwrDtKnHztwCTXWeH/CFn4lljuLy8gttOVhNcuvzSRwL88pXg4IRW5wcHtiuB8W6h/bniXUL4QJaLcTs8dsnyi3Q8LGMAcKoC9B0oA5m23q5V2wo5xW3a3EU9oba5JbAyjnkiornRJ4IRchd8DHblTnBqobd4mDhjgDoBzQAy5tUQkxk5PpTDlnC7SDjrVsbXUZyTTCozg5B+lAFSVinyMxGelSIxihBkPHrTLvYCobdt9apTzM/ylsqOgoAW4nMrY6L2BqGiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAcn3hU9xwF+lFFAEMf3mpg60UUATQfej+tTWw/040UUAaMn3V+tVurnPrRRQBO/BUjrT5ACOaKKAK0IH2o8DpWtDzeKD0wOKKKAOk0kk6aQTwHbisfRYozNNlE9envRRQBsXBJ04AngBse1c1Jxbce9FFAFKEnd1NJITuPPeiigDP1X/AI+R9Kp0UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFADlqdxiGPHrRRQBGv36jb71FFADk6D61YJIvkxxkgHHpmiigD0f40W0Fn45vo7SGKCNrazlKxIFBd7aNmbA7liST3JJrgpP8AWH6UUUATN9wVI/KjPpRRQBQmJ+1gZ4rcUAmDPNFFAHpfwphiltPGQljRxFpTum5QdjeZGuR6HazDPoxHevPVUf8ACT3i4G0OwA7daKKAN5uLF1HC7unbpXLJykpP96iigCq/EoxxTJv9aaKKAKeq/ejrOoooAKKKKACiiigAooooAKKKKAP/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Two-dimensional color-flow Doppler four-chamber image across common AV valve in systole in a patient with an AV canal defect. In the right panel, color Doppler image demonstrates right AV valve regurgitation (asterisk), left AV valve regurgitation (double asterisk) and left-to-right shunting (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_56_12166=[""].join("\n");
var outline_f11_56_12166=null;
var title_f11_56_12167="Breast cancer guide to diagnosis and treatment";
var content_f11_56_12167=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?11/56/12167/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/56/12167/contributors\" id=\"au2913\">",
"       Christine Laronga, MD, FACS",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?11/56/12167/contributors\">",
"       Section Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/56/12167/contributors\" id=\"se4959\">",
"       Daniel F Hayes, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/56/12167/contributors\" id=\"se2589\">",
"       Anees B Chagpar, MD, MSc, MA, MPH, FACS, FRCS(C)",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?11/56/12167/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/56/12167/contributors\" id=\"de3439\">",
"       Rosemary B Duda, MD, MPH, FACS",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?11/56/12167?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Breast cancer is the most common female cancer in the United States, the second most common cause of cancer death in women (after lung cancer), and the main cause of death in women ages 45 to 55. When found and treated early, breast cancer is often curable.",
"    </p>",
"    <p>",
"     UpToDate contains a number of patient information articles that discuss breast cancer. The purpose of this overview is to provide a guide to the issues and questions that arise in women with newly diagnosed breast cancer. This topic can serve as a \"road map\" to the patient information articles that are relevant to your particular situation.",
"    </p>",
"    <p>",
"     This guide will focus only on the diagnosis and treatment of breast cancer. Other articles within UpToDate discuss the risk factors for breast cancer and methods to prevent breast cancer in women who are at high risk. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/6/44134?source=see_link\">",
"      \"Patient information: Factors that modify breast cancer risk in women (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/31/499?source=see_link\">",
"      \"Patient information: Medications for the prevention of breast cancer (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      IMPROVEMENTS IN CANCER CARE",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Increased screening",
"     </span>",
"     &nbsp;&mdash;&nbsp;The death rate from breast cancer has declined about 20 percent over the past decade. This is due in part to increased screening as well as earlier and improved treatment for breast cancer. Screening usually detects the disease at an earlier stage when the chances of successful treatment are higher. Early detection and treatment of breast cancer improve survival because the breast tumor can be removed before it has a chance to spread (metastasize). In addition, other treatments, called adjuvant systemic therapies (described below) can be used to prevent cancer cells that have escaped the breast from growing in other organs. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/40/36481?source=see_link\">",
"      \"Patient information: Breast cancer screening (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Adjuvant systemic therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Systemic (body-wide) anti-cancer treatment that is given before or after surgery is called adjuvant systemic therapy. Adjuvant systemic therapy prevents cancer cells that may have escaped from the breast before detection from growing into metastases, which are usually not curable. Thus, adjuvant systemic therapy also contributes to the decline in mortality due to breast cancer.",
"    </p>",
"    <p>",
"     Three types of anticancer agents are used for breast cancer adjuvant therapy:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Endocrine therapy (Anti-estrogen treatment)",
"      </li>",
"      <li>",
"       Chemotherapy",
"      </li>",
"      <li>",
"       Molecularly targeted therapy against a protein (termed HER2)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The goal of adjuvant systemic therapy is to eliminate or prevent the growth of any cancer cells that may have escaped the breast and that might grow in other organs. Areas of breast cancer growth outside the breast are called &ldquo;metastases.&rdquo; Axillary lymph nodes are the first and therefore the most common location of metastatic disease. Patients with metastases or cancer cells in other organs such as liver, lung, bone are rarely cured. However, adjuvant systemic therapy may prevent metastases in a large fraction of patients and thus cure many women who would not be cured otherwise. Adjuvant systemic therapy, therefore, has become an important component of breast cancer treatment because it significantly decreases the chance that a cancer will return. This in turn improves the chances of surviving breast cancer.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      DIAGNOSING BREAST CANCER",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Abnormal lump",
"     </span>",
"     &nbsp;&mdash;&nbsp;Breast cancer can be discovered when a lump or other change in the breast or armpit is found by a woman herself or by her healthcare provider. In addition to a lump, other abnormal changes may include dimpling of the skin, a change in the size or shape of one breast, inversion (pulling in) of the nipple when it previously pointed outward, or a discoloration of the skin of the breast.",
"    </p>",
"    <p>",
"     To evaluate a breast lump, a mammogram and a breast ultrasound are usually recommended. A breast biopsy may also be recommended (see",
"     <a class=\"local\" href=\"#H9\">",
"      'Breast biopsy'",
"     </a>",
"     below). A suspicious lump should never be ignored, even if a mammogram is negative. Up to 20 percent of new breast cancers are not visible on a mammogram.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Mammogram",
"     </span>",
"     &nbsp;&mdash;&nbsp;A mammogram is a low-dose x-ray of the breast. The breast tissue is compressed for the x-ray, which decreases the thickness of the tissue and holds the breast in position, so the radiologist can find abnormalities more accurately. Each breast is compressed between 2 panels and x-rayed from two directions (top-down and side-to-side) to make sure all the tissue is examined. Mammograms are currently the best screening modality to detect breast cancer.",
"    </p>",
"    <p>",
"     Breast cancer is often diagnosed with a routine mammogram, before a lump or other change in the breast develops. Even if the mammogram is performed because a lump was felt in one breast, both breasts need to be examined because there is a small risk of having cancer in both breasts.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2397203\">",
"     <span class=\"h3\">",
"      Breast ultrasound",
"     </span>",
"     &nbsp;&mdash;&nbsp;An ultrasound uses sound waves to look at breast tissue and can tell if a lump is a fluid filled cyst or a solid lump. An ultrasound is only used to examine a limited area of the breast and is not used as a screening test of the entire breast.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Breast MRI",
"     </span>",
"     &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) uses a strong magnet to create a detailed image of a part of the body. It does not use x-rays or radiation, but does require injection of a contrast agent into a vein. Breast MRI may be recommended to aid in the diagnosis of breast cancer in selected situations. MRI is not recommended to detect breast cancer in most women because it is not as good as a mammogram for certain breast conditions, such as ductal carcinoma in situ (a type of noninvasive or early breast cancer). In addition MRI testing is more likely to identify suspicious findings that turn out",
"     <strong>",
"      not",
"     </strong>",
"     to be cancer (false positives).",
"    </p>",
"    <p>",
"     The role of breast MRI for the diagnosis and management of breast cancer is evolving, and there is disagreement as to which women should undergo breast MRI in addition to mammography. Many experts restrict the use of breast MRI to the following situations:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Breast cancer screening for young women (particularly those with dense breasts) who have an increased risk of breast cancer (eg, mutations in the genes BRCA1 or BRCA2). (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?30/15/30963?source=see_link\">",
"        \"Patient information: Genetic testing for breast and ovarian cancer (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Evaluation for breast cancer in a woman who is diagnosed with cancer of the lymph nodes (glands) under the arm but who has a no sign of breast cancer on physical examination or mammogram of the breast on that side. Sometimes the breast MRI can be used to determine if the cancer first developed in the breast and its location.",
"      </li>",
"      <li>",
"       Evaluation of a woman with newly diagnosed breast cancer with",
"       <strong>",
"        extremely",
"       </strong>",
"       dense breasts on mammograms, because the density makes the mammograms difficult to interpret.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Breast biopsy",
"     </span>",
"     &nbsp;&mdash;&nbsp;If breast cancer is suspected, the next step is to sample the abnormal area with a core needle biopsy to confirm the diagnosis. If the physician feels a lump, the biopsy can be performed in the office. If possible, the technique should be performed using x-ray guidance, with mammography, ultrasound, or MRI. Core needle biopsies are performed with local anesthesia and do not require sedation.",
"    </p>",
"    <p>",
"     After the breast biopsy, a tiny metal clip is usually placed into the breast lump or imaging abnormality to mark the spot. If the diagnosis of breast cancer or atypical cells is made, the metal clip is targeted with a thin wire inserted into the abnormal area under x-ray guidance. A surgeon then uses the wire to guide the operation and remove the proper area of the breast. This procedure is called a needle (wire) localization excisional breast biopsy if the surgery is being done for diagnosis, or needle (wire) localization lumpectomy if the surgery is done for cancer.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Types of breast cancer",
"     </span>",
"     &nbsp;&mdash;&nbsp;Although there are several different types of breast cancer, they are treated similarly, with some exceptions (",
"     <a class=\"graphic graphic_figure graphicRef53453 \" href=\"UTD.htm?23/5/23640\">",
"      figure 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      In situ breast cancer",
"     </span>",
"     &nbsp;&mdash;&nbsp;The earliest breast cancers are called \"in situ\" cancers.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20173281\">",
"     <span class=\"h4\">",
"      Ductal carcinoma in situ (DCIS)",
"     </span>",
"     &nbsp;&mdash;&nbsp;If cancers arise in the ducts of the breast (the tubes that carry milk to the nipple when a woman is breastfeeding) and do not grow outside of the ducts, the tumor is called ductal carcinoma in situ (abbreviated DCIS). DCIS cancers do not spread beyond the breast tissue. However DCIS may develop into invasive cancers if not treated.",
"    </p>",
"    <p>",
"     The best local treatment for DCIS will depend on the size of the area of disease, the grade of the disease, and overall health of the woman. Most women are treated with removal of the cancerous area (lumpectomy) followed by radiation therapy. Surgical removal of the cancerous area alone may be an option, particularly for older women with a very small area of low grade disease that is completely removed. Women with small areas of DCIS who are being treated with lumpectomy do not need their lymph nodes checked for spread of tumor.",
"    </p>",
"    <p>",
"     Women with extensive DCIS may need a mastectomy which may be done with or without reconstruction. A sentinel lymph node biopsy, a special technique to identify and remove only the most important lymph nodes in the armpit is usually recommended for women who are having a mastectomy for DCIS. Large areas of DCIS have an increased chance of being associated with hidden invasive cancer and if the lymph nodes are involved this will affect treatment decisions. It is not possible to perform sentinel node biopsy after a mastectomy. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/44/27335?source=see_link\">",
"      \"Patient information: Surgical procedures for breast cancer &mdash; Mastectomy and breast conserving therapy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Chemotherapy is not necessary for women with DCIS but endocrine (also called hormonal therapy) treatment with tamoxifen may be recommended for prevention of recurrence if the DCIS tests positive for responsiveness to estrogen (estrogen receptor positive), particularly if they did not have a mastectomy. The tamoxifen reduces the chances that the cancer will come back in the treated breast and also decreases the chances of developing a new breast cancer in the other breast.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20173288\">",
"     <span class=\"h4\">",
"      Lobular carcinoma in situ (LCIS)",
"     </span>",
"     &nbsp;&mdash;&nbsp;If abnormal cells arise in the lobules of the breast (where breast milk is made), and they do not extend outside of the breast lobule, this are referred to as lobular carcinoma in situ (LCIS). LCIS is",
"     <strong>",
"      not",
"     </strong>",
"     considered a true cancer but instead is considered a risk factor for developing cancer in the future in either breast. Women with LCIS should see a high risk specialist and discuss risk reduction strategies, such as medication to reduce the risk of breast cancer. In some cases preventive mastectomies are considered for women with a strong family history of breast cancer, who are diagnosed with LCIS. Women with LCIS should have yearly mammograms and report any changes in their breasts to their physicians. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/6/44134?source=see_link\">",
"      \"Patient information: Factors that modify breast cancer risk in women (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/31/499?source=see_link\">",
"      \"Patient information: Medications for the prevention of breast cancer (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Invasive breast cancer",
"     </span>",
"     &nbsp;&mdash;&nbsp;The majority of breast cancers are referred to as invasive breast cancers because they have grown or \"invaded\" beyond the ducts or lobules of the breast into the surrounding tissue (",
"     <a class=\"graphic graphic_figure graphicRef53453 \" href=\"UTD.htm?23/5/23640\">",
"      figure 1",
"     </a>",
"     ). Several varieties of invasive breast cancers are possible (eg, ductal, lobular, medullary, tubular, metaplastic). In general, they are all treated similarly.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Features of a breast cancer that influence the choice of treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;At the time breast cancer is diagnosed",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     treated, the cancer should be studied for the presence of two types of proteins; hormone receptors (estrogen and progesterone receptors) and HER2. These proteins are important for selecting medical treatment. These tests are performed by the pathologist, the doctor responsible for examining the breast cancer tissue under the microscope and making the diagnosis. The pathologist will also grade the cancer. Grade is assigned to the tumor cells based on how aggressive the individual cancer cells look under the microscope.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Hormone receptors",
"     </span>",
"     &nbsp;&mdash;&nbsp;More than one-half of breast cancers require the female hormone estrogen to grow, while other breast cancers are able to grow without estrogen. Estrogen-dependent breast cancer cells produce proteins called hormone receptors, which can be estrogen receptors (ER), progesterone receptors (PR), or both.",
"    </p>",
"    <p>",
"     If hormone receptors are present within a woman&rsquo;s breast cancer, she is likely to benefit from treatments that lower estrogen levels or block the actions of estrogen. These treatments are referred to as endocrine or hormone therapies and such tumors are referred to as hormone-responsive or hormone receptor positive.",
"    </p>",
"    <p>",
"     In contrast, women whose tumors do not contain any ER or PR do not benefit from endocrine therapy, and it is not recommended. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/2/39970?source=see_link\">",
"      \"Patient information: Early stage breast cancer treatment in premenopausal women (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      HER2",
"     </span>",
"     &nbsp;&mdash;&nbsp;HER2 is a protein that is present in about one out of every five breast cancers. The presence of HER2 in the breast cancer identifies women who might benefit from treatments directed against the HER2 protein. Drugs that target the HER2 protein include trastuzumab (Herceptin) and lapatinib (Tykerb&reg;). The benefit from trastuzumab and lapatinib appears to be limited to women whose breast cancers make very high levels of this protein. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/53/25426?source=see_link\">",
"      \"Patient information: Adjuvant medical therapy for HER2-positive breast cancer (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      HAS THE BREAST CANCER SPREAD?",
"     </span>",
"    </p>",
"    <p>",
"     Once a diagnosis of breast cancer is established, the next important questions to be answered are the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       How extensive is the cancer involvement within the breast?",
"      </li>",
"      <li>",
"       Is there evidence that the tumor has spread outside of the breast?",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The extent of cancer involvement within the breast is usually determined by the findings on the biopsy, the results of the mammogram and, in some cases, the results of the breast MRI scan.",
"    </p>",
"    <p>",
"     Although by definition, breast cancer starts within the breast, tiny microscopic cells or pieces of the cancer may break off from the breast tumor at any point and travel to other places through the bloodstream or the lymph channels; this process is called metastasis (",
"     <a class=\"graphic graphic_figure graphicRef53453 \" href=\"UTD.htm?23/5/23640\">",
"      figure 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     When these stray tumor cells lodge themselves in a lymph node (also called glands) or an organ such as the liver or the bones, they grow, eventually producing a mass or lump that can sometimes be felt (eg, if it involves the skin or the lymph nodes in the armpit). In other cases, metastases may only be evident because they cause symptoms such as bone pain and can be seen on an x-ray such as a CT scan, a bone scan, or a PET scan. The use of these studies is discussed below. (See",
"     <a class=\"local\" href=\"#H19\">",
"      'Staging and the staging workup'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      The importance of the axillary lymph nodes",
"     </span>",
"     &nbsp;&mdash;&nbsp;One of the first sites of breast cancer spread is to the lymph nodes located in the armpit (axilla). These nodes (referred to as axillary lymph nodes) can become enlarged and can sometimes be felt during a breast examination. However, even if the lymph nodes are enlarged, the only way to determine if they truly contain cancer is to examine a sample of the tissue under the microscope.",
"    </p>",
"    <p>",
"     The presence or absence of lymph node involvement is one of the most important factors in determining the long-term outcome of the cancer (prognosis), and it often guides decisions about treatment.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       If the axillary lymph nodes contain cancer (positive nodes), there is a higher chance that cancer cells have spread elsewhere, and most of these women are advised to have adjuvant systemic therapy.",
"      </li>",
"      <li>",
"       Systemic therapy, especially chemotherapy, is recommended less often for women who have no cancer cells detected in the axillary lymph nodes (node-negative breast cancer); particularly if the tumor is small or other prognostic factors are all favorable. Adjuvant endocrine therapy is usually recommended to all patients with estrogen receptor positive breast cancer, even if the lymph nodes are negative, because it generally has less toxicity than chemotherapy.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Even if the axillary lymph nodes are negative, there is a small chance that the tumor has spread elsewhere in the body, and adjuvant therapy is recommended for some of these women.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1022248\">",
"     <span class=\"h2\">",
"      21 gene test (Oncotype DX)",
"     </span>",
"     &nbsp;&mdash;&nbsp;A 21 gene test called Oncotype DX can be performed on the tumor tissue to help with decision making about chemotherapy. The 21 gene test evaluates the genetic make-up of the tumor and provides a number score to help predict the chance of recurrence. The score is called the &ldquo;recurrence score&rdquo; and the results range from 1 to 100. Women with estrogen receptor positive, node negative breast cancer that have low recurrence scores will not need chemotherapy while women with high scores may benefit from chemotherapy. This test is only appropriate for women with estrogen receptor positive tumors. A further discussion of factors that affect the choice of breast cancer treatment is presented elsewhere. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19177?source=see_link\">",
"      \"Overview of the treatment of newly diagnosed, non-metastatic breast cancer\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Examination of the axillary lymph nodes",
"     </span>",
"     &nbsp;&mdash;&nbsp;The axillary lymph nodes should be examined for tumor spread. This is done first by physical exam and, sometimes with ultrasound. If the nodes are enlarged or feel suspicious, a needle biopsy can be performed. If the needle biopsy is positive and the nodes contain cancer cells then surgical removal of additional axillary lymph nodes may be performed. This is called axillary lymph node dissection, or ALND.",
"    </p>",
"    <p>",
"     In cases where the axillary lymph nodes are not enlarged, the ultrasound is negative, or if the needle biopsy of the lymph node is negative, a surgical procedure called a sentinel lymph node biopsy is performed. In this procedure, one, or at most a few, of the most important nodes are removed. The major benefit of the sentinel lymph node procedure is that it provides important staging information, while causing fewer problems such as arm swelling (also called lymphedema) than a more extensive axillary lymph node dissection. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/32/15876?source=see_link\">",
"      \"Patient information: Lymphedema after breast cancer surgery (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Most patients do not have cancer in their sentinel lymph nodes and will not need additional surgery. Some studies have shown that there are patients for whom an axillary lymph node dissection is not necessary even if the sentinel lymph nodes are positive. This issue remains controversial and should be discussed with your oncology team. This is discussed in more detail elsewhere. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/44/27335?source=see_link&amp;anchor=H27#H27\">",
"      \"Patient information: Surgical procedures for breast cancer &mdash; Mastectomy and breast conserving therapy (Beyond the Basics)\", section on 'Management of axillary lymph nodes'",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Staging and the staging workup",
"     </span>",
"     &nbsp;&mdash;&nbsp;Doctors who care for cancer patients (oncologists) use a standard set of abbreviations, called the TNM staging system, to describe the stage of individual cancers. The \"T\" status stands for the primary tumor, \"N\" status stands for the status of the regional lymph nodes, and the \"M\" status stands for the presence or absence of metastases to other organs. The T, N, and M designations are then grouped together to form the stage grouping of a breast cancer, which ranges from stage I (least advanced) to IV (most advanced). The \"stage\" of the cancer is an indication of whether and how far it has spread. The following table describes these stages (",
"     <a class=\"graphic graphic_table graphicRef65393 \" href=\"UTD.htm?29/14/29920\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1022347\">",
"     <span class=\"h3\">",
"      Tumor size (T) and nodes (N)",
"     </span>",
"     &nbsp;&mdash;&nbsp;To establish the stage of a breast cancer, the first step is to evaluate the size of the cancer (T) and establish whether the lymph nodes have cancer in them or not (N). This is accomplished with:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       A complete physical, including careful examination of the breast and lymph nodes",
"      </li>",
"      <li>",
"       Mammogram (and if indicated, other means of breast imaging such as ultrasound or breast MRI)",
"      </li>",
"      <li>",
"       Pathologic examination of the cancer and lymph nodes after they are removed",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1022354\">",
"     <span class=\"h3\">",
"      Metastases (M)",
"     </span>",
"     &nbsp;&mdash;&nbsp;If any cancer is detectable outside of the breast, these deposits are called metastases (M).",
"    </p>",
"    <p>",
"     Several \"staging\" studies may be carried out to help determine if the cancer has spread beyond the breast and axillary lymph nodes. These may include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Blood tests, including a complete blood count and liver function tests",
"      </li>",
"      <li>",
"       Bone scan",
"      </li>",
"      <li>",
"       Chest X-ray or CT scan",
"      </li>",
"      <li>",
"       CT scan of the abdomen and pelvis",
"      </li>",
"      <li>",
"       CT scan or magnetic resonance imaging (MRI) of the brain",
"      </li>",
"      <li>",
"       A PET scan",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Not all of these studies will be recommended during the staging process. Indeed for most women, including those who have no suspicious symptoms and who have small tumors with negative or only a few positive lymph nodes, no staging is needed other than physical exam and routine blood tests. The components of the staging evaluation are covered in more detail elsewhere. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/44/27335?source=see_link\">",
"      \"Patient information: Surgical procedures for breast cancer &mdash; Mastectomy and breast conserving therapy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h3\">",
"      Stage I and II breast cancer",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women with stage I or II breast cancers are said to have early stage localized breast cancer. A stage I breast cancer refers to a tumor less than 2 cm in size that is node-negative.",
"    </p>",
"    <p>",
"     Stage II tumors are those with spread to the axillary lymph nodes",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     a tumor size larger than 2 cm but not larger than 5 cm (",
"     <a class=\"graphic graphic_table graphicRef65393 \" href=\"UTD.htm?29/14/29920\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h3\">",
"      Stage III breast cancers",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women with stage III tumors are referred to as having locally advanced breast cancer. These consist of large breast tumors (greater than 5 cm across), those with extensive axillary nodal involvement, or nodal involvement of the soft tissues above or below the collarbone (termed the infraclavicular and supraclavicular lymph nodes) (",
"     <a class=\"graphic graphic_table graphicRef65393 \" href=\"UTD.htm?29/14/29920\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     A tumor is also designated stage III if it extends to underlying muscles of the chest wall or the overlying skin. Stage III breast cancer also includes inflammatory breast cancer, a rapidly growing form of cancer that makes the breast appear red and swollen (hence the term inflammatory).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h3\">",
"      Stage IV breast cancer",
"     </span>",
"     &nbsp;&mdash;&nbsp;Stage IV breast cancer refers to tumors that have metastasized to areas outside the breast and lymph nodes to the brain, bones, skin, or other organs. The primary tumor may be any size, and there may be any number of affected lymph nodes. This is referred to as metastatic breast cancer (",
"     <a class=\"graphic graphic_table graphicRef65393 \" href=\"UTD.htm?29/14/29920\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H23\">",
"     <span class=\"h1\">",
"      OVERVIEW OF TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The treatment of breast cancer must be individualized and is based upon several factors. Optimal management in most cases requires collaboration between surgeons (breast cancer surgeons and reconstructive surgeons, who are typically plastic surgeons) and physicians who specialize in radiation and medical oncology. Each woman should discuss the available treatment options with her doctors to determine what treatment is best for her.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h2\">",
"      Early stage localized breast cancer",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women with stage I and II breast cancer are treated similarly with minor exceptions. Two surgical options are available for treating localized breast cancer: mastectomy (removal of the breast) and breast conserving surgery (removal of the cancerous tissue, called lumpectomy).",
"    </p>",
"    <p>",
"     Breast conserving surgery may also be referred to as wide excision, quadrantectomy, or partial mastectomy. Breast conserving therapy (BCT) consists of breast conserving surgery in conjunction with radiation therapy of the remainder of the affected breast. The combination of surgery and radiation usually results in cosmetically acceptable preservation of the breast without compromising breast cancer outcomes.",
"    </p>",
"    <p>",
"     In centers that specialize in breast cancer treatment, approximately 60 percent of women with early stage breast cancer are candidates for BCT. In 25 to 50 percent of women, there are medical, cosmetic,",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     social and emotional reasons for having a mastectomy rather than BCT. Survival outcomes are the same whether BCT or mastectomy is performed. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/44/27335?source=see_link\">",
"      \"Patient information: Surgical procedures for breast cancer &mdash; Mastectomy and breast conserving therapy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Breast reconstruction is an important option for women who undergo mastectomy and may be considered at the time of the mastectomy or at a later date. Consultation with a plastic surgeon prior to the mastectomy is essential if immediate reconstruction is desired.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H25\">",
"     <span class=\"h3\">",
"      Adjuvant therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Adjuvant systemic therapy is recommended for the vast majority of women with stage II breast cancer and for some women with stage I disease. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/2/39970?source=see_link\">",
"      \"Patient information: Early stage breast cancer treatment in premenopausal women (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/52/26437?source=see_link\">",
"      \"Patient information: Early stage breast cancer treatment in postmenopausal women (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The selection of the type of adjuvant therapy depends on several factors:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <strong>",
"        Hormone receptor-positive breast cancer",
"       </strong>",
"       &ndash; Adjuvant endocrine therapy is recommended for most women with hormone receptor-positive breast cancer, while selected women also receive chemotherapy. The need for chemotherapy among women with hormone receptor-positive breast cancer depends on the characteristics of the tumor, whether the axillary lymph nodes are positive, the results of the Recurrence Score (if done), the overall health of the woman, and whether she is pre- or postmenopausal. The 21 gene Recurrence Score has permitted identification of women who have such a favorable prognosis that the benefits of chemotherapy do not outweigh the risks (see",
"       <a class=\"local\" href=\"#H1022248\">",
"        '21 gene test (Oncotype DX)'",
"       </a>",
"       above).",
"      </li>",
"      <li>",
"       <strong>",
"        Hormone receptor-negative breast cancer",
"       </strong>",
"       &ndash; Adjuvant chemotherapy is generally recommended for women who have hormone receptor-negative invasive breast cancers.",
"      </li>",
"      <li>",
"       <strong>",
"        HER2-positive breast cancer",
"       </strong>",
"       &ndash; For women with HER2-positive breast cancer, trastuzumab (Herceptin) plus chemotherapy is generally recommended. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?24/53/25426?source=see_link\">",
"        \"Patient information: Adjuvant medical therapy for HER2-positive breast cancer (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H26\">",
"     <span class=\"h2\">",
"      Locally advanced and inflammatory breast cancer",
"     </span>",
"     &nbsp;&mdash;&nbsp;The likelihood of curing locally advanced and inflammatory breast cancer is lower than it would be if the cancer were small and confined to the breast, but is still possible with appropriate treatment. Treatment generally includes a combination of chemotherapy, endocrine therapy (if the tumor is hormone receptor-positive), trastuzumab (if the tumor is HER2-positive), radiation therapy, and surgery. In most cases, systemic therapy (chemotherapy, trastuzumab, and sometimes endocrine therapy) is given before surgery. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/47/5875?source=see_link\">",
"      \"Patient information: Locally advanced and inflammatory breast cancer (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27\">",
"     <span class=\"h2\">",
"      Metastatic breast cancer",
"     </span>",
"     &nbsp;&mdash;&nbsp;Metastatic breast cancer is generally treated with &ldquo;systemic therapy&rdquo; that treats the whole body, such as chemotherapy, endocrine therapy, trastuzumab, or some combination of these options. Surgery and radiation therapy that are more localized can sometimes be added to control disease in certain areas. While metastatic disease is often aggressive, treatment can prolong life, delay the progression of the cancer, relieve cancer-related symptoms, and improve quality of life. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/11/27827?source=see_link\">",
"      \"Patient information: Treatment of metastatic breast cancer (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The choice of treatment for metastatic breast cancer depends upon many individual factors, including features of the woman's breast cancer (especially whether it produces hormone receptors and HER2), the expected response of the cancer to various therapies, treatment-related side effects, the extent and location of metastases, and a woman's personal preferences.",
"    </p>",
"    <p>",
"     Each woman should discuss the available treatment options with her physician to determine which choice is best for her. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/11/27827?source=see_link\">",
"      \"Patient information: Treatment of metastatic breast cancer (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3467907\">",
"     <span class=\"h1\">",
"      CLINICAL TRIALS",
"     </span>",
"    </p>",
"    <p>",
"     There are many unanswered questions about the evaluation and treatment of breast cancer. Many advances have been made that have led to more effective and less toxic treatments over the last several decades. Ask your doctor if you are eligible for a clinical trial and then decide if participation is right for you.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H28\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H366312\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H366319\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/19/2357?source=see_link\">",
"      Patient information: Breast cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/59/19379?source=see_link\">",
"      Patient information: Breast cancer screening (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/62/6115?source=see_link\">",
"      Patient information: Common breast problems (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/26/27043?source=see_link\">",
"      Patient information: Genetic testing for breast and ovarian cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/62/11236?source=see_link\">",
"      Patient information: Breast reconstruction after mastectomy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/8/8321?source=see_link\">",
"      Patient information: Choosing treatment for early-stage breast cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/26/3492?source=see_link\">",
"      Patient information: Ductal carcinoma in situ (DCIS) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/39/8818?source=see_link\">",
"      Patient information: Inflammatory breast cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?43/10/44193?source=see_link\">",
"      Patient information: Breast biopsy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/59/6066?source=see_link\">",
"      Patient information: Sentinel lymph node biopsy for breast cancer (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H366332\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/6/44134?source=see_link\">",
"      Patient information: Factors that modify breast cancer risk in women (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/31/499?source=see_link\">",
"      Patient information: Medications for the prevention of breast cancer (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/40/36481?source=see_link\">",
"      Patient information: Breast cancer screening (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/15/30963?source=see_link\">",
"      Patient information: Genetic testing for breast and ovarian cancer (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/44/27335?source=see_link\">",
"      Patient information: Surgical procedures for breast cancer &mdash; Mastectomy and breast conserving therapy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/2/39970?source=see_link\">",
"      Patient information: Early stage breast cancer treatment in premenopausal women (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/53/25426?source=see_link\">",
"      Patient information: Adjuvant medical therapy for HER2-positive breast cancer (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/32/15876?source=see_link\">",
"      Patient information: Lymphedema after breast cancer surgery (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/52/26437?source=see_link\">",
"      Patient information: Early stage breast cancer treatment in postmenopausal women (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/47/5875?source=see_link\">",
"      Patient information: Locally advanced and inflammatory breast cancer (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/11/27827?source=see_link\">",
"      Patient information: Treatment of metastatic breast cancer (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H366343\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11384?source=see_link\">",
"      Adjuvant medical therapy for HER2-positive breast cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=see_link\">",
"      Adjuvant endocrine therapy for hormone receptor-positive breast cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34826?source=see_link\">",
"      Adjuvant systemic therapy for older women with early stage breast cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19177?source=see_link\">",
"      Overview of the treatment of newly diagnosed, non-metastatic breast cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31402?source=see_link\">",
"      Breast conserving therapy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39482?source=see_link\">",
"      Breast imaging: Mammography and ultrasonography",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24825?source=see_link\">",
"      Breast masses and other common breast problems",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24138?source=see_link\">",
"      Diagnostic evaluation of women with suspected breast cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/58/13226?source=see_link\">",
"      General principles on the treatment of early stage and locally advanced breast cancer in older women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=see_link\">",
"      Genetic testing for hereditary breast and ovarian cancer syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17418?source=see_link\">",
"      Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12586?source=see_link\">",
"      Mastectomy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24278?source=see_link\">",
"      Tumor node metastasis (TNM) staging classification for breast cancer",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; 1-800-4-CANCER",
"     <br/>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.nci.nih.gov/\">",
"      www.nci.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Society of Clinical Oncology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.net/portal/site/patient\">",
"      www.cancer.net/portal/site/patient",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Comprehensive Cancer Network",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nccn.com/\">",
"      www.nccn.com",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Cancer Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; 1-800-ACS-2345",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.org/\">",
"      www.cancer.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Susan G. Komen Breast Cancer Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.komen.org/\">",
"      www.komen.org",
"     </a>",
"     )",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H30\">",
"     <span class=\"h2\">",
"      Patient support",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://about.com/\">",
"        About.com",
"       </a>",
"       Breast Cancer Forum",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://breastcancer.about.com/forum\">",
"      file://breastcancer.about.com/forum",
"     </a>",
"     )",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 16, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?11/56/12167?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f11_56_12167=[""].join("\n");
var outline_f11_56_12167=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           IMPROVEMENTS IN CANCER CARE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           DIAGNOSING BREAST CANCER",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           HAS THE BREAST CANCER SPREAD?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H23\">",
"           OVERVIEW OF TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3467907\">",
"           CLINICAL TRIALS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H28\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/5/23640\" title=\"figure 1\">",
"           Breast cancer development",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?29/14/29920\" title=\"table 1\">",
"           TNM stage breast cancer",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f11_56_12168="Gynecologic laparoscopy: Non-umbilical entry sites";
var content_f11_56_12168=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Gynecologic laparoscopy: Non-umbilical entry sites",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/56/12168/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/56/12168/contributors\">",
"     Howard T Sharp, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/56/12168/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/56/12168/contributors\">",
"     Tommaso Falcone, MD, FRCSC, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/56/12168/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/56/12168/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/56/12168/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopic surgery has transformed many gynecologic surgeries into minimally invasive procedures. The complication rate of laparoscopy is 5.7 per 1000 procedures; approximately one-half of these complications are related to initial entry into the peritoneal cavity [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12168/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The small incisions used in laparoscopy provide many benefits; however, visualization is limited for initial trocar insertion. To ensure patient safety during blind insertion, surgeons use known anatomic landmarks and elevate the abdominal wall. In most cases, blind insertions are performed safely, but visceral or vascular injury can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12168/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Standard gynecologic laparoscopic entry is through the umbilicus [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12168/abstract/5\">",
"     5",
"    </a>",
"    ]. However, initial entry can also be performed through other sites in the abdominal wall or through the vagina or uterus. It is particularly useful to enter at alternative sites when umbilical entry is risky or difficult.",
"   </p>",
"   <p>",
"    Indications and techniques for non-umbilical laparoscopic entry in gynecologic surgery will be reviewed here. Umbilical entry and general principles of gynecologic laparoscopy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17334?source=see_link\">",
"     \"Overview of conventional gynecologic laparoscopic surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TECHNIQUES FOR LAPAROSCOPIC ENTRY",
"    </span>",
"    &nbsp;&mdash;&nbsp;During laparoscopic entry, the first instrument is introduced and gas is insufflated into the peritoneal cavity. The resulting pneumoperitoneum separates the entry site from the surrounding viscera and vessels, serving both to protect against injury during insertion of additional instruments and to allow visualization of the operative site.",
"   </p>",
"   <p>",
"    The traditional technique for laparoscopic entry is to blindly pass a sharp Veress needle, insufflate, and then blindly pass a sharp trocar. Newer entry methods have been developed to improve safety. Techniques for entry vary according to the degree of visualization and whether the trocar is sharp or blunt:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For blind entry with a sharp instrument",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Veress needle followed by a sharp trocar inserted blindly or with an optical access trocar",
"     </li>",
"     <li>",
"      Veress needle followed by a blunt trocar using an optical access trocar or radially expanding system",
"     </li>",
"     <li>",
"      Direct entry with a sharp trocar",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Optical access system with a sharp or blunt trocar (Veress needle may be used; an optical access Veress needle is also available)",
"     </li>",
"     <li>",
"      Open technique followed by insertion of a blunt trocar",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Optical access, also called visual entry, trocars are made of transparent material",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    use a camera to allow the surgeon to view the tissue layers during insertion. With a radially expanding entry system, a Veress needle surrounded by expandable material is inserted, followed by a blunt dilating trocar.",
"   </p>",
"   <p>",
"    In the open technique (Hasson method), the layers of the abdominal wall and parietal peritoneum are entered using sharp dissection under direct visualization, followed by insertion of a blunt trocar.",
"   </p>",
"   <p>",
"    Comparison of umbilical laparoscopic entry using an open versus closed technique and optical access or radially expanding trocars is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17334?source=see_link&amp;anchor=H17048863#H17048863\">",
"     \"Overview of conventional gynecologic laparoscopic surgery\", section on 'Laparoscopic entry and insufflation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISKS OF UMBILICAL ENTRY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common site of initial entry is the umbilicus and the Veress needle is the most commonly used instrument in gynecologic surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12168/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The umbilicus overlies the omentum, bowel, and the bifurcations of the aorta and vena cava. Thus, the challenge of initial umbilical entry is to enter the peritoneal cavity without injuring these structures.",
"   </p>",
"   <p>",
"    The risk of injury with umbilical entry with a Veress needle was evaluated in a systematic review of 55 studies comprising over 600,000 laparoscopies that found injury to the blood vessels or hollow viscera (bowel, bladder) occurred in 0.02 percent of procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12168/abstract/4\">",
"     4",
"    </a>",
"    ]. Among injuries to hollow viscera, 17 of 28 were major; among the vascular injuries, 8 of 98 involved major retroperitoneal vessels. The study did not evaluate the role of risk factors (eg, adhesive disease) in these complications.",
"   </p>",
"   <p>",
"    Risk factors for injury during umbilical entry are discussed below. In addition, umbilical entry may be difficult or impossible in certain women, including those who are obese or have extreme abdominal wall laxity (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Candidates for non-umbilical entry'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Use of optical access, radially expanding instruments, or the open technique helps to avoid failed insufflation or injury during entry. However, for patients with risk factors for injury or failed entry using the umbilicus, using a non-umbilical site is an option (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Candidates for non-umbilical entry'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CANDIDATES FOR NON-UMBILICAL ENTRY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anatomic alterations of the periumbilical abdominal wall or peritoneal surface can make umbilical entry difficult or risky [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12168/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Suspected adhesive disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adhesive disease may be suspected in women with bowel obstruction or a history of prior intraabdominal surgery, malignancy, or infection. Those who have had a prior periumbilical incision (eg, postpartum tubal ligation, laparoscopy, umbilical or other ventral hernia repair) are at particular risk for adhesions of omentum or bowel to the anterior abdominal wall [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12168/abstract/5,8\">",
"     5,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a systematic review, the estimated risks for umbilical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anterior abdominal wall adhesions were 0 to 5 percent for women with no prior surgery, 20 to 30 percent for those with a previous transverse suprapubic laparotomy, and 50 to 65 percent for those with a previous midline laparotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12168/abstract/5\">",
"     5",
"    </a>",
"    ]. The reported risk of adhesions after prior laparoscopic surgery ranges from 2 to 21 percent in series of over 100 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12168/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Avoidance of umbilical entry in patients who have had a previous laparotomy is supported by a multivariate analysis of over 25,000 laparoscopies in which previous laparotomy was a significant risk factor for a complication [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12168/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is difficult to quantify the increase in risk of visceral injury in women with versus without adhesions. Thus, while the safest approach is to use non-umbilical entry in women with prior laparotomy, many surgeons do enter through the umbilicus.",
"   </p>",
"   <p>",
"    Periumbilical tattoos or jewelry do not cause intraabdominal adhesions, and are not a contraindication to umbilical entry. However, umbilical jewelry should be removed prior to surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17334?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of conventional gynecologic laparoscopic surgery\", section on 'Navel jewelry'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Prior ventral hernia repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;Umbilical entry should be avoided in women who have undergone umbilical or other ventral wall herniorrhaphy and have surgical mesh at or near the umbilicus. In such patients, there is a high likelihood of adhesions to the mesh site and it is also possible that umbilical entry will disrupt the hernia repair [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12168/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proximity of the aortic bifurcation to the umbilicus is a primary factor in determining the risk of injury to the major vessels during initial umbilical entry. Surgeons attempt to avoid vascular injury both by elevating the abdominal wall and by inserting the initial instrument at a 45&ordm; angle from vertical (aimed in the direction of the pelvis).",
"   </p>",
"   <p>",
"    In obese patients, use of an angle more than 45&ordm; from vertical often results in preperitoneal insertion and failure of insufflation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12168/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. In a review of 138 morbidly obese women (weight greater than 114 kg) undergoing laparoscopy, insufflation failure rates were significantly higher with transumbilical insufflation compared with transuterine insufflation (13.9 versus 3.6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12168/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To address this issue in obese women, many surgeons position the initial Veress needle or trocar at an angle closer to vertical. This is based on the assumption that the umbilicus is likely to be inferior to the level of the aortic bifurcation in obese women. However, the safety of this approach cannot be ensured. The relative position of the umbilicus to the aortic bifurcation varies in obese women. While the umbilicus is inferior to the level of the aortic bifurcation in some obese women, in others (6 of 20 in one series), the umbilicus and bifurcation are at the same level [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12168/abstract/7\">",
"     7",
"    </a>",
"    ]. Insertion at a nearly vertical angle could result in vascular injury in the latter group (",
"    <a class=\"graphic graphic_figure graphicRef52807 \" href=\"UTD.htm?17/22/17765\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Extreme thinness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are extremely thin are also at increased risk, particularly when the sacral promontory is easily palpable [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12168/abstract/7,17,18\">",
"     7,17,18",
"    </a>",
"    ]. In such patients, the great vessels may be within centimeters of the umbilicus and use of a 45&ordm; angle from the vertical may not be protective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Abdominal wall laxity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women can develop extreme abdominal wall laxity due to prior pregnancy or current or prior obesity. Upon attempted initial entry in this setting, the abdominal wall may tent with pressure from the instrument. As a result, the instrument cannot enter the peritoneal cavity and umbilical entry is not possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Large pelvic mass",
"    </span>",
"    &nbsp;&mdash;&nbsp;A surgeon may prefer to avoid umbilical entry in women with a pelvic mass that is within the path of the initial entry instrument. Puncture of a mass may lead to bleeding or to rupture of an ovarian malignancy, thereby worsening prognosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12393?source=see_link&amp;anchor=H25#H25\">",
"     \"Oophorectomy and ovarian cystectomy\", section on 'Spillage of malignant cells'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The surgeon can calculate the point of contact of the insufflating instrument. The standard Veress needle is 12 cm long from tip to hub, and thus may puncture a mass within this distance from the point of entry. If a 45&ordm; angle from the plane of the abdominal wall is used for entry, such a mass would be palpable at approximately 8.5 cm inferior to the umbilicus. However, entry would require adding a margin of safety to this measurement to allow for variations in the insertion angle and changes in the plane of the abdominal wall with elevation or pressure during insertion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;When laparoscopic surgery is performed in pregnant women, care must be taken to avoid uterine and fetal trauma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15482?source=see_link&amp;anchor=H11#H11\">",
"     \"Management of pregnant women undergoing nonobstetric surgery\", section on 'Surgical approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar to a large pelvic mass, the risk of trauma during umbilical entry depends upon the size of the gravid uterus and its position relative to the umbilicus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     NON-UMBILICAL ENTRY SITES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of non-umbilical sites during gynecologic laparoscopy is performed with the patient supine and in the dorsal lithotomy position.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Left upper quadrant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left upper quadrant entry is easily performed and has a low risk of complications [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12168/abstract/8,19,20\">",
"     8,19,20",
"    </a>",
"    ]. Thus, it can be used in any patients, even if those without contraindications to umbilical entry.",
"   </p>",
"   <p>",
"    There are two commonly used methods for gaining laparoscopic access in the left upper quadrant: Palmer's point (3 cm below the left costal margin in the mid-clavicular line) and the ninth intercostal space.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Palmer's point",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palmer's point is located 3 cm below the left costal margin in the mid-clavicular line, where there is a relatively low likelihood of encountering adhesions since most patients will not have had surgery at this site (",
"    <a class=\"graphic graphic_figure graphicRef64551 \" href=\"UTD.htm?31/34/32292\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12168/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The organs closest to Palmer's point are the stomach, spleen, left lobe of the liver, pancreas, and transverse colon; the stomach may be as close as 1.5 cm (depending on the degree of gastric distention) and the left liver lobe as close as 1.6 cm from the abdominal wall at Palmer's point [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12168/abstract/23\">",
"     23",
"    </a>",
"    ]. The distance between the abdominal wall and vital organs is greatest in obese women. Based on these anatomic factors, relative contraindications to using this entry site are current enlargement of or prior surgery involving these structures [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12168/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Observational studies have consistently reported successful insufflation and port placement in nearly all patients at Palmer's point [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12168/abstract/9,11,12,19,22,25-28\">",
"     9,11,12,19,22,25-28",
"    </a>",
"    ]. Serious complications are rare, with bowel injury occurring in 0.02 percent or fewer cases and liver injury reported in only one study, in 3 of 267 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12168/abstract/28\">",
"     28",
"    </a>",
"    ]. Minor complications include subcutaneous or omental insufflation. As an example, the largest series included over 800 patients who underwent insertion of a Veress needle followed by insertion of a 2-mm diameter microlaparoscope [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12168/abstract/9\">",
"     9",
"    </a>",
"    ]. All patients had successful entry and the single complication was omental emphysema.",
"   </p>",
"   <p>",
"    The following steps are involved in using Palmer's point for laparoscopic entry:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Empty the stomach using suction and palpate the left upper quadrant to exclude splenomegaly or other mass.",
"     </li>",
"     <li>",
"      Make a skin incision at 3 cm below the costal margin at the mid-clavicular line.",
"     </li>",
"     <li>",
"      Elevate the abdominal skin and insert the Veress needle into the incision, aiming at either a 45&ordm; angle from vertical in the non-obese patient or a 90&ordm; angle in the obese patient; the needle should be aimed directly inferiorly, since a medial axis may increase risk of injury to medial structures [",
"      <a class=\"abstract\" href=\"UTD.htm?11/56/12168/abstract/19,29\">",
"       19,29",
"      </a>",
"      ]. Two popping sounds or sensations should be noted as the needle passes through the fascia and then the peritoneum.",
"     </li>",
"     <li>",
"      Insufflate; a pressure below 10 mmHg indicates correct intraperitoneal placement.",
"     </li>",
"     <li>",
"      After insufflation, elevate the abdominal wall again and insert a trocar. Alternatively, a trocar can be placed directly without a preceding Veress needle. Trocars &le; 7 mm are preferred, since larger trocars may increase the risk of injury [",
"      <a class=\"abstract\" href=\"UTD.htm?11/56/12168/abstract/11\">",
"       11",
"      </a>",
"      ]. If this approach is used, insufflation may be carried out after the camera is placed and intraperitoneal placement is confirmed visually.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Left ninth intercostal space",
"    </span>",
"    &nbsp;&mdash;&nbsp;A second option for entry in the left upper quadrant is the ninth intercostal space at the anterior axillary line (",
"    <a class=\"graphic graphic_figure graphicRef64551 \" href=\"UTD.htm?31/34/32292\">",
"     figure 2",
"    </a>",
"    ). The neurovascular bundles travel along the inferior edge of each rib. Thus, the entry point is placed close to the superior margin of the tenth rib (",
"    <a class=\"graphic graphic_figure graphicRef59415 \" href=\"UTD.htm?23/32/24069\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The ninth intercostal point is well below the pleural cavity, so pneumothorax is unlikely [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12168/abstract/30\">",
"     30",
"    </a>",
"    ]. Adhesions are rare and failed insufflation is uncommon since the peritoneum is adherent to the fascia underlying the ribs. The stomach, spleen, and descending colon are also proximal to the ninth intercostal space. Based on these anatomic factors, relative contraindications to using this entry site are current enlargement of or prior surgery involving these structures [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12168/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complication rates are low with use of the left ninth intercostal space [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12168/abstract/8,11\">",
"     8,11",
"    </a>",
"    ]. In the largest series, 918 patients with prior surgery underwent laparoscopy using insufflation at the left ninth intercostal space followed by trocar insertion at Palmer's point [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12168/abstract/8\">",
"     8",
"    </a>",
"    ]. Entry with the Veress in the ninth intercostal space was successful in all but two patients; a pneumothorax occurred in one patient and a stomach injury in another patient.",
"   </p>",
"   <p>",
"    The following steps are involved in the left ninth intercostal space for laparoscopic entry:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Empty the stomach using suction and palpate the left upper quadrant to exclude splenomegaly or other mass.",
"     </li>",
"     <li>",
"      Palpate the ninth and tenth ribs at the left anterior axillary line; the tenth rib is the most inferior rib before the floating ribs. Make a small stab incision through the skin to insert the Veress needle just superior to the tenth rib through the skin at a 45&ordm; to the horizontal [",
"      <a class=\"abstract\" href=\"UTD.htm?11/56/12168/abstract/31\">",
"       31",
"      </a>",
"      ]. A single pop will be heard or felt during passage through the fascia and peritoneum.",
"     </li>",
"     <li>",
"      Insufflate; a pressure below 10 mmHg indicates correct intraperitoneal placement.",
"     </li>",
"     <li>",
"      Remove the Veress needle and insert a trocar at another site.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other entry sites",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Transuterine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The transuterine approach to insufflation is not commonly used and data are limited. Small studies have found this method to be feasible and have reported minimal uterine blood loss [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12168/abstract/32-36\">",
"     32-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Care must be taken when using the transuterine approach to avoid injury to the bowel or Fallopian tubes. The exit point for the Veress needle for this approach should be the uterine fundus. Severe retroflexion of the uterus may lead to passage of the needle through the lower uterine segment, with possible bladder injury. Other contraindications to the transuterine approach include uterine or cervical malignancy, suspected bowel adhesions to the uterus, large fundal or anterior uterine fibroids, previous myomectomy, and pelvic inflammatory disease.",
"   </p>",
"   <p>",
"    In addition, carbon dioxide embolism is a theoretic complication that could occur if the needle is not completely through the myometrium. Concern for this complication is increased since a high flow laparoscopic insufflator is used. This is in contrast with hysteroscopic insufflators that are designed for low flow specifically to avoid this complication.",
"   </p>",
"   <p>",
"    The only randomized trial to evaluate the transuterine approach found the rate of successful insufflation to be comparable to transumbilical entry (50 of 50 for transuterine, 49 of 50 for transumbilical) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12168/abstract/33\">",
"     33",
"    </a>",
"    ]. Neither group had clinically significant bleeding or other complications.",
"   </p>",
"   <p>",
"    The following steps are involved in transuterine laparoscopic entry:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Place the patient in moderate Trendelenburg position to allow the bowel to fall away from the uterus.",
"     </li>",
"     <li>",
"      Place a tenaculum on the anterior lip of the cervix and hold under tension to straighten uterine axis. Sound the uterus to determine cavity length and confirm uterine position.",
"     </li>",
"     <li>",
"      Antevert the uterus with the Veress needle so that the needle tip is directed away from the sacrum, great vessels, and rectosigmoid colon (",
"      <a class=\"graphic graphic_figure graphicRef55345 \" href=\"UTD.htm?6/49/6929\">",
"       figure 4",
"      </a>",
"      ). Advance the Veress needle tip through the myometrium until the snap of the spring loaded Veress needle mechanism is felt, indicating that the needle has entered the peritoneal cavity.",
"     </li>",
"     <li>",
"      Insufflate; a 10 mmHg pressure reading indicates peritoneal placement.",
"     </li>",
"     <li>",
"      Remove the Veress needle and return the patient to horizontal to insert a trocar at another site.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Transvaginal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pouch of Douglas or posterior cul-de-sac is posterior to the uterus and vagina. It has long been accessed through the posterior vaginal fornix for diagnostic purposes (culdocentesis) or for surgical access (colpotomy). Access through this site is also referred to as culdolaparoscopy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/54/24420?source=see_link\">",
"     \"Culdocentesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35401?source=see_link\">",
"     \"Vaginal hysterectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although rarely used in current practice, the posterior vaginal fornix is a useful site for laparoscopic entry. It has primarily been used for insufflation, but there are reports of vaginal port placement [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12168/abstract/37\">",
"     37",
"    </a>",
"    ]. Data regarding this approach are from the 1970s and 1980s, a time when gynecologists were more familiar with culdocentesis and with colpotomy for procedures other than vaginal hysterectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12168/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. Nevertheless, this is still a valid approach for a surgeon who is familiar with the use of this site. There has been renewed interest in vaginal entry use for non-gynecologic procedures using a natural orifice transluminal endoscopic approach. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/3/2103?source=see_link\">",
"     \"Natural orifice transluminal endoscopic surgery (NOTES)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The posterior cul-de-sac is proximal to the uterine vessels, ureter, and rectum. However, the uterus may be adherent to the rectum if the patient has had prior posterior fornix surgery or if fixed uterine retroversion is present. Thus, these factors are relative contraindications to using the posterior vaginal fornix approach.",
"   </p>",
"   <p>",
"    The utility of this procedure was evaluated in a series of patients who underwent laparoscopy using the posterior vaginal fornix entry; insufflation was successful in 103 of 107 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12168/abstract/39\">",
"     39",
"    </a>",
"    ]. One failure was due to instrumentation, and the other three were due to lateral placement of the Veress needle. No serious complications were reported.",
"   </p>",
"   <p>",
"    The following steps are involved in using the posterior vaginal fornix for laparoscopic entry:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Place the patient in moderate Trendelenburg position to allow the bowel to fall away from the cervix and uterus.",
"     </li>",
"     <li>",
"      Place a tenaculum on the anterior lip of the cervix and elevate the cervix (",
"      <a class=\"graphic graphic_figure graphicRef66928 \" href=\"UTD.htm?9/14/9440\">",
"       figure 5",
"      </a>",
"      ). This exposes the posterior fornix and places the vaginal mucosa under tension.",
"     </li>",
"     <li>",
"      Insert the Veress needle through the posterior fornix at a point approximately 1.75 cm posterior to the cervicovaginal junction [",
"      <a class=\"abstract\" href=\"UTD.htm?11/56/12168/abstract/39\">",
"       39",
"      </a>",
"      ]. Stay in the midline to avoid injury to the uterine vessels or ureters, which are lateral. A longer Veress needle (150 mm rather than 120 mm) is typically easier to use. Do not advance the needle more than 3 cm to avoid injury to the presacral vessels.",
"     </li>",
"     <li>",
"      Insufflate; a 10 mmHg pressure reading indicates peritoneal placement.",
"     </li>",
"     <li>",
"      Remove the Veress needle and return the patient to horizontal to insert a trocar at another site.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     CHOOSING AN ENTRY SITE",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients in whom non-umbilical entry is planned, the first decision is whether to use the site for insufflation alone or for both insufflation and trocar insertion. Among the non-umbilical sites, only Palmer's point (3 cm below the left costal margin in the left mid-clavicular line) can be used for both insufflation and trocar insertion. The other sites are used for insufflation alone, followed by trocar insertion at Palmer's point or the umbilicus.",
"   </p>",
"   <p>",
"    This choice depends on the indication for non-umbilical entry. If umbilical entry is thought to be a risk for the blind insertion of any instrument, then both insufflation and trocar insertion should be performed at a non-umbilical site. On the other hand, insufflation may ameliorate alter the concerning anatomical relationships (eg, close proximity of the abdominal wall to the aortic bifurcation). Trocar insertion can then be performed at the umbilicus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Insufflation with trocar insertion at the same site",
"    </span>",
"    &nbsp;&mdash;&nbsp;Umbilical entry should be avoided entirely in women with periumbilical mesh. Women in whom periumbilical adhesions are suspected require both insufflation and trocar insertion at a non-umbilical site. In this setting, the peritoneal surface of the umbilicus cannot be assessed until the trocar and port have been placed and the camera inserted. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Suspected adhesive disease'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H6\">",
"     'Prior ventral hernia repair'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Thus, in women with possible adhesive disease or prior periumbilical hernia repair, Palmer's point entry is preferred to other sites since insufflating and inserting the trocar at a single site avoids additional skin puncture.",
"   </p>",
"   <p>",
"    Following initial entry, it is often possible to use the umbilicus as a secondary port site in women with suspected adhesive disease. Once the camera is in place, the peritoneal surface of the umbilicus may be found to be free of adhesions or, in many cases, adhesions can be removed. In such patients, an umbilical trocar and port can then be placed safely under direct visualization if this is surgically useful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Insufflation and trocar insertion at separate sites",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women without suspected adhesive disease or a history of periumbilical hernia repair, it is potentially useful to insufflate at a non-umbilical site followed by trocar insertion at the umbilicus. This is because insufflation ameliorates the original reasons for avoiding umbilical entry in these patients, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Close proximity of the umbilicus to viscera or major vessels &mdash; extreme thinness, pelvic mass, pregnancy",
"     </li>",
"     <li>",
"      Require use of an angle approaching vertical to avoid preperitoneal insufflation &mdash; obesity",
"     </li>",
"     <li>",
"      Inability to penetrate the peritoneum &mdash; abdominal wall laxity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After insufflation, the initial trocar can be placed at Palmer's point or the umbilicus.",
"   </p>",
"   <p>",
"    The second decision, therefore, is which site to use when insufflation alone is planned. As noted above, if Palmer's point is planned for trocar insertion, insufflation should also be performed at this site to avoid unnecessary skin incisions.",
"   </p>",
"   <p>",
"    However, if umbilical trocar insertion is planned, the choice of insufflation site depends on surgeon preference. There are no studies comparing the use of different non-umbilical sites in obese or other patients. In current practice, there is greater familiarity with use of the left upper quadrant than the vaginal or uterine approaches.",
"   </p>",
"   <p>",
"    In obese patients, however, use of the posterior vaginal fornix or transuterine approach is potentially easier than the left upper quadrant sites. This is because obesity distorts the anatomy of the abdominal wall, but not of the vagina or uterus. However, use of these techniques depends upon surgeon expertise, and the left upper quadrant sites are more commonly used. In addition, the risk of carbon dioxide embolism with transuterine entry is uncertain.",
"   </p>",
"   <p>",
"    The left upper quadrant approach has been reported to be successful in morbidly obese patients with slight modifications [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12168/abstract/16\">",
"     16",
"    </a>",
"    ]. In a series of 600 successful consecutive left upper quadrant Veress needle placements, a site &lt;1 cm beneath the left costal margin, between the mid-clavicular line and the anterior axillary line was used with only one injury to the muscularis of the transverse colon [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12168/abstract/16\">",
"     16",
"    </a>",
"    ]. During insufflation in this study, intraperitoneal pressures between 7 to 14 mmHg were associated with successful entry and those greater than 20 mmHg with abdominal wall insufflation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately half of laparoscopic complications are related to initial entry into the peritoneal cavity. The most common site of entry is the umbilicus. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Risks of umbilical entry'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anatomic alterations of the periumbilical abdominal wall or peritoneal surface can make umbilical entry difficult or risky. Use of optical access or radially expanding instruments or the open technique have been developed to avoid failed insufflation or injury. However, non-umbilical sites are also an option. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risks of umbilical entry'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Candidates for non-umbilical entry'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Non-umbilical entry sites are: Palmer's point (3 cm below the left costal margin in the left mid-clavicular line), left ninth intercostal space, posterior vaginal fornix, and transuterine. Choice of entry site may depend upon the surgeon's experience with a specific site. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Non-umbilical entry sites'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among the non-umbilical sites, Palmer's point and the posterior uterine cul-de-sac can be used for both insufflation and trocar insertion. The transuterine approach is used for insufflation alone, followed by trocar insertion at Palmer's point or the umbilicus. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Choosing an entry site'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Umbilical entry should be avoided in women with surgical mesh at or near the umbilicus, since this would disrupt a prior hernia repair. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Prior ventral hernia repair'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with a history of periumbilical laparotomy who are undergoing laparoscopy:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We recommend use of a non-umbilical entry site rather than umbilical entry (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Suspected adhesive disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest use of Palmer's point rather than other non-umbilical sites for insufflation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Choosing an entry site'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For obese women who are undergoing laparoscopy and in whom pneumoperitoneum cannot be achieved with the insufflating instrument at 45&ordm; (aimed in the direction of the pelvis), we suggest non-umbilical entry over umbilical entry with an angle closer to vertical (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      In this population, we suggest left upper quadrant entry rather than posterior vaginal fornix or transuterine entry (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Modifications to adjust for alterations in the abdominal wall anatomy may be needed. Alternatively, it may be reasonable to use transvaginal or transuterine entry if access in the left upper quadrant is difficult and precautions are taken to avoid carbon dioxide embolism. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Obesity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Choosing an entry site'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For extremely thin patients in whom the sacral promontory is palpable and is within the insertion path of the insufflating instrument, we suggest non-umbilical entry (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Entry at the umbilicus using an open technique is a reasonable alternative. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Extreme thinness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a pelvic mass or pregnancy which is palpable and is within the insertion path of the insufflating instrument, we recommend non-umbilical entry (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Large pelvic mass'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Non-umbilical entry is a reasonable option for women with extreme abdominal wall laxity in whom umbilical entry is unsuccessful. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Abdominal wall laxity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An open approach or use of an optical access system may be reasonable alternatives to non-umbilical entry in all women with contraindications to blind umbilical entry, with the exception of those who have periumbilical mesh. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Techniques for laparoscopic entry'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12168/abstract/1\">",
"      Jansen FW, Kapiteyn K, Trimbos-Kemper T, et al. Complications of laparoscopy: a prospective multicentre observational study. Br J Obstet Gynaecol 1997; 104:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12168/abstract/2\">",
"      H&auml;rkki-Sir&eacute;n P, Kurki T. A nationwide analysis of laparoscopic complications. Obstet Gynecol 1997; 89:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12168/abstract/3\">",
"      Neudecker J, Sauerland S, Neugebauer E, et al. The European Association for Endoscopic Surgery clinical practice guideline on the pneumoperitoneum for laparoscopic surgery. Surg Endosc 2002; 16:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12168/abstract/4\">",
"      Azevedo JL, Azevedo OC, Miyahira SA, et al. Injuries caused by Veress needle insertion for creation of pneumoperitoneum: a systematic literature review. Surg Endosc 2009; 23:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12168/abstract/5\">",
"      Varma R, Gupta JK. Laparoscopic entry techniques: clinical guideline, national survey, and medicolegal ramifications. Surg Endosc 2008; 22:2686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12168/abstract/6\">",
"      Molloy D, Kaloo PD, Cooper M, Nguyen TV. Laparoscopic entry: a literature review and analysis of techniques and complications of primary port entry. Aust N Z J Obstet Gynaecol 2002; 42:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12168/abstract/7\">",
"      Hurd WW, Bude RO, DeLancey JO, Pearl ML. The relationship of the umbilicus to the aortic bifurcation: implications for laparoscopic technique. Obstet Gynecol 1992; 80:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12168/abstract/8\">",
"      Agarwala N, Liu CY. Safe entry techniques during laparoscopy: left upper quadrant entry using the ninth intercostal space--a review of 918 procedures. J Minim Invasive Gynecol 2005; 12:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12168/abstract/9\">",
"      Audebert AJ, Gomel V. Role of microlaparoscopy in the diagnosis of peritoneal and visceral adhesions and in the prevention of bowel injury associated with blind trocar insertion. Fertil Steril 2000; 73:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12168/abstract/10\">",
"      Sepilian V, Ku L, Wong H, et al. Prevalence of infraumbilical adhesions in women with previous laparoscopy. JSLS 2007; 11:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12168/abstract/11\">",
"      Childers JM, Brzechffa PR, Surwit EA. Laparoscopy using the left upper quadrant as the primary trocar site. Gynecol Oncol 1993; 50:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12168/abstract/12\">",
"      Granata M, Tsimpanakos I, Moeity F, Magos A. Are we underutilizing Palmer's point entry in gynecologic laparoscopy? Fertil Steril 2010; 94:2716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12168/abstract/13\">",
"      Parker J, Rahimpanah F. The advantages of microlaparoscopic left upper quadrant entry in selected patients. Aust N Z J Obstet Gynaecol 2001; 41:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12168/abstract/14\">",
"      Pasic R, Levine RL, Wolf WM Jr. Laparoscopy in morbidly obese patients. J Am Assoc Gynecol Laparosc 1999; 6:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12168/abstract/15\">",
"      Pelosi MA 3rd, Pelosi MA. Alignment of the umbilical axis: an effective maneuver for laparoscopic entry in the obese patient. Obstet Gynecol 1998; 92:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12168/abstract/16\">",
"      Schwartz ML, Drew RL, Andersen JN. Induction of pneumoperitoneum in morbidly obese patients. Obes Surg 2003; 13:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12168/abstract/17\">",
"      Hurd WH, Bude RO, DeLancey JO, et al. Abdominal wall characterization with magnetic resonance imaging and computed tomography. The effect of obesity on the laparoscopic approach. J Reprod Med 1991; 36:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12168/abstract/18\">",
"      Nezhat F, Brill AI, Nezhat CH, et al. Laparoscopic appraisal of the anatomic relationship of the umbilicus to the aortic bifurcation. J Am Assoc Gynecol Laparosc 1998; 5:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12168/abstract/19\">",
"      Howard FM, El-Minawi AM, DeLoach VE. Direct laparoscopic cannula insertion at the left upper quadrant. J Am Assoc Gynecol Laparosc 1997; 4:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12168/abstract/20\">",
"      Berch BR, Torquati A, Lutfi RE, Richards WO. Experience with the optical access trocar for safe and rapid entry in the performance of laparoscopic gastric bypass. Surg Endosc 2006; 20:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12168/abstract/21\">",
"      Palmer R. Safety in laparoscopy. J Reprod Med 1974; 13:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12168/abstract/22\">",
"      Cohen MR, Scoccia B. Double laparoscopy: an alternative two-stage procedure to minimize bowel and blood vessel surgery. J Gynecol Surg 1991; 7:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12168/abstract/23\">",
"      Tulikangas PK, Nicklas A, Falcone T, Price LL. Anatomy of the left upper quadrant for cannula insertion. J Am Assoc Gynecol Laparosc 2000; 7:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12168/abstract/24\">",
"      Vilos GA, Ternamian A, Dempster J, et al. Laparoscopic entry: a review of techniques, technologies, and complications. J Obstet Gynaecol Can 2007; 29:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12168/abstract/25\">",
"      Patsner B. Laparoscopy using the left upper quadrant approach. J Am Assoc Gynecol Laparosc 1999; 6:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12168/abstract/26\">",
"      Lam KW, Pun TC. Left upper quadrant approach in gynecologic laparoscopic surgery using reusable instruments. J Am Assoc Gynecol Laparosc 2002; 9:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12168/abstract/27\">",
"      Rafii A, Camatte S, Leli&egrave;vre L, et al. Previous abdominal surgery and closed entry for gynaecological laparoscopy: a prospective study. BJOG 2005; 112:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12168/abstract/28\">",
"      McDanald DM, Levine RL, Pasic R. Left upper quadrant entry during gynecologic laparoscopy. Surg Laparosc Endosc Percutan Tech 2005; 15:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12168/abstract/29\">",
"      Giannios NM, Gulani V, Rohlck K, et al. Left upper quadrant laparoscopic placement: effects of insertion angle and body mass index on distance to posterior peritoneum by magnetic resonance imaging. Am J Obstet Gynecol 2009; 201:522.e1.",
"     </a>",
"    </li>",
"    <li>",
"     Hulka, JF, Reich, H. Textbook of laparoscopy, 3rd ed, W.B. Saunders, Philadelphia 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12168/abstract/31\">",
"      Reich H. Laparoscopic bowel injury. Surg Laparosc Endosc 1992; 2:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12168/abstract/32\">",
"      Wolfe WM, Pasic R. Transuterine insertion of Veress needle in laparoscopy. Obstet Gynecol 1990; 75:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12168/abstract/33\">",
"      Santala M, J&auml;rvel&auml; I, Kauppila A. Transfundal insertion of a Veress needle in laparoscopy of obese subjects: a practical alternative. Hum Reprod 1999; 14:2277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12168/abstract/34\">",
"      Sanders RR, Filshie GM. Transfundal induction of pneumoperitoneum prior to laparoscopy. J Obstet Gynaecol Br Commonw 1974; 81:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12168/abstract/35\">",
"      Trivedi AN, MacLean NE. Transuterine insertion of Verres needle for gynaecological laparoscopy at Southland Hospital. N Z Med J 1994; 107:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12168/abstract/36\">",
"      Morgan HR. Laparoscopy: induction of pneumoperitoneum via transfundal puncture. Obstet Gynecol 1979; 54:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12168/abstract/37\">",
"      Tsin DA, Colombero LT, Mahmood D, et al. Operative culdolaparoscopy: a new approach combining operative culdoscopy and minilaparoscopy. J Am Assoc Gynecol Laparosc 2001; 8:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12168/abstract/38\">",
"      Howard RE Jr. Laparoscopy. Preliminary experience. Va Med Mon (1918) 1972; 99:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12168/abstract/39\">",
"      Neely MR, McWilliams R, Makhlouf HA. Laparoscopy: routine pneumoperitoneum via the posterior fornix. Obstet Gynecol 1975; 45:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12168/abstract/40\">",
"      Mintz M. Risks and prophylaxis in laparoscopy: a survey of 100,000 cases. J Reprod Med 1977; 18:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12168/abstract/41\">",
"      van Lith DA, van Schie KJ, Beekhuizen W, du Plessis M. Cul-de-sac insufflation: an easy alternative route for safely inducing pneumoperitoneum. Int J Gynaecol Obstet 1980; 17:375.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3274 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-4F64B2DDF4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_56_12168=[""].join("\n");
var outline_f11_56_12168=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TECHNIQUES FOR LAPAROSCOPIC ENTRY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISKS OF UMBILICAL ENTRY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CANDIDATES FOR NON-UMBILICAL ENTRY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Suspected adhesive disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Prior ventral hernia repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Extreme thinness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Abdominal wall laxity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Large pelvic mass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      NON-UMBILICAL ENTRY SITES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Left upper quadrant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Palmer's point",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Left ninth intercostal space",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other entry sites",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Transuterine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Transvaginal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      CHOOSING AN ENTRY SITE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Insufflation with trocar insertion at the same site",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Insufflation and trocar insertion at separate sites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/3274\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3274|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/22/17765\" title=\"figure 1\">",
"      Laparoscopy anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/34/32292\" title=\"figure 2\">",
"      Laparoscopy LUQ entry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/32/24069\" title=\"figure 3\">",
"      Intercostal space",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/49/6929\" title=\"figure 4\">",
"      Laparosc transuterine entry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/14/9440\" title=\"figure 5\">",
"      Laparosc tranvaginal entry",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/54/24420?source=related_link\">",
"      Culdocentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15482?source=related_link\">",
"      Management of pregnant women undergoing nonobstetric surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/3/2103?source=related_link\">",
"      Natural orifice transluminal endoscopic surgery (NOTES)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12393?source=related_link\">",
"      Oophorectomy and ovarian cystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17334?source=related_link\">",
"      Overview of conventional gynecologic laparoscopic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35401?source=related_link\">",
"      Vaginal hysterectomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_56_12169="Use of peritoneal dialysis for the treatment of acute kidney injury (acute renal failure)";
var content_f11_56_12169=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Use of peritoneal dialysis for the treatment of acute kidney injury (acute renal failure)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/56/12169/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/56/12169/contributors\">",
"     Thomas A Golper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/56/12169/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/56/12169/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/56/12169/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/56/12169/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/56/12169/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of the patient with acute kidney injury (AKI) requires meticulous attention to fluid, acid-base, and electrolyte balance as well as the removal of uremic toxins. Peritoneal dialysis (PD) is an overlooked procedure for dialytic support in AKI, as it is primarily used for the treatment of patients with end-stage renal disease (ESRD). Nevertheless, acute PD remains a viable option for the treatment of selected patients with AKI, particularly those who are hemodynamically compromised or have severe coagulation abnormalities or when other modalities are not readily available [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12169/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The advantages, indications, and contraindications of acute PD and the components of an acute PD prescription will be reviewed here. The indications for dialysis in ARF and the use of hemodialysis or continuous renal replacement therapies are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4696?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/40/28295?source=see_link\">",
"     \"Continuous renal replacement therapy in acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ADVANTAGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with other available modalities, PD has several advantages as a renal replacement therapy in patients with ARF:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      It is widely available and technically easy to perform.",
"     </li>",
"     <li>",
"      Large amounts of fluid can be removed in hemodynamically unstable patients; this fluid removal may also permit the administration of parenteral nutrition.",
"     </li>",
"     <li>",
"      Disequilibrium syndrome is not precipitated because of slow rate of solute removal.",
"     </li>",
"     <li>",
"      Easy and gradual correction of acid-base and electrolyte imbalance may be performed.",
"     </li>",
"     <li>",
"      PD access placement is relatively easy, particularly in children.",
"     </li>",
"     <li>",
"      Arterial or venous puncture and anticoagulation are not required.",
"     </li>",
"     <li>",
"      It is a highly biocompatible technique.",
"     </li>",
"     <li>",
"      Dosing is easy, particularly in children.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Logistics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute PD is widely available and can be provided without significant inconvenience in any hospital. The procedure is relatively simple, can be performed by trained intensive care unit (ICU) nursing staff, and is less labor intensive compared to other continuous renal replacement therapies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6136?source=see_link\">",
"     \"Placement and maintenance of the peritoneal dialysis catheter\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hemodynamic stability",
"    </span>",
"    &nbsp;&mdash;&nbsp;The continuous nature of acute PD involves the slow removal of solutes (eg, urea) and fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12169/abstract/4\">",
"     4",
"    </a>",
"    ]. It is therefore desirable in hemodynamically unstable patients because large amounts of fluid can be removed over a prolonged period of time. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/32/31240?source=see_link\">",
"     \"Hemodynamic instability during hemodialysis: Overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Slow correction of metabolic imbalances",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute PD enables continuous correction of acid-base status and electrolyte imbalance and the gradual removal of nitrogenous waste products. The slow removal of uremic toxins with acute PD is not associated with the development of the disequilibrium syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13125?source=see_link\">",
"     \"Dialysis disequilibrium syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Easy access placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute PD access can be achieved without serious difficulty by inserting a semirigid catheter or by placing a single cuff Tenckhoff catheter. The semirigid catheter insertion can be performed at the bedside by a nephrologist or surgeon. The Tenckhoff catheter is usually placed in the operating room by a surgeon; this flexible catheter is more comfortable for the patient who is moving around in bed and operative insertion avoids the occasional development of intestinal perforation with percutaneous insertion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6136?source=see_link\">",
"     \"Placement and maintenance of the peritoneal dialysis catheter\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many nephrologists insert their own catheters using either a fluoroscopy table with guidewire directed insertion or a peritoneoscope insertion technique. Both techniques are suitable for bedside catheter insertion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Systemic anticoagulation not required",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the PD procedure does not require systemic anticoagulation, excellent candidates for this modality include the following patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12169/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Those with a bleeding diathesis",
"     </li>",
"     <li>",
"      Patients in the immediate postoperative period",
"     </li>",
"     <li>",
"      Trauma patients",
"     </li>",
"     <li>",
"      Patients with intracerebral hemorrhage",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This is not an absolute advantage compared to hemodialysis since techniques are available to perform that latter procedure without systemic anticoagulant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/14/38120?source=see_link\">",
"     \"Hemodialysis anticoagulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hyperalimentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of hypertonic glucose PD solutions provides additional calories, which is a benefit in malnourished patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9274?source=see_link\">",
"     \"Pathogenesis and treatment of malnutrition in maintenance dialysis\"",
"    </a>",
"    .) On the other hand, glucose loading can be problematic in some patients with the use of hypertonic (2.5 and 4.25 percent dextrose) dialysates, so surveillance is important.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Tolerated in children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute PD has been frequently utilized and is the preferred form of therapy for dialysis among children with ARF [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12169/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The technique is convenient, relatively simple, and safe to perform in children, particularly since peritoneal access is easily obtained. Acute PD circumvents the need for arterial or venous puncture, both of which are difficult in children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The absolute indication for acute PD is the need for dialysis and the inability to perform any other renal replacement technique. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4696?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane\"",
"    </a>",
"    .) Given the possible advantages of PD in the acute setting, other relative indications in adults include [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12169/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemodynamically unstable patients",
"     </li>",
"     <li>",
"      The presence of a bleeding diathesis or hemorrhagic conditions",
"     </li>",
"     <li>",
"      Difficulty in obtaining blood access",
"     </li>",
"     <li>",
"      Removal of high molecular weight toxins (&gt;10 kD)",
"     </li>",
"     <li>",
"      Clinically significant hypothermia and hyperthermia",
"     </li>",
"     <li>",
"      Heart failure refractory to medical management",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since there are very few absolute contraindications for acute PD, most of the following conditions are only relative contraindications to this modality [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12169/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Recent abdominal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cardiothoracic surgery",
"     </li>",
"     <li>",
"      Diaphragmatic peritoneal-pleural connections",
"     </li>",
"     <li>",
"      Severe respiratory failure",
"     </li>",
"     <li>",
"      Life-threatening hyperkalemia",
"     </li>",
"     <li>",
"      Extremely high catabolism",
"     </li>",
"     <li>",
"      Severe volume overload in a patient not on a ventilator",
"     </li>",
"     <li>",
"      Severe gastroesophageal reflux disease",
"     </li>",
"     <li>",
"      Low peritoneal clearances",
"     </li>",
"     <li>",
"      Fecal or fungal peritonitis",
"     </li>",
"     <li>",
"      Abdominal wall cellulitis",
"     </li>",
"     <li>",
"      Acute renal failure in pregnancy",
"     </li>",
"     <li>",
"      Poorly controlled glucose intolerance",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several of these relative contraindications are often present simultaneously in patients with acute kidney injury. This has probably been the major explanation for the less frequent use of PD in the setting of acute renal failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Recent abdominal and/or cardiothoracic surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The performance of acute PD may be difficult after abdominal surgery because of the violation of the peritoneal cavity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the placement of multiple abdominal drains. Abdominal drains increase the incidence of infection and confound fluid accounting with ongoing PD. The presence of abdominal hernia or intraabdominal adhesions in these patients may also make PD difficult.",
"   </p>",
"   <p>",
"    In addition, a diaphragmatic pleuroperitoneal communication may be present in patients after cardiothoracic (CT) surgery, thereby resulting in a large pleural effusion if PD is initiated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16728?source=see_link\">",
"     \"Pleural effusions following cardiac surgery\"",
"    </a>",
"    .) However, CT surgery patients in whom the peritoneal cavity is intact and the integrity of the diaphragm is maintained, as well as those who have adequate vital capacity, are acceptable candidates for acute PD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Respiratory insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Instilling fluid in the peritoneal cavity will increase intraabdominal pressure. Among patients with respiratory failure, this increase in pressure may compromise lung function (by limiting diaphragmatic excursion), thereby interfering with respiratory exchange. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20761?source=see_link\">",
"     \"Abdominal compartment syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Severe gastroesophageal reflux disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased intraabdominal pressure may worsen symptoms in patients with severe gastroesophageal reflux disease. If PD is required, such symptoms may be diminished with the placement of patients in body positions that minimize reflux. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link\">",
"     \"Medical management of gastroesophageal reflux disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Severe hyperkalemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since PD does not remove potassium quickly, this modality is less desirable than other renal replacement therapies for the treatment of life-threatening hyperkalemia not responding to medical measures [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12169/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=see_link\">",
"     \"Treatment and prevention of hyperkalemia in adults\"",
"    </a>",
"    .) However, PD is still useful in the management of less severe hyperkalemia. In addition to the gradual removal of potassium, PD may also enhance the intracellular movement of potassium by generating bicarbonate and stimulating insulin production (via the administration of intraperitoneal glucose).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Severe volume overload",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since fluid removal is relatively limited with PD, patients with life-threatening fluid overload may not be the best candidates for the modality. The rate of ultrafiltration in PD is dependent upon multiple factors, including the hypertonicity of the glucose solution; as a result, titration of fluid removal is not as easily achieved as it is with hemodialysis.",
"   </p>",
"   <p>",
"    Nevertheless, rapid volume removal is possible using high glucose concentrations and rapid exchanges. The concern with this approach is the complication of hypernatremia (see below). Patients with severe volume overload who are not supported by a ventilator probably should not be treated with PD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Hypercatabolic patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since acute PD is limited with respect to the rate of solute removal, hypercatabolic patients should be offered an alternate renal replacement therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12169/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     ARF in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant women with ARF are potentially good candidates for acute PD therapy because of the hemodynamic stability associated with the technique. However, there is a paucity of literature related to this issue. For obvious reasons, acute semirigid PD catheters should be avoided in this setting, and permanent PD catheters should be placed under direct visualization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute PD can be performed intermittently or continuously (depending upon the desired amount of fluid and solute removal) and either manually or via an automated device [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12169/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute manual PD is usually performed by nurses, since it requires constant supervision to ensure proper inflow and accurate dwell and drain times. Nursing assistance is also required for the maintenance of a record of exchange and drain volumes, and the documentation of net ultrafiltration.",
"   </p>",
"   <p>",
"    By comparison, the use of the automated device or cycler reduces the need for constant nursing supervision. The number of interruptions is significantly decreased, since large volumes of solutions can be prepared at the beginning of the procedure. In addition, the next generation of cyclers will have modems for remote monitoring and adjustments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Acute intermittent peritoneal dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;This technique can either be performed manually or can be delivered by an automated cycling device. The prescription usually involves short dwell times with 2.0 to 3.0 liter dialysate volumes and dialysate flow rates of 2 to 6 liters per hour [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12169/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Chronic equilibrated peritoneal dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic equilibrated peritoneal dialysis (CEPD) is similar to chronic ambulatory peritoneal dialysis except that CEPD is performed in patients who are not ambulatory. This technique maintains a fairly stable fluid and solute balance and can be performed manually approximately four times daily with dwell times of four to six hours. CEPD can also be performed using an automated machine [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12169/abstract/10-12\">",
"     10-12",
"    </a>",
"    ] that provides reliable and timed exchanges, thereby eliminating the need for interruptions or breaks in the sterile technique. CEPD dosing can be adjusted based upon the amount of fluid or nitrogenous wastes that require removal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Tidal peritoneal dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tidal peritoneal dialysis (TPD) is a form of PD prescription that leaves a constant 'tidal' volume of 10 to 50 percent of the inflow volume in the peritoneal cavity after the peritoneum is filled with a large (3.0 liter) dialysate volume. This allows for rapid exchange, using a cycler, of approximately half the peritoneal fluid instilled, thereby improving overall solute clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12169/abstract/2,13,14\">",
"     2,13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Continuous flow peritoneal dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous flow peritoneal dialysis (CFPD) is an old technique that has regained popularity in the management of patients with ARF. CFPD utilizes two accesses, one for ingress and the other for egress of dialysate. A large intraperitoneal volume of dialysate is replenished in a continuous manner (single pass CFPD) or by using an external dialyzer to regenerate the sterile dialysate. This technique allows for increased dialysate flow rates of up to 300",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    and urea clearances in the range of 30 to 50",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    Several catheter designs are now available for CFPD to facilitate adequate mixing of intraperitoneal dialysate [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12169/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Peritoneal access",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the important determinants of a successful acute PD procedure is a reliable peritoneal access [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12169/abstract/9\">",
"     9",
"    </a>",
"    ]. Peritoneal access can easily be obtained by inserting a semirigid acute catheter or a single cuff Tenckhoff catheter. Each has advantages and disadvantages.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Semirigid acute catheter",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main advantage of a semirigid acute PD catheter is that it can be placed relatively easily at the bedside by a nephrologist, without the help of a surgeon [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12169/abstract/17\">",
"     17",
"    </a>",
"    ]. Since it is usually performed under local anesthesia, the potential risks of general anesthesia are avoided in the critically ill and unstable patient.",
"   </p>",
"   <p>",
"    However, there are several disadvantages to the use of semirigid catheters. The most important is the enhanced risk of infection because acute catheters do not have cuffs that protect against bacterial migration. The incidence of peritonitis is high, particularly if the catheter is left in place for more than 72 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12169/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. There is also a risk of bowel perforation both at the time of insertion and with increased length of time of placement. Thus, these catheters must be removed within 72 hours. They are also uncomfortable for the alert patient. Proper function is enhanced by keeping the colon evacuated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Cuffed permanent catheter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placement of a cuffed permanent catheter in ARF patients has several advantages [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12169/abstract/1,9,19,20\">",
"     1,9,19,20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A good immediate functioning catheter is almost assured.",
"     </li>",
"     <li>",
"      The overall incidence of infection is decreased.",
"     </li>",
"     <li>",
"      The need for repeated punctures for intermittent dialysis is obviated; such punctures are occasionally required with the acute semirigid catheter since the course of ARF and the number of PD treatments is very unpredictable.",
"     </li>",
"     <li>",
"      These soft catheters pose minimal risk to the bowel or other intraperitoneal organs and are more comfortable for the patient.",
"     </li>",
"     <li>",
"      These catheters are preferable in acute PD patients on cyclers, since acute semirigid catheters can sometimes trigger cycler alarms, leading to frequent interruptions of dialysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These advantages must be carefully weighed against the potential risks, which include complications and morbidity associated with a surgical procedure (if not inserted at the bedside by a percutaneous technique), the risks of general anesthesia, and overall stability of the patients, particularly those in the intensive care unit. We feel that the benefits outweigh the risks in most patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     COMPONENTS OF ACUTE PERITONEAL DIALYSIS PRESCRIPTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard acute PD prescription includes the following components:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Length of the dialysis session",
"     </li>",
"     <li>",
"      Dialysate composition",
"     </li>",
"     <li>",
"      Exchange volume",
"     </li>",
"     <li>",
"      Inflow and outflow (drain) periods",
"     </li>",
"     <li>",
"      Dwell time",
"     </li>",
"     <li>",
"      Number of exchanges",
"     </li>",
"     <li>",
"      Dialysate additives",
"     </li>",
"     <li>",
"      Monitoring fluid balance",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Length of dialysis session",
"    </span>",
"    &nbsp;&mdash;&nbsp;The total length of an acute PD session averages about 48 to 72 hours since a session usually consists of 48 to 72 exchanges, each of which lasts approximately one hour [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12169/abstract/18\">",
"     18",
"    </a>",
"    ].(See",
"    <a class=\"local\" href=\"#H36\">",
"     'Dwell time'",
"    </a>",
"    below.) Nevertheless, the length of the PD session can vary significantly since it is dependent upon the cause and duration of AKI, the amount of solute and fluid removal that is desired, and the risk of infection, particularly with rigid catheters.",
"   </p>",
"   <p>",
"    To accommodate the unpredictable course of AKI and the overall condition of these critically unstable patients, acute PD orders should only be written for a period of 24 hours. Periodic adjustments may need to be made based upon the patient evaluation and laboratory parameters, which should be performed at least daily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Dialysate composition",
"    </span>",
"    &nbsp;&mdash;&nbsp;PD dialysate is available in standard hydrous dextrose concentrations of 1.5, 2.5, and 4.25 percent. Most other solutions (eg, amino acids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/36/44612?source=see_link\">",
"     icodextrin",
"    </a>",
"    ) probably have little utility in the AKI setting. Dialysate solutions should be warmed to body temperature prior to infusion to avoid discomfort and enhance solute transport.",
"   </p>",
"   <p>",
"    To obtain better ultrafiltration, it is reasonable to initiate acute PD in most patients with the 2.5 percent dialysate solution. An initial dialysis solution dextrose concentration of 1.5 percent may be more appropriate in patients with only moderate amounts of fluid overload and in those who are hemodynamically unstable.",
"   </p>",
"   <p>",
"    Dialysis solutions with higher dextrose concentration can be substituted based upon the ultrafiltration requirements and the patient's hemodynamic parameters. With a standard regimen, such as a two liter exchange volume and one hour dwell time, the following average amounts of fluid can be removed over a 24 hour period:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      2.5 liters with 1.5 percent dextrose",
"     </li>",
"     <li>",
"      4.5 liters with 2.5 percent dextrose",
"     </li>",
"     <li>",
"      8.5 liters with 4.25 percent dextrose",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most practical way to achieve adequate fluid removal is by mixing and matching low and high dextrose concentration solutions. Once the patient is euvolemic, the dialysis solution should be switched to a dextrose concentration of 1.5 percent and the rate of exchange slowed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Exchange volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exchange volume is the amount of dialysate solution instilled into the peritoneal cavity during an exchange. Factors affecting this volume include the peritoneal cavity size, the presence of pulmonary disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hernia(s), the degree of uremic toxicity, and the desire to limit leakage of dialysate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Peritoneal cavity size",
"    </span>",
"    &nbsp;&mdash;&nbsp;The area of the peritoneal cavity, which can be estimated by the size of the patient, is the most important determinant of exchange volume. An average 60 to 80 kg adult can tolerate two liter exchanges without much difficulty. Smaller patients may require smaller exchange volumes, while exchange volumes of 2.5 to 3 liters may be utilized to improve dialysis efficiency in larger patients with no obvious contraindications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Respiratory insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with pulmonary diseases, such as pneumonia, chronic",
"    <span class=\"nowrap\">",
"     obstructive/restrictive",
"    </span>",
"    lung disease and respiratory failure requiring ventilatory support, may require smaller exchange volumes to prevent compromise of diaphragmatic excursions and respiration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Hernias",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with abdominal wall or inguinal hernias, the exchange volume must be reduced to limit the increase in intraabdominal pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Leakage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most clinicians keep the exchange volume low for the first day to avoid leaks from the new catheter insertion site. The dialysate volume can then be gradually increased over the ensuing three to four days as tolerated by the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Inflow time",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflow time is the time required to instill the dialysate into the peritoneal cavity, a process usually driven by gravity. Inflow usually takes approximately 10 to 15 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12169/abstract/9\">",
"     9",
"    </a>",
"    ]. Factors that determine the inflow time include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The dialysate volume",
"     </li>",
"     <li>",
"      Degree of elevation of the dialysate bag above the patient's abdomen",
"     </li>",
"     <li>",
"      The presence of absence inflow resistance resulting from kinking of the peritoneal catheter or from reduced bowel motility. Bowel evacuation is helpful.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To maximize the efficiency of dialysis, it is imperative to keep the inflow time to a minimum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Dwell time",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dwell time is the period in which the full exchange volume remains in the peritoneal cavity, or the time between the end of inflow to the beginning of the drain period. In tidal PD, some volume is intentionally left in the peritoneal cavity (ie, the peritoneal cavity is intentionally not completely emptied during drainage).",
"   </p>",
"   <p>",
"    The dwell time for standard acute PD is approximately 30 to 90 minutes, the time at which the gradients favoring urea and fluid removal are most favorable [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12169/abstract/9\">",
"     9",
"    </a>",
"    ]. A dwell time of less than 30 minutes is usually not adequate [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12169/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The usual dwell time for patients on acute CEPD is about three to six hours [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12169/abstract/9\">",
"     9",
"    </a>",
"    ]. In these patients, dwell times can be shortened to increase the total number of exchanges, thereby enhancing solute clearance. In patients with peritonitis, it is necessary to shorten the dwell time because the glucose gradient dissipates more quickly across the more permeable peritoneum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Outflow time",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outflow time is the time required to drain the effluent dialysate from the peritoneal cavity. The outflow of the dialysate is controlled by gravity and usually takes about 20 to 30 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12169/abstract/9\">",
"     9",
"    </a>",
"    ]. Some of the major determinants of the outflow time include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Volume of the dialysate effluent to be drained",
"     </li>",
"     <li>",
"      Outflow resistance, which results from kinks in the catheter, decreased bowel motility, and fibrin in the dialysate. Bowel evacuation often shortens drainage time.",
"     </li>",
"     <li>",
"      The height difference between the patient and the drainage bag",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As with the inflow time, it is important to keep the outflow time to a minimum. This can be done by adjusting the height of the drainage bag.",
"   </p>",
"   <p>",
"    It is extremely important to ensure complete drainage since incomplete drainage can result in progressive accumulation of dialysate in the peritoneal cavity, leading to respiratory embarrassment",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    abdominal discomfort. This differs from the intentional fluid left in the peritoneal cavity during tidal PD. The PD orders should specify to \"continue outflow until drainage stops\" to avoid incomplete drainage. However, complete drainage at each exchange is not mandatory, and an alternative is to assure that it occurs after every second or third exchange. This obviates the wasting of crucial dialysis with slow or inefficient drainage. Outflow is the rate-limiting step. If slow (requiring 20 to 30 minutes to complete) drainage occurs, dwell time should be increased, and the number of exchanges per day should be decreased. This is to avoid the lost contact time during slow drainages, which decreases solute removal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Number of exchanges",
"    </span>",
"    &nbsp;&mdash;&nbsp;The number of exchanges is usually determined by the amount of fluid and solute removal required in a particular patient. Although it may vary, the usual number of exchanges is about 24 per day with standard acute PD and approximately four to six per day with CEPD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Dialysis solution additives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drugs can be added to the dialysis solution to treat specific conditions. It is imperative to follow sterile technique when adding additives into dialysate solutions. Some of the commonly used dialysate additives are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , insulin, and potassium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     Heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    is occasionally added to dialysate solutions at a dose of 200 to 500 units per liter to prevent fibrin clot formation, which can obstruct the peritoneal catheter [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12169/abstract/18\">",
"     18",
"    </a>",
"    ]. Although it is usually added when plugs or strands of fibrin are visible in the drained fluid, heparin is more beneficial when added prophylactically. Once outflow obstruction is established, there is usually a poor response to heparin. Instillation of fibrinolytic agents would be necessary. Since neither heparin nor fibrinolytic agents is absorbed through the peritoneum, neither produces systemic anticoagulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h3\">",
"     Insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin is commonly administered intraperitoneally in diabetic patients on PD. The use of hypertonic dextrose-containing dialysate solutions in diabetics results in a significant glucose load; this burden can result in uncontrolled blood glucose levels if not managed with appropriate insulin dosing. Intraperitoneal insulin is usually added to the dialysate solutions and adjusted based upon frequent blood glucose monitoring (approximately every six hours). One simple algorithm consists of an increasing insulin dose to be administered in the dialysis bag with increasing dextrose concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12169/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      4 to 5",
"      <span class=\"nowrap\">",
"       units/L",
"      </span>",
"      for 1.5 percent dextrose",
"     </li>",
"     <li>",
"      5 to 7",
"      <span class=\"nowrap\">",
"       units/L",
"      </span>",
"      for 2.5 percent dextrose",
"     </li>",
"     <li>",
"      7 to 10",
"      <span class=\"nowrap\">",
"       units/L",
"      </span>",
"      for 4.5 percent dextrose",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h3\">",
"     Potassium",
"    </span>",
"    &nbsp;&mdash;&nbsp;The addition of potassium to dialysate in acute PD should never be used to correct serious hypokalemia since other routes are preferred to correct hypokalemia. Instead, the addition of potassium to dialysate in PD in the acute kidney injury setting can be used to maintain serum potassium in the normal range, especially when the avoidance of hypokalemia is imperative. Since standard PD solutions do not contain any potassium,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    can be added to the dialysate (usually 3 to 4",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    to prevent hypokalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12169/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Monitoring fluid balance",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is essential to maintain accurate flow records that monitor intake and output, and document net ultrafiltration. Daily intake and output charting and weights need to be incorporated into acute PD orders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute PD is associated with complications, some of which are serious and potentially life-threatening [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12169/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Many are preventable. A brief listing of these complications is found in this section. The approach to the diagnosis and management of peritonitis is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22617?source=see_link\">",
"     \"Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17594?source=see_link\">",
"     \"Microbiology and therapy of peritonitis in continuous peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Mechanical complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the mechanical complications are not a serious threat to life, but may result in reduced dialysis efficiency. These include the following:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h3\">",
"     Abdominal pain or discomfort",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild abdominal pain or discomfort is common and is usually secondary to abdominal distention. By comparison, moderate to severe pain may be due to a catheter-related complication or infection and warrants investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h3\">",
"     Intraabdominal hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild bleeding is frequent and can be observed with catheter placement. However, severe intraabdominal hemorrhage has been reported from catheters, particularly semirigid acute catheters.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h3\">",
"     Leakage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leakage around the PD catheter site is a common occurrence, which can be managed by reducing the exchange volume for the first 24 hours. In some cases, temporary cessation of PD may be necessary. Again, bowel evacuation may mitigate this problem.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h3\">",
"     Inadequate drainage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inadequate drainage is usually due to decreased bowel motility. Administration of bowel cathartics will improve drainage in most situations, while manipulation of the catheter may occasionally be necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h3\">",
"     Bowel perforation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bowel perforations may be observed, particularly with the placement of semirigid acute PD catheters. Patients may have severe abdominal pain, blood-tinged peritoneal effluent, intraabdominal hemorrhage, and (rarely) shock.",
"    <span class=\"nowrap\">",
"     Bowel/fecal",
"    </span>",
"    material may be noted in the effluent dialysate. Therapy consists of the cessation of acute PD treatments, catheter removal, intravenous antibiotics, and bowel repair. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6136?source=see_link\">",
"     \"Placement and maintenance of the peritoneal dialysis catheter\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h2\">",
"     Infectious complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infectious complications are common, particularly peritonitis. The incidence of peritonitis can be significantly decreased by maintaining sterile precautions during the placement of acute PD catheters and by preventing contamination during exchanges. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22617?source=see_link\">",
"     \"Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis\"",
"    </a>",
"    .) Leaking dialysate predisposes to peritonitis.",
"   </p>",
"   <p>",
"    In addition, a puncture site abscess can result from the bedside placement of acute PD catheters, particularly if meticulous attention is not given to sterile technique.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52\">",
"    <span class=\"h2\">",
"     Pulmonary complications",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53\">",
"    <span class=\"h3\">",
"     Basal atelectasis and pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atelectasis and pneumonia can result from the increase in intraabdominal pressure associated with acute PD treatments. The increased intraabdominal pressure results in inadequate lung expansion and stasis of secretions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54\">",
"    <span class=\"h3\">",
"     Pleural effusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Migration of fluid into the thoracic cavity, hydrothorax, can occur via a defect in the diaphragm or diaphragmatic lymphatics. A right sided effusion is most common. Decreasing intraabdominal pressure by lowering exchange volumes and performing acute PD in a supine position may help in most situations. Pleurodesis is rarely required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55\">",
"    <span class=\"h3\">",
"     Aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increase in intraperitoneal pressure predisposes patients to gastroesophageal reflux, increasing the risk of aspiration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56\">",
"    <span class=\"h2\">",
"     Cardiovascular complications",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57\">",
"    <span class=\"h3\">",
"     Hypovolemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excessive ultrafiltration [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12169/abstract/25\">",
"     25",
"    </a>",
"    ] or diaphragmatic elevation secondary to increased intraabdominal pressure (resulting in decreased venous return) can reduce effective tissue perfusion due to unrelated inadequate cardiac filling. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20761?source=see_link\">",
"     \"Abdominal compartment syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58\">",
"    <span class=\"h3\">",
"     Cardiac arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac arrhythmias are common, due most frequently to electrolyte and metabolic disturbances, or diaphragmatic elevation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59\">",
"    <span class=\"h2\">",
"     Metabolic complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metabolic complications are common and often preventable complications of acute PD:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60\">",
"    <span class=\"h3\">",
"     Hyperglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperglycemia can result from the high glucose concentration of the PD fluid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61\">",
"    <span class=\"h3\">",
"     Hypoglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoglycemia may occur following the cessation of PD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62\">",
"    <span class=\"h3\">",
"     Hypernatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypernatremia can be induced by the disproportionate loss of free water in the PD fluid when hypertonic exchanges are repeatedly used. Since aquaporin 1 water channels in peritoneal capillaries are activated by the glucose-generated tonicity of the dialysate, free water moves down these channels. Sodium will then diffuse down its diffusion gradient from blood to dialysate through the small intercellular \"pores.\" However, if the exchange is short in duration, there may be inadequate time for sodium diffusion to occur and the patient slowly becomes hypernatremic. This is best corrected by lengthening the duration of the exchanges so that diffusion can occur",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    using less hypertonic dialysate. Lower sodium concentration dialysates are not available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63\">",
"    <span class=\"h3\">",
"     Hypokalemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously mentioned, hypokalemia may ensue because standard PD solutions do not contain any potassium. This can be corrected by adding potassium to the dialysate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64\">",
"    <span class=\"h3\">",
"     Protein losses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protein losses occur in the dialysate, occasionally exceeding 5",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"    This is exacerbated by aggressive ultrafiltration and infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H65\">",
"    <span class=\"h1\">",
"     EFFECT ON MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A paucity of data exists concerning the effect on mortality of PD versus intermittent hemodialysis or continuous renal replacement therapies other than PD in patients with acute renal failure. Most studies have shown that the mortality and incidence of renal recovery with acute PD was at least comparable to hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12169/abstract/16\">",
"     16",
"    </a>",
"    ]. To address this question, a prospective study was performed in Vietnam in which 70 patients with acute renal failure due to either malaria or sepsis (48 and 22 individuals, respectively) were randomly assigned to either peritoneal dialysis or continuous venovenous hemofiltration (CVVH) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12169/abstract/26\">",
"     26",
"    </a>",
"    ]. A markedly increased risk of death was observed among the group administered PD (47 versus 15 percent, odds ratio 5.1, 95 percent CI 1.6 to 16). In addition, the mortality rate for patients on CVVH was unusually low. Possible reasons for the poorer survival in the PD group include lower overall creatinine clearance, use of acetate (not bicarbonate) in the PD dialysate, use of rigid PD catheters and other PD-specific factors that are not yet defined [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12169/abstract/27\">",
"     27",
"    </a>",
"    ]. In addition, the peritoneal dialysate was made in the study hospital pharmacy, while commercial peritoneal dialysate used in most countries contains lactate instead of acetate. It is likely that when CFPD gains popularity, outcome studies with this modality will be performed with an expected benefit superior to that of current acute PD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/46/5859?source=see_link\">",
"       \"Patient information: Acute kidney failure (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H116998515\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The management of the patient with acute kidney injury (AKI) requires meticulous attention to fluid, acid-base, and electrolyte balance as well as the removal of uremic toxins. Although peritoneal dialysis (PD) is an overlooked procedure for dialytic support in AKI, acute PD remains a viable option for the treatment of selected patients with AKI. This is particularly true for those who are hemodynamically compromised or have severe coagulation abnormalities or when other modalities are not readily available. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Compared with other available modalities, PD has several advantages as a renal replacement therapy in patients with AKI. These include wide availability, ease of performance and access placement, ability to remove large amounts of fluid in hemodynamically unstable patients, easy and gradual correction of acid-base and electrolyte imbalance, no need for anticoagulation, and highly biocompatible. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Advantages'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are a number of indications and contraindications for acute PD in AKI. Most are only relative indications or relative contraindications for the technique. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute PD can be performed intermittently or continuously (depending upon the desired amount of fluid and solute removal) and either manually or via an automated device.",
"     </li>",
"     <li>",
"      Acute manual PD is usually performed by nurses. By comparison, the use of the automated device or cycler reduces the need for constant nursing supervision. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The standard acute PD prescription includes the length of the dialysis session, dialysate composition, exchange volume, inflow and outflow (drain) periods, dwell time, number of exchanges, dialysate additives, and monitoring fluid balance. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Components of acute peritoneal dialysis prescription'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute PD is associated with complications, some of which are serious and potentially life-threatening. Many are preventable. (See",
"      <a class=\"local\" href=\"#H44\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12169/abstract/1\">",
"      Ash SR, Bever SL. Peritoneal dialysis for acute renal failure: the safe, effective, and low-cost modality. Adv Ren Replace Ther 1995; 2:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12169/abstract/2\">",
"      Passadakis P, Oreopoulos D. Peritoneal dialysis in acute renal failure. Int J Artif Organs 2003; 26:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12169/abstract/3\">",
"      Gabriel DP, Nascimento GV, Caramori JT, et al. High volume peritoneal dialysis for acute renal failure. Perit Dial Int 2007; 27:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12169/abstract/4\">",
"      Nolph KD. Peritoneal dialysis for acute renal failure. ASAIO Trans 1988; 34:54.",
"     </a>",
"    </li>",
"    <li>",
"     Alexander, SR, Balfe, JW, Harvey, E. Peritoneal dialysis in children. In: The Textbook of Peritoneal Dialysis, Gokal, R, Nolph, KD (Eds), Kluwer Academic Publishers, Dordrecht, 1994, p. 591.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12169/abstract/6\">",
"      Ehrich JH. Acute renal failure in infants and children. Int J Artif Organs 1996; 19:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12169/abstract/7\">",
"      Brown ST, Ahearn DJ, Nolph KD. Potassium removal with peritoneal dialysis. Kidney Int 1973; 4:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12169/abstract/8\">",
"      Cameron JS, Ogg C, Trounce JR. Peritoneal dialysis in hypercatabolic acute renal failure. Lancet 1967; 1:1188.",
"     </a>",
"    </li>",
"    <li>",
"     Lamiere, N. Principles of peritoneal dialysis and its application in acute renal failure. In: Critical Care Nephrology, Ronco, C, Bellomo, R (Eds), Kluwer Academic Publishers, Dordrecht 1998. p.1357.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12169/abstract/10\">",
"      Posen, GA, Luisello, J. Continuous equilibration peritoneal dialysis in the treatment of acute renal failure. Perit Dial Bull 1980; 1:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12169/abstract/11\">",
"      Kartirtzoglou, A, Kontesis, P, Myopoulou-Symvoulidis, D, et al. Continuous equilibration peritoneal dialysis in hypercatabolic renal failure. Perit Dial Bull 1983; 3:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12169/abstract/12\">",
"      Steiner RW. Continuous equilibration peritoneal dialysis in acute renal failure. Perit Dial Int 1989; 9:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12169/abstract/13\">",
"      Juergensen PH, Murphy AL, Pherson KA, et al. Tidal peritoneal dialysis to achieve comfort in chronic peritoneal dialysis patients. Adv Perit Dial 1999; 15:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12169/abstract/14\">",
"      Jiang L, Zeng R, Yang K, et al. Tidal versus other forms of peritoneal dialysis for acute kidney injury. Cochrane Database Syst Rev 2012; 6:CD007016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12169/abstract/15\">",
"      Amerling R, Glezerman I, Savransky E, et al. Continuous flow peritoneal dialysis: principles and applications. Semin Dial 2003; 16:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12169/abstract/16\">",
"      Ash SR. Peritoneal dialysis in acute renal failure of adults: the under-utilized modality. Contrib Nephrol 2004; 144:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12169/abstract/17\">",
"      Wong SN, Geary DF. Comparison of temporary and permanent catheters for acute peritoneal dialysis. Arch Dis Child 1988; 63:827.",
"     </a>",
"    </li>",
"    <li>",
"     Kronfol, NO. Acute Peritoneal Dialysis Prescription. In: Handbook of Dialysis, 2nd ed, Daugirdas, JT, Ing, TS (Eds), Little, Brown and Company. 1994. p.301.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12169/abstract/19\">",
"      Twardowski ZJ, Nolph KD. Blood purification in acute renal failure. Ann Intern Med 1984; 100:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12169/abstract/20\">",
"      Chadha V, Warady BA, Blowey DL, et al. Tenckhoff catheters prove superior to cook catheters in pediatric acute peritoneal dialysis. Am J Kidney Dis 2000; 35:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12169/abstract/21\">",
"      Rubin J, Adair C, Barnes T, Bower J. Dialysate flow rate and peritoneal clearance. Am J Kidney Dis 1984; 4:260.",
"     </a>",
"    </li>",
"    <li>",
"     Korbet, SM. Acute Peritoneal Dialysis Prescription. In: Handbook of Dialysis, 4th, Daugirdas, JT, Blake, PG, Ing, TS (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007. p.382.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12169/abstract/23\">",
"      Vaamonde CA, Michael UF, Metzger RA, Carroll KE Jr. Complications of acute peritoneal dialysis. J Chronic Dis 1975; 28:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12169/abstract/24\">",
"      Gault MH, Ferguson EL, Sidhu JS, Corbin RP. Fluid and electrolyte complications of peritoneal dialysis. Choice of dialysis solutions. Ann Intern Med 1971; 75:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12169/abstract/25\">",
"      Passadakis P, Malliara M, Thodis E, et al. Arterial hypotension in patients on peritoneal dialysis. Int J Artif Organs 2002; 25:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12169/abstract/26\">",
"      Phu NH, Hien TT, Mai NT, et al. Hemofiltration and peritoneal dialysis in infection-associated acute renal failure in Vietnam. N Engl J Med 2002; 347:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12169/abstract/27\">",
"      Daugirdas JT. Peritoneal dialysis in acute renal failure--why the bad outcome? N Engl J Med 2002; 347:933.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1884 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-14B9D587E9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_56_12169=[""].join("\n");
var outline_f11_56_12169=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H116998515\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ADVANTAGES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Logistics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hemodynamic stability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Slow correction of metabolic imbalances",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Easy access placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Systemic anticoagulation not required",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hyperalimentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Tolerated in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Recent abdominal and/or cardiothoracic surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Respiratory insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Severe gastroesophageal reflux disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Severe hyperkalemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Severe volume overload",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Hypercatabolic patient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ARF in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Acute intermittent peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Chronic equilibrated peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Tidal peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Continuous flow peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Peritoneal access",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Semirigid acute catheter",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Cuffed permanent catheter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      COMPONENTS OF ACUTE PERITONEAL DIALYSIS PRESCRIPTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Length of dialysis session",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Dialysate composition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Exchange volume",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Peritoneal cavity size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Respiratory insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Hernias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Leakage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Inflow time",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Dwell time",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Outflow time",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Number of exchanges",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Dialysis solution additives",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - Heparin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      - Insulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      - Potassium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Monitoring fluid balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Mechanical complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      - Abdominal pain or discomfort",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      - Intraabdominal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      - Leakage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      - Inadequate drainage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      - Bowel perforation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      Infectious complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H52\">",
"      Pulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H53\">",
"      - Basal atelectasis and pneumonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H54\">",
"      - Pleural effusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H55\">",
"      - Aspiration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H56\">",
"      Cardiovascular complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H57\">",
"      - Hypovolemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H58\">",
"      - Cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59\">",
"      Metabolic complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H60\">",
"      - Hyperglycemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H61\">",
"      - Hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H62\">",
"      - Hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H63\">",
"      - Hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H64\">",
"      - Protein losses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H65\">",
"      EFFECT ON MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H116998515\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20761?source=related_link\">",
"      Abdominal compartment syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22617?source=related_link\">",
"      Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/40/28295?source=related_link\">",
"      Continuous renal replacement therapy in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13125?source=related_link\">",
"      Dialysis disequilibrium syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/14/38120?source=related_link\">",
"      Hemodialysis anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/32/31240?source=related_link\">",
"      Hemodynamic instability during hemodialysis: Overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=related_link\">",
"      Medical management of gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17594?source=related_link\">",
"      Microbiology and therapy of peritonitis in continuous peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9274?source=related_link\">",
"      Pathogenesis and treatment of malnutrition in maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/46/5859?source=related_link\">",
"      Patient information: Acute kidney failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6136?source=related_link\">",
"      Placement and maintenance of the peritoneal dialysis catheter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16728?source=related_link\">",
"      Pleural effusions following cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4696?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=related_link\">",
"      Treatment and prevention of hyperkalemia in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_56_12170="Calcium and vitamin D supplementation in osteoporosis";
var content_f11_56_12170=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Calcium and vitamin D supplementation in osteoporosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/56/12170/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/56/12170/contributors\">",
"     Harold N Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/56/12170/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/56/12170/contributors\">",
"     Clifford J Rosen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/56/12170/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/56/12170/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/56/12170/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/56/12170/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoporosis is a disorder of bone characterized by reduced mineral density and bone mass. Multiple therapeutic regimens have been designed to prevent or treat bone loss in postmenopausal women and the elderly.",
"   </p>",
"   <p>",
"    The first step in the prevention or treatment of osteoporosis is ensuring adequate nutrition, particularly maintaining an adequate intake of calcium and vitamin D. Adequate calcium and vitamin D nutrition is important in people of all ages, especially in children and the elderly [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. In the latter group, for example, the administration of calcium and vitamin D reduces the rate of bone loss and may decrease fracture risk [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/3\">",
"     3",
"    </a>",
"    ]. In this same population, calcium and vitamin D supplementation also reduces tooth loss [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Calcium and vitamin D supplementation in the treatment of osteoporosis will be reviewed here. Detailed information regarding pharmacologic therapy for osteoporosis and the role of calcium in the pathogenesis of osteoporosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=see_link\">",
"     \"Treatment of osteoporosis in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3929?source=see_link\">",
"     \"Pathogenesis of osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcium and vitamin D are necessary for normal skeletal homeostasis. Vitamin D enhances intestinal absorption of calcium. Low concentrations of vitamin D are associated with impaired calcium absorption, a negative calcium balance, and a compensatory rise in parathyroid hormone, which results in excessive bone resorption.",
"   </p>",
"   <p>",
"    Careful calcium balance studies have shown that calcium balance is related to calcium intake; the less calcium one takes in, the more negative the calcium balance. This can be reversed by increasing calcium intake and maintaining adequate vitamin D stores. In general, calcium balance becomes positive at an average calcium intake of 1000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in premenopausal women and 1500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in postmenopausal women who do not take estrogen (",
"    <a class=\"graphic graphic_figure graphicRef71592 \" href=\"UTD.htm?6/39/6782\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of adequate calcium and vitamin D intake for skeletal health is supported by several observational studies and by randomized trial data.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Observational data",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many studies have shown an inverse relationship between serum concentrations of 25-hydroxyvitamin D (25OHD) and parathyroid hormone (PTH) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. The maximal suppression of PTH by vitamin D is one criterion by which the optimal serum 25OHD concentration is defined. Estimates vary widely but range from 20 to 40",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (50 to 100",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Other experts support the thesis that suppression of PTH by 25OHD follows a continuum across a wide range of vitamin D concentrations, and levels above 20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    are adequate to suppress PTH, assuming normal renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of vitamin D deficiency in adults\", section on 'Biochemical criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The compensatory rise in parathyroid hormone, which occurs in the setting of low vitamin D, results in excessive bone resorption. Many studies, including a large population-based study (NHANES-III) that included 13,432 participants, have shown a positive association between serum 25OHD and bone mineral density [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/6,7,10\">",
"     6,7,10",
"    </a>",
"    ]. In addition, in a prospective cohort study of 1279 community-dwelling older men, those with 25OHD &lt;20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (50",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    had significantly higher rates of hip bone loss over time (approximately 0.5 compared with 0.3",
"    <span class=\"nowrap\">",
"     percent/year",
"    </span>",
"    in men with serum 25OHD &gt;20",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In several [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/12-17\">",
"     12-17",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/18\">",
"     18",
"    </a>",
"    ], observational studies, lower serum concentrations of 25-hydroxyvitamin D (25OHD, calcidiol) were associated with a higher risk of hip fracture. In one of the largest of these studies, 400 women with hip fracture were compared with 400 matched controls and followed for seven years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/12\">",
"     12",
"    </a>",
"    ]. The mean serum 25OHD concentrations measured at study entry were significantly lower in patients who subsequently had a hip fracture (22 versus 24",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [56 versus 60",
"    <span class=\"nowrap\">",
"     nmol/L])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/12\">",
"     12",
"    </a>",
"    ]. The increased risk of hip fracture was most apparent in women with the lowest serum 25OHD concentrations (OR 1.7, 95% CI 1.0-2.8 for women in quartile one [&lt;19",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (47.5",
"    <span class=\"nowrap\">",
"     nmol/L)])",
"    </span>",
"    compared with women in quartile four (&gt;28",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [70.7",
"    <span class=\"nowrap\">",
"     nmol/L]).",
"    </span>",
"    Similar findings were reported in men (hazard ratio 2.36, 95% CI 1.08-5.15 for men in the lowest versus highest quartile of total 25OHD) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to hip fracture, serum 25OHD concentrations below 20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (30",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    have been associated with a higher risk of other osteoporotic fractures, including vertebral, wrist, and proximal humerus fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/16\">",
"     16",
"    </a>",
"    ]. In a prospective cohort study of elderly Swedish men (mean age 71 years), serum 25OHD levels below 16",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (40",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    were associated with a modestly increased risk for fracture (HR 1.65, 95% CI 1.09-2.49) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the aggregate, these observations suggest that calcium and vitamin D supplementation could protect bone by preventing bone loss and by healing subclinical osteomalacia. Although the optimal serum 25OHD concentration to maintain skeletal health is not firmly established, serum values exceeding 19 to 24",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (47.5 to 60",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    are supported by observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/11,12,15,16\">",
"     11,12,15,16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Optimal intake'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Randomized trial data",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence supporting the benefit of calcium and vitamin D supplementation in patients with osteoporosis comes largely from prospective, randomized, placebo-controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/3,20-23\">",
"     3,20-23",
"    </a>",
"    ]. Although a number of trials have reported a beneficial effect of calcium or calcium plus vitamin D on bone density in postmenopausal women and older men [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/20-29\">",
"     20-29",
"    </a>",
"    ], the data on fracture rates are more variable [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Some trials have reported a reduction in fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/3,26,32,33\">",
"     3,26,32,33",
"    </a>",
"    ], but large randomized trials have not shown any reduction in fracture risk with calcium plus vitamin D [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/22,34-36\">",
"     22,34-36",
"    </a>",
"    ]. In the largest of these trials (Women's Health Initiative), however, subgroup analysis revealed that calcium and vitamin D supplementation was associated with reduced fracture incidence in those subjects who were most compliant [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Women's Health Initiative trial randomly assigned 36,282 postmenopausal women ages 50 to 69 years (not selected for low bone density or osteoporosis) to calcium (1000",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    plus vitamin D (400 int.",
"    <span class=\"nowrap\">",
"     units/day)",
"    </span>",
"    or placebo (personal supplementation of up to 1000 mg additional calcium and 600 units vitamin D was also allowed, as was bisphosphonate, calcitonin, and hormone therapy use [over one-half of subjects were taking hormone therapy]) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/22\">",
"     22",
"    </a>",
"    ]. The following results were seen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After an average follow-up period of seven years in a subset of women who had bone mass measurements performed, hip bone mineral density was 1.06 percent higher in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/62/7143?source=see_link\">",
"       calcium-vitamin D",
"      </a>",
"      group when compared with the placebo group.",
"     </li>",
"     <li>",
"      The risk of hip fracture with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/62/7143?source=see_link\">",
"       calcium-vitamin D",
"      </a>",
"      (intention-to-treat analysis) was lower than placebo although this was not statistically significant (HR 0.88, 95% CI 0.72-1.08). However, when only compliant subjects were analyzed (predefined as those who took more than 80 percent of medication), a significant decrease in hip fracture was seen (HR 0.71, 95% 0.52-0.97).",
"     </li>",
"     <li>",
"      In all subjects, the risk of kidney stones was increased with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/62/7143?source=see_link\">",
"       calcium-vitamin D",
"      </a>",
"      supplementation (HR 1.17. 95% CI 1.02-1.34).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The trial had a number of limitations: a greater fracture reduction might have been seen if subjects had been selected on the basis of low bone density or low",
"    <span class=\"nowrap\">",
"     calcium/vitamin",
"    </span>",
"    D intake at baseline. In addition, the high percentage of women taking hormone therapy may have made it difficult to see an effect of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/62/7143?source=see_link\">",
"     calcium-vitamin D",
"    </a>",
"    on bone, and lastly, the vitamin D supplementation may have been too low.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Calcium versus vitamin D",
"    </span>",
"    &nbsp;&mdash;&nbsp;In many of these trials, it is difficult to differentiate the effect of calcium from that of vitamin D. Randomized trials of calcium only [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/37,38\">",
"     37,38",
"    </a>",
"    ] or vitamin D only [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/39-43\">",
"     39-43",
"    </a>",
"    ] have shown mixed results, likely due to differences in patient populations and study design. A meta-analysis of five trials comparing vitamin D (400 to 1370",
"    <span class=\"nowrap\">",
"     units/day)",
"    </span>",
"    with placebo in over 14,500 elderly men and women reported that vitamin D supplementation alone did not reduce fracture risk (RR 1.03, 95% CI 0.84-1.26) (",
"    <a class=\"graphic graphic_figure graphicRef56076 \" href=\"UTD.htm?13/18/13615\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/44\">",
"     44",
"    </a>",
"    ]. In the same review, a separate meta-analysis of 11 trials comparing calcium (500 to 1200",
"    <span class=\"nowrap\">",
"     mg/d)",
"    </span>",
"    plus vitamin D (300 to 1100",
"    <span class=\"nowrap\">",
"     units/day)",
"    </span>",
"    with placebo showed that combined supplementation reduced the risk for total fractures (RR 0.88, 95% CI 0.78-0.99) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/44\">",
"     44",
"    </a>",
"    ]. In a subgroup analysis, the risk reduction was larger among institutionalized elderly than community dwelling individuals (RR 0.71 versus 0.89) (",
"    <a class=\"graphic graphic_figure graphicRef63742 \" href=\"UTD.htm?24/0/24577\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Other meta-analyses of trials comparing calcium, vitamin D, or both with placebo or no treatment reported a beneficial reduction in fracture with calcium [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/45\">",
"     45",
"    </a>",
"    ] and calcium plus vitamin D [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/45-49\">",
"     45-49",
"    </a>",
"    ], but not with vitamin D alone [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. Relative risk reductions for hip fracture ranged from 0.81 to 0.87 for combined calcium plus D supplementation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/45,47,48\">",
"     45,47,48",
"    </a>",
"    ]. These findings suggest that supplementation with both calcium and vitamin D reduces the risk of fracture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     OPTIMAL INTAKE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal dose of calcium and vitamin D is uncertain. In a number of trials that reported a beneficial effect of calcium on bone density in postmenopausal women and older men, calcium supplement doses ranged from 500 to 1200 mg daily [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/20-22,25,26,28,29,50\">",
"     20-22,25,26,28,29,50",
"    </a>",
"    ]. Baseline calcium from diet varied from approximately 600 to 1000 mg daily. Thus, total (diet plus supplement) calcium intake ranged from approximately 1100 to 2000 mg daily.",
"   </p>",
"   <p>",
"    A wide range of vitamin D doses were used in the clinical trials. Some of the trials were designed to study intermittent dosing of vitamin D, specifically 100,000 units administered every three to four months [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/39,42,43\">",
"     39,42,43",
"    </a>",
"    ], whereas others used 400 units of vitamin D daily [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. One meta-analysis of randomized trials did not show differential effects on fracture risk reduction based upon the dose of vitamin D [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/44\">",
"     44",
"    </a>",
"    ]. However, another analysis showed a significant effect of vitamin D dose when the actual vitamin D intake (rather than assigned vitamin D dose) was calculated [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/51\">",
"     51",
"    </a>",
"    ]. In this pooled analysis of patient level data from 11 randomized trials (31,022 persons, mean age 76 years) of oral vitamin D supplementation, with or without calcium, compared with placebo or calcium alone, there was a significant reduction in incidence of hip (RR 0.70, 95% CI 0.58-0.86) and nonvertebral (RR 0.86, 95% CI 0.76-0.96) fracture in the individuals with the highest calculated actual vitamin D intake (median 800 units daily, range 792 to 2000 units daily) compared with controls. There was no reduction in risk of hip fracture at actual intake levels less than 792 units daily. Very few of the trials included in the meta-analysis provided information on baseline and follow-up serum 25-hydroxyvitamin D levels and, therefore, the optimal serum 25-hydroxyvitamin D concentration for fracture prevention could not be established.",
"   </p>",
"   <p>",
"    In two placebo-controlled trials of high-dose (300,000 to 500,000 units) vitamin D administered once yearly (without calcium supplementation), vitamin D did not reduce the risk of fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. In one of the trials, the risk of falls and fracture was increased in the vitamin D group (RRs 1.15, 95% CI 1.02-1.30 and 1.26, 95% CI 1.00-1.59 for falls and fracture, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/53\">",
"     53",
"    </a>",
"    ]. In the vitamin D group, the median 25OHD concentrations after one and three months were approximately 48 and 36",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (120 and 90",
"    <span class=\"nowrap\">",
"     nmol/L),",
"    </span>",
"    respectively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/12/8393?source=see_link&amp;anchor=H6#H6\">",
"     \"Prevention of falls and complications of falls in community-dwelling older persons\", section on 'Vitamin D supplementation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon the meta-analyses discussed above, we recommend 1200 mg of calcium (total of diet and supplement) and 800 int. units of vitamin D daily for most postmenopausal women with osteoporosis. Although the optimal intake (diet plus supplement) has not been clearly established in premenopausal women or in men with osteoporosis, 1000 mg of calcium (total of diet and supplement) and 400 to 600 int. units of vitamin D daily are generally suggested. We recommend",
"    <strong>",
"     not",
"    </strong>",
"    administering yearly high-dose (eg, 500,000 units) vitamin D. These recommendations are consistent with the Institute of Medicine Dietary Reference Intakes for calcium and vitamin D [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Calcium versus vitamin D'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Certain coexisting medical problems may alter these requirements. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Coexisting medical problems'",
"    </a>",
"    below.) In patients at very high risk for fracture in whom there is a clinical suspicion that the usual doses are inadequate (malabsorption, decreasing bone mass), measurement of 25OHD concentrations may be necessary to ensure that supplementation is adequate. Commercial assays measure total 25OHD, but some labs report vitamin D2 (25OHD2) and D3 (25OHD3) values separately. The optimal serum concentration refers to the combined total. The optimal serum 25OHD concentration for skeletal health is controversial. The Institute of Medicine supports 25OHD concentrations above 20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (50",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    but not chronically exceeding 50",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (125",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/9\">",
"     9",
"    </a>",
"    ]. A higher serum concentration may be necessary for skeletal benefits, particularly in older individuals at greater risk. Thus, some patients require more than 800 units daily to maintain serum levels of 30 to 40",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (75 to 100",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. Optimal serum 25OHD concentrations are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of vitamin D deficiency in adults\", section on 'Biochemical criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Optimal intake can be achieved with a combination of diet plus supplements. Calcium appears to be as well absorbed from supplements as from milk [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/57\">",
"     57",
"    </a>",
"    ] and supplements were used in the above trials demonstrating benefit from increased calcium intake. It is likely, therefore, that supplements are not less effective than calcium found naturally in dairy products.",
"   </p>",
"   <p>",
"    It is important for patients to be aware that calcium and vitamin D alone are probably insufficient to prevent bone loss [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/58,59\">",
"     58,59",
"    </a>",
"    ], although they may be beneficial in some subgroups (the elderly, those with low intake at baseline). Vitamin D supplementation is essential for a number of other reasons independent of bone health; these are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/18/38184?source=see_link\">",
"     \"Causes of vitamin D deficiency and resistance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31193?source=see_link\">",
"     \"Vitamin D and extraskeletal health\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIETARY SOURCES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Calcium",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rough method of estimating dietary calcium intake is to multiply the number of dairy servings consumed per day by 300 mg. One serving is 8 oz (240 mL) of milk or yogurt or 1 oz of hard cheese. Cottage cheese and ice cream contain approximately 150 mg of calcium per 4 oz (120 mL). Other foods in a well-balanced diet (dark green vegetables, some nuts, breads, and cereals) supply an average of 100 mg of calcium daily (",
"    <a class=\"graphic graphic_table graphicRef63342 \" href=\"UTD.htm?24/45/25307\">",
"     table 1",
"    </a>",
"    ). Some cereals, soy products, and fruit juices are fortified with up to 1000 mg of calcium.",
"   </p>",
"   <p>",
"    While it is possible to estimate the amount of calcium in other sources of dietary calcium such as green vegetables and nuts, calcium absorption from these sources is more variable. In addition, vegetables and nuts have much lower calcium content than dairy products so that much more would need to be consumed to meet daily requirements. Detailed lists of the calcium content of various foods are available from the US Department of Agriculture [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Calcium supplements or increased intake of dairy products should be recommended if dietary calcium intake is below recommended levels. If supplements are needed, it is important to note that the intake suggested above reflects the amount of elemental calcium in supplements, not the total calcium content. In addition, the total intake of calcium (diet plus supplements) should not routinely exceed 2000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    because of the possibility of adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Adverse effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Vitamin D",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, commercially fortified milk is the largest source of dietary vitamin D, containing approximately 100 int. units of vitamin D per 8 oz [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/62\">",
"     62",
"    </a>",
"    ]. Thus, vitamin D intake can be estimated by multiplying the number of cups of milk consumed per day by 100. Vitamin D is also found in cod liver oil, but some fish oils also contain high doses of vitamin A, and therefore they are not the best source of vitamin D [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/63\">",
"     63",
"    </a>",
"    ]. Sunlight exposure also increases vitamin D concentrations. However, the use of sunscreen products effectively blocks vitamin D synthesis. In addition, the skin of those older than 70 years of age does not convert vitamin D as efficiently as in younger individuals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9462?source=see_link\">",
"     \"Metabolism of vitamin D\"",
"    </a>",
"    .) Thus, vitamin D supplements are generally necessary. The safe upper limit for vitamin D is unclear but is above 2000 units daily. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Adverse effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUPPLEMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients requiring calcium and vitamin D supplementation, a daily multivitamin is both convenient and economical. However, most multivitamins contain only 400 int. units of vitamin D, which is insufficient, and not all individuals require or tolerate multivitamins. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=see_link\">",
"     \"Vitamin supplementation in disease prevention\"",
"    </a>",
"    .) Postmenopausal women with osteoporosis can also increase vitamin D and calcium intake by taking plain vitamin D supplements (usually 400 units per tablet)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    calcium supplements that also contain vitamin D, usually 200 units per 500 mg or 600 mg of calcium. It is important to note that there is not a direct linear relationship between supplemental dosing and level of serum 250HD. Individuals with low levels at baseline (&lt;10",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    generally have an increase in 250HD of 1.0 to 1.5",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    for every 100 IU of vitamin D; however, individuals at levels above 20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    show an attenuated increase in serum 250HD (ie, usually 0.5",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    for every 100 units).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Calcium",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most widely available calcium supplements are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38628?source=see_link\">",
"     calcium citrate",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef78814 \" href=\"UTD.htm?36/12/37068\">",
"     table 2",
"    </a>",
"    ). Calcium carbonate is cheapest and therefore often a good first choice. However, there are some limitations to its use compared with calcium citrate:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"       Calcium carbonate",
"      </a>",
"      absorption is better when taken with meals; in comparison,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38628?source=see_link\">",
"       calcium citrate",
"      </a>",
"      is well absorbed in the fasting state [",
"      <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/57,64\">",
"       57,64",
"      </a>",
"      ] and is better [",
"      <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/65\">",
"       65",
"      </a>",
"      ] or equally absorbed [",
"      <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/66\">",
"       66",
"      </a>",
"      ] compared with calcium carbonate taken with a meal. This may be particularly important in patients with achlorhydria. Thus, it seems prudent to take calcium carbonate with meals, since it is often hard to know who has achlorhydria.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"       Calcium carbonate",
"      </a>",
"      is also poorly absorbed in patients taking proton pump inhibitors or H2 blockers. We usually recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38628?source=see_link\">",
"       calcium citrate",
"      </a>",
"      as a first line calcium supplement in these patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9562?source=see_link&amp;anchor=H16#H16\">",
"       \"Drugs that affect bone metabolism\", section on 'Proton pump inhibitors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Many natural",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"       calcium carbonate",
"      </a>",
"      preparations such as oyster shells or bone meal contain some lead, and small amounts are present in refined (antacid) calcium carbonate or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38628?source=see_link\">",
"       calcium citrate",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/67,68\">",
"       67,68",
"      </a>",
"      ]. The low lead levels in calcium supplements are unlikely to be a health risk, because calcium blocks lead absorption [",
"      <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intake recommendations given above refer to the amount of",
"    <strong>",
"     elemental calcium",
"    </strong>",
"    . (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Optimal intake'",
"    </a>",
"    above.) As an example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    is 40 percent elemental calcium, so that 1250 mg of calcium carbonate contains 500 mg of elemental calcium. The dose of elemental calcium is listed on most supplement labels.",
"   </p>",
"   <p>",
"    Calcium supplementation in excess of 500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    should be given in divided doses. Higher individual doses are associated with a plateau in calcium absorption that may prevent the attainment of positive calcium balance [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, concern that high dietary calcium increases the risk of nephrolithiasis in otherwise healthy patients is unfounded, as the incidence of stone formation appears to be reduced in both men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/65,71\">",
"     65,71",
"    </a>",
"    ]. This issue is discussed in detail separately. However, calcium supplements have been associated with an increased risk of kidney stones [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/65\">",
"     65",
"    </a>",
"    ]. The Women&rsquo;s Health Initiative (WHI) trial described above also reported an increased risk of kidney stones in postmenopausal women who were supplemented with calcium and vitamin D when compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=see_link&amp;anchor=H18#H18\">",
"     \"Risk factors for calcium stones in adults\", section on 'Calcium'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other potential side effects of high calcium intake include dyspepsia and constipation. In addition, calcium supplements interfere with the absorption of iron and thyroid hormone and, therefore, these medications should be taken at different times.",
"   </p>",
"   <p>",
"    The effect of calcium supplementation on risk of cardiovascular disease is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/72-76\">",
"     72-76",
"    </a>",
"    ]. There may be benefits of calcium supplementation on risk factors, such as a reduction in weight, blood pressure, and in serum cholesterol concentrations (of about 5 percent) in patients with mild to moderate hypercholesterolemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33866?source=see_link&amp;anchor=H35#H35\">",
"     \"Drug therapy of obesity\", section on 'Calcium'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42679?source=see_link&amp;anchor=H13#H13\">",
"     \"Diet in the treatment and prevention of hypertension\", section on 'Calcium'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28474?source=see_link&amp;anchor=H17#H17\">",
"     \"Lipid lowering with diet or dietary supplements\", section on 'Calcium'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the WHI trial described above, 36,282 postmenopausal women ages 50 to 69 years were randomly assigned to calcium (1000",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    plus vitamin D (400 int.",
"    <span class=\"nowrap\">",
"     units/day)",
"    </span>",
"    or placebo (personal supplementation of up to 1000 mg additional calcium and 600 units vitamin D was also allowed) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/22\">",
"     22",
"    </a>",
"    ]. Cardiovascular disease was a prespecified secondary outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/72\">",
"     72",
"    </a>",
"    ]. At baseline, mean calcium intake (diet plus supplements) was approximately 1150",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    and 54 percent of participants were taking non-protocol calcium supplements. After seven years, calcium plus vitamin D supplementation had no significant effect on the incidence of myocardial infarction (confirmed in 411 and 390 women assigned to",
"    <span class=\"nowrap\">",
"     calcium/vitamin",
"    </span>",
"    D and placebo, respectively; HR 1.05, 95% CI 0.91-1.20) or stroke (362 versus 377 strokes, HR 0.95, 95% CI 0.82-1.10).",
"   </p>",
"   <p>",
"    However, the findings of two meta-analyses evaluating calcium or calcium with or without vitamin D supplementation (eight and nine trials, respectively) raised some concern about an increased risk of myocardial infarction (MI) in patients randomly assigned to calcium versus placebo (166 versus 130 MIs, pooled relative risk 1.27, 95% CI 1.01-1.59) or calcium with or without vitamin D versus placebo (374 versus 302 MIs, RR 1.24, 95% CI 1.07-1.45) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. The meta-analyses had several limitations. The trials in the meta-analyses were not designed to explore cardiovascular outcomes, which were not uniformly collected or adjudicated. Patient level data were not available from all the trials. In one of the meta-analyses, only data from a subgroup of participants in the Women&rsquo;s Health Initiative (those not taking personal calcium supplements at randomization), rather than all participants, were included in the analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/74\">",
"     74",
"    </a>",
"    ]. The baseline dietary calcium intake in the trials ranged from 750 to 1240 mg daily and the addition of calcium supplements raised total intake over 1500 to 2000 mg daily in many patients, which is higher than recommended.",
"   </p>",
"   <p>",
"    Another meta-analysis evaluated the effects of supplementation with calcium, vitamin D, or both on cardiovascular disease (CVD), including CVD death, nonfatal coronary heart disease or myocardial infarction, and nonfatal stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/75\">",
"     75",
"    </a>",
"    ]. In a pooled analysis of four trials, calcium supplementation did not significantly increase the risk of CVD events compared with placebo (RR 1.14, 95% CI 0.92-1.41). In these trials, dietary intake of calcium ranged from 800 to 900 mg daily and the dose of calcium supplements ranged from 600 to 1200 mg daily. In a pooled analysis of two trials (one of which was the Women&rsquo;s Health Initiative and included data from all participants), combined vitamin D and calcium supplementation versus double placebos (RR 1.04, 95% CI 0.92-1.18) and vitamin D alone compared with placebo (RR 0.90, 95% CI 0.77-1.05) also did not significantly increase the risk of CVD, and there was a suggestion of a benefit in CVD reduction with vitamin D alone. As in the meta-analyses described above, none of the trials were designed to assess the effects of calcium or vitamin D on cardiovascular outcomes.",
"   </p>",
"   <p>",
"    A prospective cohort study (23,980 participants with mean follow-up of 11 years) published after the meta-analyses showed a significant reduction in MI risk in patients with higher versus lower total dietary calcium intake (HR 0.69, 95% CI 0.50-0.94 for the third compared with lowest quartile of total dietary calcium intake) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/77\">",
"     77",
"    </a>",
"    ]. In a separate analysis using the same cohort, there was a significant increased risk of myocardial infarction in users versus nonusers of calcium supplements (HR 1.86, 95% CI 1.17-2.96). However, there were only 20 events in the calcium group, which reduced the precision of the analysis. Thus, it is unclear from the present data whether intake of dietary calcium versus calcium supplements confers different cardiovascular risks.",
"   </p>",
"   <p>",
"    Randomized trials of calcium and vitamin D supplementation with CVD events ascertained as a primary endpoint are required to determine if calcium supplementation is associated with an increased occurrence of these events [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/78\">",
"     78",
"    </a>",
"    ]. In the interim, we suggest combined calcium and vitamin D supplementation, as reviewed above. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Optimal intake'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Vitamin D",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin D is generally easier to absorb than calcium and it may be taken as one dose with or without food. The two commonly available forms of vitamin D supplements are ergocalciferol and cholecalciferol. Some [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/79,80\">",
"     79,80",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/81\">",
"     81",
"    </a>",
"    ], studies suggest that cholecalciferol (vitamin D3) increases serum 25OHD more efficiently than does ergocalciferol (vitamin D2) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. In addition, vitamin D2 is not accurately measured in all vitamin D assays [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/82\">",
"     82",
"    </a>",
"    ]. For these reasons, we suggest supplementation with cholecalciferol when possible, rather than ergocalciferol.",
"   </p>",
"   <p>",
"    Calcitriol is the most active metabolite of vitamin D. It can frequently cause hypercalcemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypercalciuria, necessitating close monitoring and adjustment of calcium intake and calcitriol dose. Therefore, we do not recommend calcitriol for vitamin D supplementation in osteoporosis. However, calcitriol or other vitamin D analogs are an important component of therapy for secondary hyperparathyroidism in chronic kidney disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32681?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intake at which the dose of vitamin D becomes toxic is not clear. In 2010, the Institute of Medicine defined the Safe Upper Limit for vitamin D as 4000 int. units per day [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/54\">",
"     54",
"    </a>",
"    ]. However, higher doses are sometimes required for the initial treatment of vitamin D deficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39990?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of vitamin D\", section on 'Excess'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of vitamin D deficiency in adults\", section on 'Dosing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is important to inquire about additional dietary supplements (some of which contain vitamin D) that patients may be taking before prescribing extra vitamin D [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/83\">",
"     83",
"    </a>",
"    ]. Excessive vitamin D, especially combined with calcium supplementation, may cause hypercalcemia, hypercalciuria, and kidney stones. In addition, chronically high levels of 250HD (exceeding 40 and 50",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [100 and 125",
"    <span class=\"nowrap\">",
"     nmol/L],",
"    </span>",
"    respectively) have been found in some association studies to be linked to a modest increase in risk of some cancers (eg, pancreatic) and mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31193?source=see_link&amp;anchor=H651662#H651662\">",
"     \"Vitamin D and extraskeletal health\", section on 'Cancer'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31193?source=see_link&amp;anchor=H651704#H651704\">",
"     \"Vitamin D and extraskeletal health\", section on 'Mortality'",
"    </a>",
"    .) More studies are needed to define the upper level of serum 250HD that is safe.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Coexisting medical problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many individuals with osteoporosis have underlying medical conditions that predispose to osteoporosis. Recommendations for calcium and vitamin D supplementation may vary with the underlying condition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Vitamin D deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin D deficiency may result from inadequate intake combined with lack of sun exposure, malabsorption, or genetic abnormalities in vitamin D metabolism. Vitamin D deficiency or insufficiency is often overlooked, unless 25OHD concentrations are measured. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11128?source=see_link&amp;anchor=H15#H15\">",
"     \"Diagnosis and evaluation of osteoporosis in postmenopausal women\", section on 'Initial evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Commonly used antiresorptive agents, such as bisphosphonates, may be less effective in patients with occult vitamin D deficiency. In addition, hypocalcemia can occur in patients with vitamin D deficiency who are treated with bisphosphonates, particularly when administered intravenously, prior to repletion of vitamin D [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. Individuals with vitamin D deficiency generally require higher doses of vitamin D initially, followed by maintenance doses as described above. The treatment of vitamin D deficiency is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=see_link\">",
"     \"Treatment of vitamin D deficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Primary hyperparathyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adequate dietary calcium (800 to 1000 mg daily) and vitamin D supplementation (400 to 600 units daily) is encouraged for patients with primary hyperparathyroidism. Cautious calcium supplementation is safe in individuals with poor dietary intake. Patients with overt vitamin D deficiency may have more clinically significant hyperparathyroidism and may require cautious supplementation with higher doses of vitamin D. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8954?source=see_link&amp;anchor=H14#H14\">",
"     \"Management of primary hyperparathyroidism\", section on 'Preventive measures'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1338?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations of primary hyperparathyroidism\", section on 'Classical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Underlying gastrointestinal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with malabsorption or short-bowel syndrome may have higher than normal calcium and vitamin D requirements due to diminished calcium absorption. This problem can occur even with relatively minor disruption of gastrointestinal function, as in patients who have undergone gastrectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/86-88\">",
"     86-88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several factors can contribute to the malabsorption of calcium in these patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduced gastric acidity and mild generalized malabsorption due to impaired mixing of food with pancreatic secretions and decreased gut transit time.",
"     </li>",
"     <li>",
"      Binding of calcium to fatty acids in patients with steatorrhea [",
"      <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/86\">",
"       86",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Vitamin D deficiency due to both malabsorption and the tendency to avoid milk [",
"      <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/87-89\">",
"       87-89",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Optimal calcium and vitamin D supplementation must be determined empirically and must be adjusted in order to normalize the serum concentrations of calcium, phosphate, alkaline phosphatase, 25OHD, and parathyroid hormone, and 24-hour urinary calcium excretion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41898?source=see_link\">",
"     \"Complications of bariatric surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/54/30569?source=see_link\">",
"     \"Metabolic bone disease in inflammatory bowel disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4714?source=see_link\">",
"     \"Management of celiac disease in adults\"",
"    </a>",
"    .) The American Gastroenterological Association (AGA) technical review and guideline for osteoporosis in gastrointestinal diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/90,91\">",
"     90,91",
"    </a>",
"    ], as well as other AGA guidelines, can be accessed through the",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     AGA website",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Proton pump inhibitor therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"     Calcium carbonate",
"    </a>",
"    is poorly absorbed in patients taking proton pump inhibitors or H2 blockers. We usually recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38628?source=see_link\">",
"     calcium citrate",
"    </a>",
"    as a first line calcium supplement in these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9562?source=see_link&amp;anchor=H16#H16\">",
"     \"Drugs that affect bone metabolism\", section on 'Proton pump inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Diuretic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concomitant administration of diuretics can influence calcium balance. Loop diuretics increase calcium excretion, while thiazide diuretics have a hypocalciuric effect that can protect against calcium stones and possible bone loss. The effect of diuretics on optimal dietary calcium intake is not known. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9562?source=see_link\">",
"     \"Drugs that affect bone metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Cystic fibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with advanced cystic fibrosis are usually deficient in vitamin D, and they require more than the usual recommended dose for young adults (eg, more than 400 int.",
"    <span class=\"nowrap\">",
"     units/day).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link&amp;anchor=H14#H14\">",
"     \"Cystic fibrosis: Clinical manifestations and diagnosis\", section on 'Musculoskeletal disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Granulomatous diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with granulomatous diseases, such as sarcoidosis, are often treated with glucocorticoids and therefore have an increased risk of osteoporosis. However, they also tend to have hypercalcemia and hypercalciuria due to extrarenal production of calcitriol by activated macrophages and consequent increased intestinal absorption of calcium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2310?source=see_link\">",
"     \"Hypercalcemia in granulomatous diseases\"",
"    </a>",
"    .) In patients with sarcoidosis and osteoporosis, serum and urinary calcium and vitamin D concentrations must be carefully monitored if supplements are required [",
"    <a class=\"abstract\" href=\"UTD.htm?11/56/12170/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/12/36034?source=see_link\">",
"       \"Patient information: Calcium and vitamin D for bone health (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=see_link\">",
"       \"Patient information: Calcium and vitamin D for bone health (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adequate calcium and vitamin D intake can result in positive calcium balance and a reduction in the rate of loss of bone; the effect upon fracture risk is less clear, although combined calcium and vitamin D supplementation appears to reduce fracture risk. Calcium and vitamin D supplementation are relatively inexpensive and seem reasonable to recommend in patients with a low dietary intake. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Efficacy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest calcium and vitamin D supplementation in patients with osteoporosis and inadequate dietary intake (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). In postmenopausal women, 1200 mg of elemental calcium daily, total diet plus supplement, and 800 int. units of vitamin D daily are suggested. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Optimal intake'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Although the optimal intake (diet plus supplement) has not been clearly established in premenopausal women or in men with osteoporosis, 1000 mg of calcium (total diet plus supplement) and 400 to 600 int. units of vitamin D daily are generally suggested. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42553?source=see_link\">",
"       \"Evaluation and treatment of premenopausal osteoporosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=see_link\">",
"       \"Treatment of osteoporosis in men\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The dose of calcium and vitamin D may vary in individuals with coexisting medical conditions. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Coexisting medical problems'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Individuals with vitamin D deficiency require higher doses of vitamin D. The evaluation and treatment of vitamin D deficiency are reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=see_link\">",
"       \"Treatment of vitamin D deficiency in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/18/38184?source=see_link\">",
"       \"Causes of vitamin D deficiency and resistance\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In most individuals,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"       calcium carbonate",
"      </a>",
"      taken with meals is adequate for supplementation and is inexpensive. However, we recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38628?source=see_link\">",
"       calcium citrate",
"      </a>",
"      in patients taking proton pump inhibitors or H2 blockers or who have achlorhydria (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Supplements'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9562?source=see_link&amp;anchor=H16#H16\">",
"       \"Drugs that affect bone metabolism\", section on 'Proton pump inhibitors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest cholecalciferol (vitamin D3), when available, rather than ergocalciferol (vitamin D2) for vitamin D supplementation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Supplements'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The total intake of calcium (diet plus supplements) should not routinely exceed 2000",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      The safe upper limit for vitamin D is 4000 int. units daily. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/1\">",
"      Heaney RP. Thinking straight about calcium. N Engl J Med 1993; 328:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/2\">",
"      Johnston CC Jr, Miller JZ, Slemenda CW, et al. Calcium supplementation and increases in bone mineral density in children. N Engl J Med 1992; 327:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/3\">",
"      Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992; 327:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/4\">",
"      Krall EA, Wehler C, Garcia RI, et al. Calcium and vitamin D supplements reduce tooth loss in the elderly. Am J Med 2001; 111:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/5\">",
"      Heaney RP, Recker RR, Saville PD. Menopausal changes in calcium balance performance. J Lab Clin Med 1978; 92:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/6\">",
"      Villareal DT, Civitelli R, Chines A, Avioli LV. Subclinical vitamin D deficiency in postmenopausal women with low vertebral bone mass. J Clin Endocrinol Metab 1991; 72:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/7\">",
"      Kuchuk NO, van Schoor NM, Pluijm SM, et al. Vitamin D status, parathyroid function, bone turnover, and BMD in postmenopausal women with osteoporosis: global perspective. J Bone Miner Res 2009; 24:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/8\">",
"      Heaney RP. Vitamin D endocrine physiology. J Bone Miner Res 2007; 22 Suppl 2:V25.",
"     </a>",
"    </li>",
"    <li>",
"     file://books.nap.edu/openbook.php?record_id=13050 (Accessed on December 08, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/10\">",
"      Bischoff-Ferrari HA, Dietrich T, Orav EJ, Dawson-Hughes B. Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am J Med 2004; 116:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/11\">",
"      Ensrud KE, Taylor BC, Paudel ML, et al. Serum 25-hydroxyvitamin D levels and rate of hip bone loss in older men. J Clin Endocrinol Metab 2009; 94:2773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/12\">",
"      Cauley JA, Lacroix AZ, Wu L, et al. Serum 25-hydroxyvitamin D concentrations and risk for hip fractures. Ann Intern Med 2008; 149:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/13\">",
"      LeBoff MS, Kohlmeier L, Hurwitz S, et al. Occult vitamin D deficiency in postmenopausal US women with acute hip fracture. JAMA 1999; 281:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/14\">",
"      Edwards BJ, Langman CB, Bunta AD, et al. Secondary contributors to bone loss in osteoporosis related hip fractures. Osteoporos Int 2008; 19:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/15\">",
"      Looker AC, Mussolino ME. Serum 25-hydroxyvitamin D and hip fracture risk in older U.S. white adults. J Bone Miner Res 2008; 23:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/16\">",
"      Gerdhem P, Ringsberg KA, Obrant KJ, Akesson K. Association between 25-hydroxy vitamin D levels, physical activity, muscle strength and fractures in the prospective population-based OPRA Study of Elderly Women. Osteoporos Int 2005; 16:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/17\">",
"      Cauley JA, Parimi N, Ensrud KE, et al. Serum 25-hydroxyvitamin D and the risk of hip and nonspine fractures in older men. J Bone Miner Res 2010; 25:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/18\">",
"      Cummings SR, Browner WS, Bauer D, et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1998; 339:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/19\">",
"      Melhus H, Snellman G, Gedeborg R, et al. Plasma 25-hydroxyvitamin D levels and fracture risk in a community-based cohort of elderly men in Sweden. J Clin Endocrinol Metab 2010; 95:2637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/20\">",
"      Daly RM, Brown M, Bass S, et al. Calcium- and vitamin D3-fortified milk reduces bone loss at clinically relevant skeletal sites in older men: a 2-year randomized controlled trial. J Bone Miner Res 2006; 21:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/21\">",
"      Meier C, Woitge HW, Witte K, et al. Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial. J Bone Miner Res 2004; 19:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/22\">",
"      Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006; 354:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/23\">",
"      Zhu K, Bruce D, Austin N, et al. Randomized controlled trial of the effects of calcium with or without vitamin D on bone structure and bone-related chemistry in elderly women with vitamin D insufficiency. J Bone Miner Res 2008; 23:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/24\">",
"      Dawson-Hughes B, Dallal GE, Krall EA, et al. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. N Engl J Med 1990; 323:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/25\">",
"      Reid IR, Ames RW, Evans MC, et al. Effect of calcium supplementation on bone loss in postmenopausal women. N Engl J Med 1993; 328:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/26\">",
"      Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/27\">",
"      Peacock M, Liu G, Carey M, et al. Effect of calcium or 25OH vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60. J Clin Endocrinol Metab 2000; 85:3011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/28\">",
"      Reid IR, Mason B, Horne A, et al. Randomized controlled trial of calcium in healthy older women. Am J Med 2006; 119:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/29\">",
"      Reid IR, Ames R, Mason B, et al. Randomized controlled trial of calcium supplementation in healthy, nonosteoporotic, older men. Arch Intern Med 2008; 168:2276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/30\">",
"      Cranney A, Weiler HA, O'Donnell S, Puil L. Summary of evidence-based review on vitamin D efficacy and safety in relation to bone health. Am J Clin Nutr 2008; 88:513S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/31\">",
"      Moyer VA, on behalf of the U.S. Preventive Services Task Force*. Vitamin D and Calcium Supplementation to Prevent Fractures in Adults: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/32\">",
"      Larsen ER, Mosekilde L, Foldspang A. Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study. J Bone Miner Res 2004; 19:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/33\">",
"      Cumming RG, Nevitt MC. Calcium for prevention of osteoporotic fractures in postmenopausal women. J Bone Miner Res 1997; 12:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/34\">",
"      Grant AM, Avenell A, Campbell MK, et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet 2005; 365:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/35\">",
"      Porthouse J, Cockayne S, King C, et al. Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ 2005; 330:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/36\">",
"      Salovaara K, Tuppurainen M, K&auml;rkk&auml;inen M, et al. Effect of vitamin D(3) and calcium on fracture risk in 65- to 71-year-old women: a population-based 3-year randomized, controlled trial--the OSTPRE-FPS. J Bone Miner Res 2010; 25:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/37\">",
"      Recker RR, Hinders S, Davies KM, et al. Correcting calcium nutritional deficiency prevents spine fractures in elderly women. J Bone Miner Res 1996; 11:1961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/38\">",
"      Prince RL, Devine A, Dhaliwal SS, Dick IM. Effects of calcium supplementation on clinical fracture and bone structure: results of a 5-year, double-blind, placebo-controlled trial in elderly women. Arch Intern Med 2006; 166:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/39\">",
"      Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 2003; 326:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/40\">",
"      Lips P, Graafmans WC, Ooms ME, et al. Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial. Ann Intern Med 1996; 124:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/41\">",
"      Meyer HE, Smedshaug GB, Kvaavik E, et al. Can vitamin D supplementation reduce the risk of fracture in the elderly? A randomized controlled trial. J Bone Miner Res 2002; 17:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/42\">",
"      Lyons RA, Johansen A, Brophy S, et al. Preventing fractures among older people living in institutional care: a pragmatic randomised double blind placebo controlled trial of vitamin D supplementation. Osteoporos Int 2007; 18:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/43\">",
"      Law M, Withers H, Morris J, Anderson F. Vitamin D supplementation and the prevention of fractures and falls: results of a randomised trial in elderly people in residential accommodation. Age Ageing 2006; 35:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/44\">",
"      Chung M, Lee J, Terasawa T, et al. Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 155:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/45\">",
"      Tang BM, Eslick GD, Nowson C, et al. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 2007; 370:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/46\">",
"      Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 2005; 293:2257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/47\">",
"      Boonen S, Lips P, Bouillon R, et al. Need for additional calcium to reduce the risk of hip fracture with vitamin d supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab 2007; 92:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/48\">",
"      Avenell A, Gillespie WJ, Gillespie LD, O'Connell D. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev 2009; :CD000227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/49\">",
"      DIPART (Vitamin D Individual Patient Analysis of Randomized Trials) Group. Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe. BMJ 2010; 340:b5463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/50\">",
"      Storm D, Eslin R, Porter ES, et al. Calcium supplementation prevents seasonal bone loss and changes in biochemical markers of bone turnover in elderly New England women: a randomized placebo-controlled trial. J Clin Endocrinol Metab 1998; 83:3817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/51\">",
"      Bischoff-Ferrari HA, Willett WC, Orav EJ, et al. A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med 2012; 367:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/52\">",
"      Smith H, Anderson F, Raphael H, et al. Effect of annual intramuscular vitamin D on fracture risk in elderly men and women--a population-based, randomized, double-blind, placebo-controlled trial. Rheumatology (Oxford) 2007; 46:1852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/53\">",
"      Sanders KM, Stuart AL, Williamson EJ, et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 2010; 303:1815.",
"     </a>",
"    </li>",
"    <li>",
"     Institute of Medicine. Report at a Glance, Report Brief: Dietary Reference Intakes for Calcium and Vitamin D, released 11/30/2010. file://www.iom.edu/Reports/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D/Report-Brief.aspx (Accessed on December 01, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/55\">",
"      Dawson-Hughes B, Heaney RP, Holick MF, et al. Estimates of optimal vitamin D status. Osteoporos Int 2005; 16:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/56\">",
"      Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96:1911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/57\">",
"      Sheikh MS, Santa Ana CA, Nicar MJ, et al. Gastrointestinal absorption of calcium from milk and calcium salts. N Engl J Med 1987; 317:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/58\">",
"      Prince RL, Smith M, Dick IM, et al. Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation, and hormone-replacement therapy. N Engl J Med 1991; 325:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/59\">",
"      Aloia JF, Vaswani A, Yeh JK, et al. Calcium supplementation with and without hormone replacement therapy to prevent postmenopausal bone loss. Ann Intern Med 1994; 120:97.",
"     </a>",
"    </li>",
"    <li>",
"     US Department of Agriculture. USDA National Nutrient Database for Standard Reference, Release 18. file://www.ars.usda.gov/Services/docs.htm?docid=9673 (Accessed on October 20, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/61\">",
"      Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/62\">",
"      Holick MF, Shao Q, Liu WW, Chen TC. The vitamin D content of fortified milk and infant formula. N Engl J Med 1992; 326:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/63\">",
"      Johansson S, Melhus H. Vitamin A antagonizes calcium response to vitamin D in man. J Bone Miner Res 2001; 16:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/64\">",
"      Recker RR. Calcium absorption and achlorhydria. N Engl J Med 1985; 313:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/65\">",
"      Heller HJ, Greer LG, Haynes SD, et al. Pharmacokinetic and pharmacodynamic comparison of two calcium supplements in postmenopausal women. J Clin Pharmacol 2000; 40:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/66\">",
"      Heaney, RP. 1999; Osteoporos Int 1999; 9:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/67\">",
"      Bourgoin BP, Evans DR, Cornett JR, et al. Lead content in 70 brands of dietary calcium supplements. Am J Public Health 1993; 83:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/68\">",
"      Ross EA, Szabo NJ, Tebbett IR. Lead content of calcium supplements. JAMA 2000; 284:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/69\">",
"      Heaney RP. Lead in calcium supplements: cause for alarm or celebration? JAMA 2000; 284:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/70\">",
"      Harvey JA, Zobitz MM, Pak CY. Dose dependency of calcium absorption: a comparison of calcium carbonate and calcium citrate. J Bone Miner Res 1988; 3:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/71\">",
"      Curhan GC, Willett WC, Speizer FE, et al. Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Intern Med 1997; 126:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/72\">",
"      Hsia J, Heiss G, Ren H, et al. Calcium/vitamin D supplementation and cardiovascular events. Circulation 2007; 115:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/73\">",
"      Bolland MJ, Avenell A, Baron JA, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010; 341:c3691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/74\">",
"      Bolland MJ, Grey A, Avenell A, et al. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ 2011; 342:d2040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/75\">",
"      Wang L, Manson JE, Song Y, Sesso HD. Systematic review: Vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med 2010; 152:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/76\">",
"      Lewis JR, Calver J, Zhu K, et al. Calcium supplementation and the risks of atherosclerotic vascular disease in older women: results of a 5-year RCT and a 4.5-year follow-up. J Bone Miner Res 2011; 26:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/77\">",
"      Li K, Kaaks R, Linseisen J, Rohrmann S. Associations of dietary calcium intake and calcium supplementation with myocardial infarction and stroke risk and overall cardiovascular mortality in the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition study (EPIC-Heidelberg). Heart 2012; 98:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/78\">",
"      Hennekens CH, Barice EJ. Calcium supplements and risk of myocardial infarction: a hypothesis formulated but not yet adequately tested. Am J Med 2011; 124:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/79\">",
"      Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 2004; 89:5387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/80\">",
"      Trang HM, Cole DE, Rubin LA, et al. Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. Am J Clin Nutr 1998; 68:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/81\">",
"      Holick MF, Biancuzzo RM, Chen TC, et al. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab 2008; 93:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/82\">",
"      Binkley N, Krueger D, Cowgill CS, et al. Assay variation confounds the diagnosis of hypovitaminosis D: a call for standardization. J Clin Endocrinol Metab 2004; 89:3152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/83\">",
"      Marriott BM. Vitamin D supplementation: a word of caution. Ann Intern Med 1997; 127:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/84\">",
"      Rosen CJ, Brown S. Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency. N Engl J Med 2003; 348:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/85\">",
"      Maalouf NM, Heller HJ, Odvina CV, et al. Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature. Endocr Pract 2006; 12:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/86\">",
"      Eddy RL. Metabolic bone disease after gastrectomy. Am J Med 1971; 50:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/87\">",
"      Nilas L, Christiansen C, Christiansen J. Regulation of vitamin D and calcium metabolism after gastrectomy. Gut 1985; 26:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/88\">",
"      Gertner JM, Lilburn M, Domenech M. 25-Hydroxycholecalciferol absorption in steatorrhoea and postgastrectomy osteomalacia. Br Med J 1977; 1:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/89\">",
"      Bisballe S, Eriksen EF, Melsen F, et al. Osteopenia and osteomalacia after gastrectomy: interrelations between biochemical markers of bone remodelling, vitamin D metabolites, and bone histomorphometry. Gut 1991; 32:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/90\">",
"      Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003; 124:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/91\">",
"      American Gastroenterological Association medical position statement: guidelines on osteoporosis in gastrointestinal diseases. Gastroenterology 2003; 124:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/56/12170/abstract/92\">",
"      Adler RA, Funkhouser HL, Petkov VI, Berger MM. Glucocorticoid-induced osteoporosis in patients with sarcoidosis. Am J Med Sci 2003; 325:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2023 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.150.3.100-7D04F74F15-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_56_12170=[""].join("\n");
var outline_f11_56_12170=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Observational data",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Randomized trial data",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Calcium versus vitamin D",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      OPTIMAL INTAKE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIETARY SOURCES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Calcium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Vitamin D",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUPPLEMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Calcium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Vitamin D",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Coexisting medical problems",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Vitamin D deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Underlying gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Proton pump inhibitor therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Diuretic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Cystic fibrosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Granulomatous diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/2023\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2023|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/39/6782\" title=\"figure 1\">",
"      Calcium intake and balance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/18/13615\" title=\"figure 2\">",
"      Effects of vitamin D supplementation on total fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/0/24577\" title=\"figure 3\">",
"      Effects vitamin D and calcium supplementation on total fracture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2023|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/45/25307\" title=\"table 1\">",
"      Foods with calcium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/12/37068\" title=\"table 2\">",
"      Calcium content of supplements",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/18/38184?source=related_link\">",
"      Causes of vitamin D deficiency and resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1338?source=related_link\">",
"      Clinical manifestations of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41898?source=related_link\">",
"      Complications of bariatric surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11128?source=related_link\">",
"      Diagnosis and evaluation of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42679?source=related_link\">",
"      Diet in the treatment and prevention of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33866?source=related_link\">",
"      Drug therapy of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9562?source=related_link\">",
"      Drugs that affect bone metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42553?source=related_link\">",
"      Evaluation and treatment of premenopausal osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2310?source=related_link\">",
"      Hypercalcemia in granulomatous diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28474?source=related_link\">",
"      Lipid lowering with diet or dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4714?source=related_link\">",
"      Management of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8954?source=related_link\">",
"      Management of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32681?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/54/30569?source=related_link\">",
"      Metabolic bone disease in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9462?source=related_link\">",
"      Metabolism of vitamin D",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=related_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39990?source=related_link\">",
"      Overview of vitamin D",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3929?source=related_link\">",
"      Pathogenesis of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/12/36034?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/12/8393?source=related_link\">",
"      Prevention of falls and complications of falls in community-dwelling older persons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=related_link\">",
"      Risk factors for calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=related_link\">",
"      Treatment of osteoporosis in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=related_link\">",
"      Treatment of vitamin D deficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31193?source=related_link\">",
"      Vitamin D and extraskeletal health",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=related_link\">",
"      Vitamin supplementation in disease prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_56_12171="Initial prenatal social and demographic assessment";
var content_f11_56_12171=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Initial prenatal social and demographic assessment",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Name of patient and emergency contact",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Marital status",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age (Date of birth)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Home address",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Telephone numbers for day, night, emergency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Education",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Occupation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Partner's name and occupation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pediatrician",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primary care physician",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hospital for delivery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Religion (Jehovah's witness?)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Insurance carrier",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_56_12171=[""].join("\n");
var outline_f11_56_12171=null;
var title_f11_56_12172="Indications for bronchoscopy";
var content_f11_56_12172=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58406&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58406&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indications for bronchoscopy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Inspection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cough (persistent, unexplained)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemoptysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wheeze (localized/fixed)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diaphragmatic paralysis*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unexplained hoarseness and/or vocal cord paralysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suspected tracheo-esophageal fistula",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chest trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        May require biopsy, BAL, or other procedure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Focal/unilateral hyperinflation or hyperlucency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Localization of broncho-pleural fistula",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atelectasis (persistent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Abnormal chest radiograph",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pleural effusion&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Paratracheal/mediastinal/hilar mass",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Parenchymal mass/nodule",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Diagnosis of etiology of pneumonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Recurrent/nonresolving (imunocompetent host)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Nosocomial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Immunocompromised host",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Foreign body in airway (known or suspected)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Evaluation for rejection in lung transplant recipient",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Delivery of brachytherapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Research",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Utility/yield for this indication are controversial.",
"     <br>",
"      &bull; Diagnostic yield &ge;40 percent only when effusion is massive or associated with hemoptysis, mass, or atelectasis.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_56_12172=[""].join("\n");
var outline_f11_56_12172=null;
var title_f11_56_12173="Survival in HBV cirrhosis";
var content_f11_56_12173=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F72204&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F72204&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Survival in HBV-related compensated cirrhosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 351px; height: 219px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cumulative probability of survival in patients with compensated cirrhosis related to hepatitis B virus (HBV) infection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Realdi G, Fattovich G, Hadziyannis S, et al. J Hepatol 1994; 21:656.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_56_12173=[""].join("\n");
var outline_f11_56_12173=null;
var title_f11_56_12174="Pustular psoriasis PI";
var content_f11_56_12174=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F75984&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F75984&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pustular psoriasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 232px; height: 156px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pustular psoriasis is characterized by widespread erythema and scaling and sheets of superficial pustules.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James C Shaw, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_56_12174=[""].join("\n");
var outline_f11_56_12174=null;
var title_f11_56_12175="Walk up wall stretch";
var content_f11_56_12175=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F55131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F55131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Walk up wall stretch",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 264px; height: 385px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Face a wall about three quarters of an arm length away from it. Using only your fingers (not your shoulder muscles), raise your arm up to shoulder level. Perform sets of 10 to 20 exercises at each session.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_56_12175=[""].join("\n");
var outline_f11_56_12175=null;
